Supercritical fluid technology for gastroretentive formulations by Ahmed, Elizabeth Hannah
Ahmed, Elizabeth Hannah (2013) Supercritical fluid 
technology for gastroretentive formulations. PhD thesis, 
University of Nottingham. 
Access from the University of Nottingham repository: 
http://eprints.nottingham.ac.uk/27853/1/604309.pdf
Copyright and reuse: 
The Nottingham ePrints service makes this work by researchers of the University of 
Nottingham available open access under the following conditions.
· Copyright and all moral rights to the version of the paper presented here belong to 
the individual author(s) and/or other copyright owners.
· To the extent reasonable and practicable the material made available in Nottingham 
ePrints has been checked for eligibility before being made available.
· Copies of full items can be used for personal research or study, educational, or not-
for-profit purposes without prior permission or charge provided that the authors, title 
and full bibliographic details are credited, a hyperlink and/or URL is given for the 
original metadata page and the content is not changed in any way.
· Quotations or similar reproductions must be sufficiently acknowledged.
Please see our full end user licence at: 
http://eprints.nottingham.ac.uk/end_user_agreement.pdf 
A note on versions: 
The version presented here may differ from the published version or from the version of 
record. If you wish to cite this item you are advised to consult the publisher’s version. Please 
see the repository url above for details on accessing the published version and note that 
access may require a subscription.
For more information, please contact eprints@nottingham.ac.uk
The University of 
Nottingham 
Division of Drug Delivery and Tissue Engineering 
School of Pharmacy 
Supercritical Fluid Technology for 
Gastroretentive Formulations 
Elizabeth Hannah Ahmed 
BSc (HoDs) 
Thesis submitted to the University of Nottingham for 
the degree of Doctor of Philosophy 
September 2012 
Abstract 
Abstract 
The oral route for drug administration offers an efficient and convenient 
method for drug delivery. However, there is an assortment of drugs which 
exhibit narrow absorption windows in the upper small intestine and as a result 
demonstrate limited bioavailabilities. One approach in the improvement of 
bioavailability in these cases is to retain the delivery system proximal to the 
absorption window for a prolonged period of time. Although controlled release 
products are widely available on the market, marketed gastroretentive systems 
remain elusive. 
This work explores the manufacture and characterisation of a multi-unit 
gastroretentive system utilising the biocompatible polymer poly (lactic-co-
glycolic acid). The novel PGSS technique enables the production of PLGA 
particles whilst omitting the use of volatile organic solvents. Morphological 
and microCT analyses of the particles revealed a highly porous matrix with 
porosity values in the order of 30-40%. The relationship between porosity, 
density and in vitro floating ability for particles with sizes between 100-2000 
J.1m revealed that particle size plays an important role; larger microparticles 
possess decreased density, higher porosity and increased buoyancy. 
Encapsulation of two model drugs, riboflavin and furosemide, was carried out 
during the processing step with high encapsulation efficiencies (80-100%) 
being revealed. Release of the drugs in PBS (pH7.4) was found to be sustained 
over a period of 24 hours with a decrease in cumulative release in simulated 
Abstract 
gastric fluid (pHl.2). The introduction of the hydrophilic polymer poly 
(ethylene glycol) was found to modulate release rate; PEG with a molecular 
weight ~ 3 3 KDa increased the rate of release in PBS media up to 20% over 24 
hrs, however this was not observed for release in SGF. A comparison of 
morphology prior to and following exposure to the release media confirms that 
the emergence of intricate porous channels on exposure to the release medium 
is related to an increase in release rate. 
In order to augment the gastroretentive potential of the system the 
mucoadhesive polymer, chitosan was incorporated both as a post processing 
surface modification and as part of the initial formulation. ToF-SIMS surface 
analysis confirmed the presence of chitosan at the surface of the particles in 
both cases. Initially the potential for the particles to interact with mucus was 
evaluated utilising in vitro tests. The presence of chitosan significantly 
improved adsorption of mucin to particles, as well as enhancing adhesion of 
particles to a mucus producing epithelial cell layer. The thiolated chitosan 
derivative chitosan-N-acetyl-cysteine demonstrated an increase in adhesion of 
mucin solution; however the modified chitosan resulted in a decrease in 
adhesion to a mucus producing cell line which was considered to be a result of 
the mucolytic actions it may exert on the mucus layer. 
Oral administration of buoyant particles to a rat model improved the 
pharmacokinetics of the anti-hypoglycaemia drug metformin, with addition of 
mucoadhesive properties providing further improvement. This study 
demonstrates that introduction of buoyancy and mucoadhesion functionalities 
to particles prepared by the PGSS method could improve delivery of drugs 
demonstrating narrow absorption windows in the upper small intestine. 
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Introduction 
1.1 Oral Drug Delivery 
In order to be effective, drugs must reach their target site of action in an 
adequate and therapeutically beneficial concentration. However, limitations in 
drug delivery may arise as a result of poor solubility [1-3], low absorption [3], 
inadequate distribution or insufficient selectivity [4]. The field of drug delivery 
aims to improve the pharmacological properties of the drug, allowing for more 
effective therapy. 
For reasons including convemence for both patient and healthcare 
professionals, oral administration of drugs has emerged as one of the preferred 
routes for drug delivery [5, 6]. The majority of commercially available 
pharmaceutical products are designed for oral administration; in the US oral 
products represented approximately 70% of pharmaceutical sales in 2010 [7]. 
Therefore, considerable efforts in pharmaceutical development concentrate on 
the design and identification of active compounds readily deliverable through 
the oral route, as well as the fabrication of delivery devices designed to 
improve oral delivery of drugs. 
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Patient compliance is an important consideration when developing any 
pharmaceutical product as, without adequate dosing, the therapeutic aim of the 
dosage form will not be achieved. There is an inverse relationship between the 
amount of doses per day and patient compliance [8]; consequently, in the 
development of novel oral therapy the design of a dosage form should be such 
to minimize the dose frequency. Owing to the ability of the majority of patients 
to easily self-administer the drugs, patient compliance is often relatively higher 
for oral dosage forms. 
There are many different formulations which serve to reduce oral dosing 
frequency. These systems often prolong drug release from the dosage form 
over an extended period decreasing dosage frequency and improving the 
therapeutic efficiency. Such systems will be described in more detail in the 
later sections. 
1.2 The Gastrointestinal Tract 
The gastrointestinal tract (GIT) includes all the anatomical structures from the 
mouth to the anus (Figure 1.1) and comprises of specialist sections capable of 
digesting food products, allowing the extraction of useful nutrients ending in 
the removal of waste products. 
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Figure 1.1 Structure o/the Human Gastrointestinal Tract 19J 
1.2.1 Structure and Function 
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The gastrointestina l tract measures around 5 meters in the average adult male. 
It is separated into two parts: upper and lower GIT (based on the function, and 
arterial suppl y), or into three parts: fore-, mid-, and hind-gut (based on 
embryolog ical development) . The digesti on process begins in the mouth with 
the addition of saliva and the chewing of food materi a ls; thi s semi -so lid mass 
is carried down the oesophagus to the stomach. 
3 
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The histological arrangement of the various sections of the GIT is similar, with 
variations allowing for specialized functions of the different anatomical 
sections. 
1.2.1.1 The Oesophagus 
The oesophagus, like much of the GIT, is a muscular tube allowing muscular 
contractions, or peristaltic waves, to push food along it. The oesophageal 
lumen is lined by thick stratified squamous epithelial cells ('squamous' refers 
to the flattened morphology of these cells). These cells are easily shed and the 
layer demonstrates a high turnover rate, providing protection from trauma and 
from the high volume transit of food, saliva, and mucus. 
The submucosal layer contains the mucous glands which are responsible for 
the secretion of mucus. This viscous secretion serves a duel function in both 
protection and digestion, aiding the transit of food materials down into the 
stomach. Below the submucosal layer, the lumen of the oesophagus is 
surrounded by a layer of muscle which is divided into three sections. 
Voluntary muscle is located in the upper third, allowing conscious control over 
swallowing, with involuntary muscles in the lower third which are 
autonomically controlled. The final third possesses both types of muscle. 
1.2.1.2 The Stomach 
Food is moved along the oesophagus by peristaltic waves into the stomach. 
The stomach receives and temporarily stores ingested food. The several 
functions of the stomach include: acting as a reservoir; processing food 
products for easier absorption of nutrients; and regulating emptying rates of 
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chyme into the small intestine. The exposure to the external environment 
leaves the GIT vulnerable to pathogens and therefore, the stomach plays an 
integral role in defence from such threats. Parietal cells present in the gastric 
epithelium, serve to secrete gastric acid. The low pH in the stomach acts as a 
defence to pathogenic organisms, and also enables pepsin to function. The 
stomach itself is divided into four anatomical regions (Figure 1.2). 
Oesophagus 
Duodenum 
Figure 1.2 The four anatomical regions of the stomach 
The different regions of the stomach are distinguished by specific cell types of 
the mucosal lining, each region with specialised functions. From the cardia 
region, food empties into the fundus, the top region of the stomach. The 
muscular contractions in this region are slow and sustained, gradually moving 
the stomach contents towards the small intestine. The largest part of the 
stomach is the body, where the ingested material is stored. Finally, the pyloric 
region is the funnel shaped region connected to the pyloric sphincter. The 
stomach can be subdivided into 2 areas with distinct roles in digestion. The 
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corpus (body) and the fundus are known as the cephalad and this is where the 
ingested materials are stored. The majority of the motility occur in the area 
known as the caudad, which comprises the distal corpus and the pyloric region 
(or antrum). This is where mixing of the contents and gastric enzyme takes 
place and the food stuff is ground into a more digestible state. 
Gastric secretions are essential for adequate digestion. The stomach secretes 2-
3 litres of gastric juice per day [10, 11], and is capable of storing volumes from 
0.5 litres to 5 litres. The majority of this fluid originates from various glands 
within the stomach wall. In the fundus, corpus and parts of the pyloru , 
invaginations extending into the gastric wall, known as ga tric pits, hou e 
various cell types secreting an assortment of substances. Different cell types 
with different functions can be found at different layers of the pits (Figure 1.3). 
Lumen of 
stomach 
eel/Types 
Parietal 
cells 
Substance 
Secreted 
Mucus 
(protects lining) 
Bicarbonate 
Gastric acid (HCI) 
Intrinsic factor 
Ca++ absorption) 
Hlst.mlne 
(stlmul.tes acid) 
Chief Pepsln(ogen) 
cells Gastric lipase 
Somatostatin 
(Inhibits acid) 
~ - - + . ; ; : : : : , , " " " - - G cells Gastrin (stimulates acid) 
Figure 1.3 Diagram depicting the gastric pit and the arrangement of 
its constituent cell types {12}. 
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There are four main constituents of gastric secretions - hydrogen ions, pepsin, 
mucus and intrinsic factors [13]. Each of these secretions plays an important 
role in GI physiology. 
Hydrogen ions (H+) are actively pumped into the stomach in exchange for 
potassium (Kl by the H+ /K+ ATPase proton pump. The movement of H+ out 
of the cell results in an accumulation of OH- in the cell, which undergoes 
catalysis by carbonic anhydrase to form the bicarbonate ion (HCO)} The 
presence of HC03- allows chloride ions to move against the gradient from the 
blood into the lumen of the stomach. HCI secretion into the stomach, although 
not essential for life, greatly aids digestion through the activation of 
pepsinogen which allows the activation of pepsin, as well as initial digestion of 
connective tissues and muscle fibres present in food. Although not related to 
digestion, the low pH Hel acts as a good non-specific defence mechanism 
against many pathogens. 
A layer of mucus protects the stomach from corrosion by the low pH of its 
contents and the actions of digestive enzymes. Mucus is secreted from the 
mucosal cells which simultaneously secrete bicarbonate ions. The mucus is a 
water-insoluble gel which traps the bicarbonate ions locally to the epithelial 
surface, providing a buffering system against the H+ within the lumen. 
The exact composition of gastric secretions changes depending on the filling 
state of the stomach [14]. Prior to stimulation (empty stomach), basal acid 
secretion in the stomach is low (10-15% of the rate during maximal stimulation 
[13]). The secretion of gastric juice is divided into three phases [15, 16]. The 
cephalic phase occurs before food has entered the stomach, which is governed 
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by neuronal signals which arise following stimuli such as tasting, smelling, 
chewing, and swallowing food. It is the vagal nerve that relays the information 
from the cerebral cortex directly to the parietal cells and stimulates the release 
of Hel. The second phase is the gastric phase which is responsible for at least 
half of gastric secretion. This is a response to both the mechanical actions on 
the stomach walls, and the chemical actions through raising the pH. Following 
extensive mixing and grinding, the chyme (partially digested food products) 
passes through the pyloric sphincter which sieves the stomach contents into the 
duodenum. This is where the third and final phase of digestion, the intestinal 
phase, takes place. The digestion products of protein entering the duodenum 
stimulate this phase, initially increasing gastrin production and accounting for 
around 5% of gastric secretions. However, after the initial increase in stimulus 
for gastric secretion, the duodenum sends inhibitory signals via the 
enterogastric reflex. This inhibits the vagal stimulation and stimulates the 
sympathetic neurons sending inhibitory signals to the secretory cells. 
1.2.1.3 The Small Intestine 
The small intestine is where the majority of absorption takes place and is 
therefore of great interest in drug delivery. The small intestine itself is 
sectioned into three divisions. The lumen of the small intestine contains areas 
where the mucosa proj ects into the lumen to create finger like structures 
known as villi. These projections increase the surface area and the absorptive 
abilities of the small intestine. Among the specialised cell types present in the 
mucosa of the villi are the two secretory cell types: goblet cells (which secrete 
mucin, a major constituent of mucus, into the lumen) and neuroendocrine cells 
(which release hormones into the blood allowing communication to take place 
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between the nervous system and the endocrine system). Within the spaces 
between the villi, (the Crypts of Lieberkiihn) additional cells are present, 
including paneth cells which secrete defensive molecules, stem cells which 
allow epithelial growth, and the intraepithelial lymphocytes which also playa 
key role in gastrointestinal defence. The submucosa connects the mucosa to 
layers of smooth muscle and provides mechanical strength to the small 
intestine. 
The smooth muscle fibres are arranged in circular and longitudinal layers, an 
arrangement which allows the generation of peristaltic waves to push food 
along the GIT. Gap junctions between muscle cells enable the spreading of 
contractions along the GIT, and result in the smooth waves of peristalsis. 
The upper small intestine, the duodenum, contains the longest villi projections 
and a high number of goblet cells; this is the site of most absorption. Within 
the Crypts of Lieberkiihn lie submucosal glands, known as Brunner's glands, 
which secrete bicarbonate containing mucus. The high pH of these secretions 
serves to neutralise and protect the duodenum from the highly acidic chyme 
which is arriving from the stomach. The higher pH levels (reported to be pH 
6.4 [17]) are also necessary for the activation of intestinal digestive enzymes. 
The duodenum also regulates the emptying of chyme from the stomach, the 
release of digestive enzymes from the pancreas, and bile secretion from the 
gall bladder. 
Following the duodenum is the jejunum, the middle section of the small 
intestine, and, as in the duodenum, it provides a good absorptive surface for 
carbohydrates. The jejunum contains the Valves of Kerckring - circular folds, 
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which increase surface area for absorption as well as providing obstacles which 
slow the passage of food materials, allowing more time for absorption to occur. 
The final section of the small intestine is the ileum where the remaining 
nutrients are absorbed. Peyer's patches are abundant in the ileum and the large 
quantity of these lymphoid nodules play a key role in the generation of an 
immune response in the small intestine to the presence of pathogens. 
1.2.1.4 The Large Intestine 
The large intestine follows on from the small intestine. This region of the GIT 
lacks the abundant villi present in the highly absorptive small intestine and as a 
result relatively little absorption of nutrients (or drugs) takes place here. The 
large intestine functions to absorb water and transport waste from the body. 
1.2.2 Physiological Barriers to Oral Delivery 
The environment within the GIT is variable and may provide physical, 
biological and chemical obstructions for adequate drug delivery as well as 
opportunity to explore in designing oral drug formulations. 
1.2.2.1 pH 
Gastric secretions tend to be highly acidic as a result of the hydrochloric acid 
content. pH is an important factor when considering the performance of a drug 
delivery system due to the influence pH has over drug solubility and delivery 
system stability [18]. 
Keeping in mind the complexity of the gastric secretions and the importance of 
the pH levels on the delivery system and the drug itself, the contents of the 
upper GI tract have been characterised with the aim of developing a more 
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appropriate media for in vitro inves tigations [1 9]. In one such study, aspirates 
were withdrawn from the stomach for analysis fo ll owing admi nistrat ion of 500 
ml of Ensure Plus® ; a model mea l that has the equi valent nutriti ve va lue and 
compos ition as the FDA's recommended meal [20]. The results showed that 
there are substanti al diffe rences in the compos ition of the gastri c flui d 
fo llowing the consumption of the mea l. pH can increase up to 6.4 and the 
buffe r capac ity increases. The pH then graduall y decreases over time back to 
the ' normal' range (reaching pH 2.7 after 2 10 mins), obviously dependent on 
contentlconstituents of the mea l. Thi s phenomenon has also been reported in 
other recent studies [2 1] as illustrated in Figu re 1.4 (taken fro m [22]). 
5.0 
4 .5 
4.0 
3 .5 
3.0 
2.5 
2 .0 
1.5 
1.0 
0 .5 i 
0.0 ~ - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - ~ ~o 60 120 180 240 300 360 420 480 
Time (minute s) 
Figure 1.4 The pH changes in the postprandial stomach. Administration 
of the meal is shown by the arrow [22 ]. 
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It is the gastri c phase of digestion which is responsib le for the majority of the 
pH changes in the post-prandial stomach. However, there is also a circadi an 
rhythm of the basal hydrogen ion flow , resulting in a cyc li ca l rise and fall of 
stomach pH over a 24 h period (Fi gure 1.5) [19]. 
9 
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Figure 1.5 The basal acidity in the stomach over a course 0/24 h. 
A circadian rhythm exists with the stomach being more acidic early 
morning and late evening [] 9]. 
The potential negative impact of the low pH on the incorporated drug and/or 
de li very system may be overcome through the use of pH responsive polymers 
[23]. These polymers respond to changes in pH leve ls, and exhibit disso lution 
on ly at pH levels higher than those in the stomach, usually pH 5.5 and abovc. 
A widely investi gated example is Eudragit [24, 25] which has been utilised in 
oral formu lations for improving delivery of drugs such as ibuprofen [26] , 
insulin [27,28] or, furosemide [29]. 
The Eudragit@ polymers are copolymers derived from esters of acrylic and 
methacrylic acids. The family of different Eudragit@ polymers, has been 
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exploited for enteric coating of oral drug delivery systems to protect the 
incorporated drug in the stomach and achieve their release in the intestines 
[30]. 
1.2.2.2 Gastric Motility 
Motility in the stomach is important for digestion, it is essential for proper 
nutrition, as well as reliable drug delivery. The stomach in essence acts as a 
mixer and a grinder, a storage chamber, and a sophisticated pump, with gastric 
motility following pre-determined patterns [31]. The motility originates from 
contraction ofGI smooth muscle, and it is used to move food along the GIT, as 
well as in the stomach, contributing to the mechanical 'digestion' of food. 
There are distinctly different patterns of stomach motility in the fed and fasted 
states. On fasting, the motility is continuous and shows a near constant force 
of 15-20 mm Hg [32]. The fasting state is also characterised by the regular 
occurrence of the migrating motor complex (MMC) which is the main pattern 
of contraction [33]. The MMC is also known as the 'housekeeper wave' and 
serves to remove debris from the stomach [34]. 
The post-prandial stomach demonstrates a different pattern of contractions, 
with two distinct patterns. Peristalsis is where the contractions occur in waves 
along the GIr, forcing the food along the tract towards the anus. The majority 
of contractile activity in the stomach however is segmentation. These relatively 
weak contractions ensure thorough mixing of ingested material with the gastric 
secretions to produce chyme. 
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The contractile activity within the stomach not on ly ensures thorough mix ing 
of the contents for di gestion, but the motility is a lso synchronised in such a 
way to empty the contents into the duodenum. Gastric empty ing is a highl y 
regulated event. In fact, the stomach wi ll demonstrate di st inct emptying 
patterns for liquids, digestibl e so lids, and indigestibl e solids [35]. As a result 
so lids and liquids do not empty from the stomach at the same rate. Figure 1.6 
illustrates that a comparison of the gastri c emptying rates for hea lthy 
volunteers followin g admini stration of either a so lid or liquid mea l revea ls 
liquids empty faster than so lids [10] . 
100 
80 
Amount 
I{emaining 60 
in Stomach 
i q ) 
40 
20 
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Time (It) 
Figure 1.6 Emptying rates of solid food (e) and liquids (0) from the 
stomach. Liquid is empties significantly faster than solid food [10]. 
In addition to the rate of gastric empty ing be ing dependent on the consistency 
of the ingested material [36] , the nature of the mea l components also impact 
gastri c emptying. For instance the presence of fatty acids, monoglycerides, and 
dig lycerides has been shown to delay gastric emptying [3 7-39]; the 
phenomenon known as the ' ileal brake' [40,4 1]. It occurs both because the fat 
wi ll separate and ' lay' on top of the stomach content due to its low density [42, 
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43] to be consequently emptied last, as well as due to the fact that the presence 
of the fat causes inhibition of antral contractile activity [44]. 
Other 'external' influences over gastric emptying rate include alcohol 
consumption [45, 46], disease state [47], gender [48], body mass index [49], 
and anxiety [50]. 
1.2.2.3 Absorption Window 
It has been demonstrated that some drugs are only absorbed at specific 
sections/sites along the GIT [51]. This may be a result of their poor solubility 
at certain pH levels along the GIT [52, 53], their degradation by digestive 
enzymes, or specific mechanisms required for their uptake [51]. As previously 
discussed, the anatomical characteristics of the small intestine are designed to 
achieve an ideal surface for absorption, with the upper small intestine being 
particularly relevant. As a result the absorption of many drugs is confined, to 
this section of intestinal tract, a so called absorption window [51, 54-56]. This 
presents a problem for drug delivery for different reasons. The variable nature 
of gastric transit time may lead to rapid transit of the delivery system 
(containing drug) past the site of drug absorption. In such an event, any 
subsequent drug release will be redundant and the delivered dose will simply 
pass through the remaining GIT. The presence of absorption windows is 
thought to limit the bioavailability of drugs [51]. 
Often, the rapid release and rapid absorption of conventional oral delivery 
systems [57] results in peaks and troughs in plasma drug concentrations. These 
fluctuations present problems with the emergence of side effects due to toxicity 
or, on the other side of the spectrum, inadequate therapy due to low drug 
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concentrations. The design of systems to overcome the limitations of narrow 
absorption windows focuses on increasing the time period that the drug is 
exposed to this area. 
1.3 Controlled Release Systems 
The coating of oral delivery systems has been common practice for purposes 
relating to taste [58] for many years. However, in 1884, a coating was 
developed which was designed to delay disintegration until the system reached 
the small intestine [59]. As early as 1952, Smith Kline & French were 
employing the concept of time-release in a formulation they named the 
Spansule [60]. Since the introduction of the Spansule, numerous controlled 
release products are now widely available on the market. 
Various designs for these controlled-release drugs have been proposed, these 
include matrix-controlled systems [61, 62] in which the drug is distributed 
throughout a polymeric matrix through which the drug may diffuse out into the 
surrounding medium. The diffusion controlled reservoir systems work in a 
similar way to matrix-controlled systems, where the drug is found in the core 
and must diffuse out into the surrounding medium. In the reservoir systems, 
the drug is found in the core and must diffuse through a membrane in order to 
be released. Finally, osmotically controlled devices are governed by osmotic 
pressure. These systems consist of an osmotic core, containing the drug and 
usually an osmagent, which is coated with a semi permeable membrane [63]. 
The influx of water into the system occurs at a rate determined by the osmotic 
pressure of the core of the system and the permeability of the membrane to 
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water. These osmotically controlled devices have proven to be relatively 
successful as the release is independent of many physiological parameters. 
Controlled-release systems span a huge spectrum of release rates which may be 
as long as months such an the case of Depo-Provera which is a progestogen-
only contraceptive injection administered every 3 months, or as short as 
systems developed for once a day oral dosing such as the extended release 
diclofenac and naproxen. 
1.4 Gastroretention 
1.4.1 Overview 
A controlled release of drug over time from a dosage form may minimise the 
peaks and troughs found in plasma drug concentrations and improve 
bioavailability of drugs [64]. In certain cases, controlled release alone may not 
however provide adequate improvements in pharmacokinetics. For drugs 
exhibiting absorption windows in a small area in the proximal GIT, when the 
delivery system has travelled past this narrow window any subsequent drug 
released will not be absorbed into the circulation. In such a case, alternative 
modifications to the delivery system may enable more efficient absorption and 
more desirable pharmacokinetic properties of the drug. 
Retention of the delivery system at or proximal to the site of absorption for a 
prolonged period of time might provide conditions in which presence of the 
released drug at the absorption window will improve the level of drug 
absorption. There are numerous drug candidates for this type of system which 
could be grouped into; (i) drugs reported to have an absorption window in the 
upper small intestine [51] such as calcium, Atenolol, Levodopa, and 
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Riboflavin; (ii) drugs which have a pH-dependant absorption [65] such as 
barbital [66]; and (iii) drugs for local action in the stomach such as antacids, 
anti-ulcer drugs, and antibiotics for Hpylori infections [65,67]. 
The various methods employed to achieve gastroretention have been reviewed 
previously [68-71] and will be considered in the following sections. 
1.4.2 Expanding Systems 
Expanding, or unfolding, delivery systems work on the principle that on 
contact with the gastric contents, the size of the system will increase to a 
diameter greater than that of the pylorus, thus delaying movement from the 
stomach to the small intestine. Once expanded, these systems must achieve a 
size appropriate for retention, whereby the size of 13mm has been proposed 
[72]. The very concept of this design however, immediately presents problems; 
for instance, premature expansion, which could result in the system unfolding 
in the oesophagus, causing discomfort for the patient. Moreover, after the 
expanding dosage form has served its purpose, there must be a mechanism of 
its removal from the stomach to avoid accumulation. 
Klausner et al 2003 [73] investigated a novel levodopa dosage form based on 
an unfolding polymeric membrane packed into a gelatine capsule. In this case, 
the rigidity and increasing size, up to 2.1 cm or larger, allowed prolonged 
gastric residence time in man reaching 5 h. Another method of creating a size 
increasing dosage form is to use a hydrogel which swells on contact with the 
gastric fluid. A hydrogel is a three-dimensional cross-linked network which 
swells hut does not dissolve in an aqueous environment [74]. The swelling is 
often dependent on the particular conditions of the environment. Enzyme-
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digestible hydro gels have demonstrated high gastric residence times of up to 
24 h in dogs [75]. 
1.4.3 Mucoadhesive Systems 
Mucoadhesive delivery systems are those which act by adhering to the 
mucosal surfaces in the body. The gastrointestinal tract is potentially an 
appropriate site for mucoadhesive systems. Bioadhesion was first explored by 
Park and Robinson in 1984 [76] who reported a delay in gastric transit time in 
rats on introduction of either poly (acrylic acid-divinyl glycol) or poly 
(methacrylic acid-divinylbenzene). Mucin is a major constituent of mucus and 
it is one of the principle targets for mucoadhesion. Mucin is a heavily 
glycosylated protein with terminal groups rich in cysteine residues which allow 
mucin to form disulfide interactions with materials. This is exploited in 
mucoadhesive delivery systems with many materials capable of forming 
disulphide bridges with these cysteine groups. 
Polyanions are polymers which demonstrate good adhesion to mucus; an 
example is polyacrylic acid [77-79]. These polymers adhere to mucus through 
hydrogen bonds between the carboxyl groups of the polymer and the hydroxyl 
groups present in the carbohydrate region of the mucin. Polyacrylic acid with a 
high charge density has been found to demonstrate good tensile stress 
(mucoadhesive strength) in vitro [80]. The Carbopol® polymers are polyacrylic 
acids with varying degrees of cross-linking and have been used widely in 
mucoadhesive drug delivery [81-84]. Studies show that the degree of cross-
linking within the Carbopol® polymers is an important factor in mucoadhesion 
[85], with greater cross linking improving mucoadhesion. 
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As well as the polyanions, cationic polymers such as chitosan exhibit good 
bioadhesion properties as a result of their overall positive charge and the 
ability to form electrostatic interactions with the negatively charged mucin. 
The use of chitosan as a mucoadhesive agent has been explored extensively 
with good mucoadhesion being demonstrated in vitro [86, 87]. Chitosan 
microspheres are one of the most widely studied drug delivery systems for the 
controlled release of many types of drugs [88]. Interactions between chitosan 
and mucin have been measured using various in vitro techniques with the 
conclusion that the interactions are strong and dependent on the positive zeta 
potential of chitosan [86]. Much promise has been found with chitosan in 
animal studies. However, the evidence is less convincing for its use in humans 
[89]. 
Other polysaccharides with proven mucoadhesive abilities include: alginic 
acid, sodium salts of carboxymethyl cellulose, hyaluronic acid, and 
carrageenan [85]. Alginic acid microspheres have been manufactured for use in 
nasal administration of carvedilol [90], as well as gastroretentive systems for 
acyclovir. In the latter application, 66% in vitro mucoadhesion was revealed 
with gastric residence time surpassing 4 h. [91]. Sodium alginate and sodium 
carboxymethy1cellulose are capable of demonstrating good sustained release of 
metformin hydrochloride in a gastric environment, with sodium alginate 
demonstrating the most effective mucoadhesion [92]. 
The aforementioned mucoadhesive polymers may improve delivery of drugs 
through enhancing the contact with the mucosal surface. However, such 
systems have not yet amounted to commercially successful products [93]. This 
has led to the development of derivatives of these polymers capable of 
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improving mucoadhesive properties. These improvements aim to introduce 
covalent bonding to constituents of mucus which should increase the integrity 
of the interaction between delivery system and mucosal surface. Polymers 
containing thiol groups (thiolated polymers, or thiomers) should be able to 
form strong disulfide bonds with the cysteine rich regions in mucin [94], and 
should therefore demonstrate more effective mucoadhesion than the non-
thiolated counterparts [85]. 
Various thiolated derivatives of chitosan have been explored, including: 
chitosan-N-acetyl cysteine (chitosan-NAC), Chitosan-4-thio-butyl-amidine 
(chitosan-TBA), and chitosan-thioglycolic acid (chitosan-TOA) [95-97]. In 
comparison with unmodified chitosan, and other mucoadhesive polymers, the 
thiolated chitosans demonstrate superior mucoadhesion in gastroretentive 
microspheres for acyclovir [98]. Mucoadhesion was also improved by a 
thiolated chitosan in a gastroretentive particulate system for riboflavin-5' 
monophosphate sodium salt dehydrate [99]. It has been reported that thiolated 
derivatives can improve mucoadhesion by as much as 250 fold (see Table 1.1 
modified from [100] ). 
It should be noted, however, that there are limitations to mucoadhesive 
systems, with the main disadvantage being the turnover rate of mucus in the 
stomach and intestine. This is relatively high but also variable [10 1]. Peristaltic 
waves may also force the delivery system further along the OJ tract. Finally, 
the adhesion of the system is not gastro-specific, and there is a chance that 
adhesion will occur earlier in the OJ tract, in the oesophagus, or even past the 
absorption window. 
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Table 1.1 The improvement in mucoadhesive strength o/various 
thiolated polymers {100J 
Polymer Improvement in mucoadhesiveness 
Chitosan-iminothiolane 250-fold improved mucoadhesive properties 
Poly( acrylic acid)--cysteine I DO-fold improved mucoadhesive properties 
Pol y( acrylicacid)-homocysteine 20-fold improved mucoadhesive properties 
Chitosan-thioglycolic acid IO-fold improved mucoadhesive properties 
Chitosan-thioethylamidine 9-fold improved mucoadhesive properties 
Alginate--cysteine 4-fold improved mucoadhesive properties 
Poly(methacrylic acid)--cysteine Improved cohesive and mucoadhesive properties 
Sodium carboxymethylcellulose- Improved mucoadhesive properties 
cysteine 
1.4.4 High Density Systems 
As a result of the anatomy of the stomach, ingested high density material 
ingested will often 'sink' into the greater curvature at the base of the stomach. 
In this position, a dosage form could release drug undisturbed by the 
aggressive mixing occurring in the stomach. It has been suggested that by 
sedimenting within the folds at the base of the stomach, it is possible for 
'heavy' particles to remain in the stomach for periods of up to 24 h [102]. It 
has been proposed that 'heavy particles' such as dense pellets must 
demonstrate a density of 3 gcm-3 or greater [54]. Such systems have not yet 
been widely investigated, presumably due to difficulties in producing systems 
with such a high density from acceptable materials. 
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1.4.5 Floating Systems 
Conversely to the high density systems described above, systems designed to 
remain buoyant on the gastric contents have shown great promise as a means 
for achieving gastroretention [71, 103, 104]. Floating drug delivery systems 
first appeared in 1968 when Davis proposed a method to overcome difficulties 
when swallowing a pill by decreasing the density of the pill to below that of 
water [105]. Drug delivery systems may achieve buoyancy on the gastric 
contents through two different mechanisms as effervescent and non-
effervescent systems. 
1.4.5.1 Effervescent Gastroretentive Formulations 
Effervescent delivery systems incorporate carbon dioxide generating agents in 
the formulation, which will lower the density of the system on contact with the 
gastric contents. The gas can be produced through two means, the first being 
the use of volatile liquid systems. In this case, a liquid which turns to a gas at 
body temperature is used to fill the delivery system lowering the overall 
density [106]. Secondly, the gas may be produced through a gas generating 
system whereby effervescent reactions are used to liberate amounts of C02. 
A tablet formulation incorporating sodium bicarbonate and anhydrous citric 
acid demonstrated floating for around 24 h in an in vitro test [107]. A major 
drawback of this type of system, however, is a lag time between the initial 
contact with the gastric contents and the generation of gas. In the above study, 
the lag time exceeded 100 seconds for some formulations [107]. A similar 
effervescent mixture of sodium bicarbonate and citric acid incorporated into a 
gastroretentive formulation demonstrated floating in vitro for 24 h, with a 
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markedly higher lag time of 10 mins [108]. This may present a problem, as the 
peristaltic waves within the stomach could result in the system being emptied 
before the gas generation has allowed sufficient floating. There have been 
efforts to decrease this lag time to reduce the risk of premature emptying. For 
example, it has been demonstrated that the ratio of sodium bicarbonate in the 
formulation can affect the lag time, and through formulation optimization, it 
has been reduced to 8 s for formulations containing 20% sodium bicarbonate 
[109]. These formulations were retained in the human stomach for 5.50 h. 
There are two ways in which the effervescent agents may be incorporated into 
the system. In a single-layered tablet, the effervescent compounds are 
combined with the components of the tablet [110]. Bilayer effervescent tablets 
have also been described [111] whereby two distinct layers are present. One of 
these layers is for the polymer and the drug. This layer may be able to convey 
sustained drug release with in the stomach, and the second layer contains the 
carbon dioxide generating components. Triple layered systems have also been 
developed, where the extra layer consists of bismuth salt. The bismuth layer 
rapidly dissolves in the gut, giving immediate release following which the 
matrix will swell [112]. 
As well as tablet based effervescent formulations, sodium alginate beads have 
also been studied and developed using effervescent compounds [113]. The 
alginate microspheres are prepared by ionotropic gelation with the gas forming 
calcium carbonate. The benefit of this method is that the dose delivered 
composes of numerous alginate beads, and so poor lag time and the loss of a 
fraction of the dose would not have as great an impact as the loss of a 
monolithic device. 
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1.4.5.2 Non-Effervescent Gastroretentive Systems 
Non-effervescent floating dosage systems demonstrate buoyancy as a result of 
their inherent low density. The density of the gastric fluid has been measured 
to be around 1.004 gcm-3[1l4], thus, any formulation with a density less than 
this should exhibit floating properties in the gastric environment. 
Buoyancy has been achieved through the incorporation of materials with a low 
density, such as polypropylene foam powder [115]. The foam powder-
containing tablets have revealed floating times of 8 h in vitro [114]. This 
system was capable of demonstrating sustained release with control over the 
rate being exerted through altering the ratios of matrix polymers and foam 
forming polymers. As an alternative to incorporating low density materials into 
the formulation, microparticles containing a hollow core (known as 
'microballoons ') [116] have been prepared, demonstrating potential for 
sustained pharmacological action in vivo. Hollow polycarbonate microspheres 
demonstrated good floating behaviour and a corresponding improvement in 
bioavailability in rabbits for piroxicam loaded microspheres [117]. 
Similarly to microballoons, microparticles demonstrating highly porous 
morphologies may demonstrate buoyancy. Calcium silicate based porous 
microparticles with porosity values in excess of 70% demonstrated good 
buoyancy, with over 80% of the particles remaining buoyant in vitro after 10 h 
[118]. This was despite true density values of the microparticles higher than 1 
gcm-3• Porous calcium silicate formulations have also been applied as a porous 
carrier for the delivery of glipizide with similar floating behaviours observed 
[119]. Particles with 34% porosity and a bulk density of less than 1 gcm-3 
prepared with calcium pectinate have been shown to remain floating in vitro 
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for up to 12 h [120]. Furthennore, the low density allowed the system to 
remain in the rabbit stomach for 5 h [120]. Porous particles of ethyl cellulose 
were capable of floating on a simulated gastric fluid for over 12 h in vitro, 
translating to good in vivo perfonnance in rabbits with improvements in 
ranitidine bioavailability [121]. 
Although these floating systems have demonstrated potential for successful 
gastroretention in in vivo studies, there are very few systems available on the 
market which exhibit gastroretention through buoyancy on the gastric media 
[122]. 
A wide variety of delivery systems has ansen from the research into 
gastroretentive delivery systems. The single-unit fonnulations such as tablets 
have a disadvantage as they demonstrate an all-or-nothing gastric emptying 
behaviour. In this case if the dose does not demonstrate adequate 
gastroretention the entire dose will be emptied into the small intestine 
prematurely. Multi-unit systems such as microparticles offer a solution, as it is 
less likely that the entire dose will fail, this improves therapeutic perfonnance. 
1.5 Methods for Particle Production 
1.5.1 Conventional Methods for Particle Production 
Microparticulate systems have attracted much interest in recent years and have 
been employed in various successful products [123]. There are different 
methods available to achieve production of microparticles. There are also 
many different manufacturing methods for use in microencapsulation of an 
API. Several of these technologies include: 
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Emulsification methods are most frequently used for the production of 
polymeric microparticles [128]. This technique is extensively studied and is 
highly versatile to allow the production of a variety of systems. The process 
can either be conducted in a single oil-in-water (o/w) emulsion or as a double 
water-in-oil-in-water (w/o/w) emulsion. In the single emulsion, a polymer that 
forms the microparticles is dissolved in a volatile organic solvent which is 
immiscible within water, typically used as continuous phase. The organic 
phase also contains the drug, dissolved or dispersed. Evaporation of the 
organic solvent results in hardening of microparticles which physically 
incorporate drug. This technique can efficiently encapsulate a range of water 
insoluble drugs such as chlorpromazine [129], doxorubicin, and hydrocortisone 
[130]. However, incorporation of water soluble drugs is not efficient and the 
preferred method may be the double-emulsion method [131] where the 
hydrophilic drug is dissolved in an aqueous phase, which is added to the 
polymer containing, organic phase before emulsification into the outer water 
phase. The double-emulsion technique has been applied in the encapsulation of 
water soluble drugs, in particular, proteins and peptides [132-134]. 
These techniques have been applied in the creation of oral sustained release 
microparticles containing the drug nitrofurantoin [135]. In this case a modified 
solvent evaporation method [136] was employed, which allowed the 
introduction of an enteric coating of the nitrofurantonin microparticIes. A 
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gastroretentive, sustained release system for ketoprofen was produced using 
the emulsion method [137] with good encapsulation and a high percentage of 
particles demonstrating buoyancy following 6 h in simulated gastric fluid. 
Although well characterised, the emulsion techniques require complex multi-
step processes which are difficult to scale up economically. The use of volatile 
organic solvents is a major limitation as any toxic residues must be removed 
from the final product. 
1.5.2 Supercritical Fluid Technology 
A recent novel method of processing polymers has been developed using 
supercritical fluids. A supercritical fluid has been described as 'any substance, 
the temperature and pressure of which are higher than their critical values, and 
which has a density close to or higher than its critical density'. Publications in 
the area appearing from 1991 [138, 139] have described a technique which 
may evade the use of toxic organic solvents ('green technology') and complex 
multi-step procedures. 
1.5.2.1 Supercritical Carbon Dioxide Technology 
Supercritical fluid refers to a phase of material which is an intermediary phase 
between gaseous and liquid. By increasing the temperature and pressure of 
substances to beyond the thermodynamic critical point, a phase boundary is 
broken and a new single phase is revealed. Supercritical fluids have the diffuse 
abilities of a gas and can dissolve materials like a liquid. 
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Carbon dioxide (C02) is an ideal choice as it is cheap, nontoxic, non-
inflammable, recyclable and has a mild critical temperature (Tc=304.2K 
Pc=7.3MPa). A typical phase diagram is illustrated in Figure 1.7 [140]. 
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Figure 1. 7 Pressure-temperature phase diagram for a pitre 
component showing the triple point (T) ami the critical point (C). The 
supercritical region (SCF) is demonstrated past tile critical point. The 
density of the component is iJ/ustrated by the grey circles {J40j. 
The phase diagram demonstrates the boundaries between the three 
conventional states of matter. As temperature and pressure of a liquid increase, 
the liquid wi ll expand and therefore the density wi ll decrease. onversely, as 
the temperature and pressure of a gas is increased the density wi ll increase. 
Eventually, as the critical temperature and pressure is reached, the densities of 
the gas and the liquid are identical and there is no longer any di stinction 
between the two phases. The disappearance of the phase boundary is indicative 
of the supercritical fluid [140, 141]. A supercritica l fluid is therefore denser 
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than a gas and with the ability to dissolve solids while simultaneously 
demonstrating diffusivity. Furthennore, it is possible to make minute changes 
to the processing conditions which will in turn have a large impact on the 
properties of the fluid enabling control over the processing of polymers. 
The use of supercritical CO2 (scC02) in particle fonnation has been around for 
a couple of decades with various reviews emerging in this area [142-146]. 
However CO2 is not the only option for supercritical fluid technology as there 
are many substances with obtainable critical points (Table 1.2). Water is an 
example of a substance with no toxicity and flammability issues. However, its 
critical temperatures and pressures are high and introduces processing issues 
which render water less viable [147]. Substances with more ambient critical 
points such as sulphur hexafluoride (SF 6) although non inflammable encounter 
other limitations such as the concerns over SF 6 as a greenhouse gas. 
Table 1.2 Critical conditions Pc, Tc, pc for selected substances 
Substance Pc (bar) Tc(OC) pc(gcm-3) 
CO2 73.8 31.1 0.47 
N20 72.5 36.5 0.45 
SF6 37.1 45.5 0.74 
Xe 58.4 16.6 1.10 
CH30H 78.9 240.5 0.27 
CH3CH(OH)CH3 47.0 235.3 0.27 
H2O 218 374 0.32 
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scC02 is widely used in extraction: for example, in the food industry, for the 
extraction of fat from meat products [148], the production of decaffeinated 
coffee [149, 150], the extraction of cholesterol from dried egg yolk [151]. The 
extraction process requires the extracted substance to be soluble in scC02. 
SCC02 can also be used for the recovery of and separation of organic products 
[152]. The plasticisation effect of scC02 on polymers is well established [153] 
and may be utilised to achieve high polymerisation rates using various 
methods. 
As well as polymer synthesis, scC02 has been applied in polymer processing 
to form various structures. SCC02 has been applied in the production of 
polymer foams, including the production of poly(methyl methacrylate) 
(PMMA) foams to generate a microcellular core surrounded by a non-porous 
skin [154]. Such microcellular structures have applications in adsorbants, 
controlled release, separation media, and catalyst supports. Foams prepared of 
a PMMA and poly (vinylidene) (PVDF) blend, have demonstrated improved 
morphologies, compared to foams composed solely of the highly crystalline 
polymer PVDF [155]. It is possible to tailor the properties of these foams by 
manipulating the molecular weight of the polymer [156], or the processing 
parameter [154]. 
SCC02 has also been applied in the production of particles of vanous 
biocompatible polymers for the encapsulation of therapeutic agents [146, 157]. 
There are a number of techniques that have been adapted to use scC02 in the 
production of particles for pharmaceutical applications. In each method, scC02 
demonstrates a different function depending on its solvent properties or its 
solubility in polymers. CO2 is a good solvent for non polar and low molecular 
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weight compounds and certain polymers such as amorphous, fluoropolymers, 
and siloxane-based polymers [158, 159]. scC02 may also diffuse within a 
liquefied polymer, the extent of the solubility depends upon the molecular 
structure and the morphology of the polymer [126]. The dissolved SCC02 in 
the polymer may reduce the glass transition temperature (T g), allowing 
plasticisation to occur at lower temperatures [160]. scC02 has been shown to 
interact with polycarbonate (PC) and polysulfonate (PSF) [161], as well as 
poly(ethylene glycol) (PEG, and polyphenylene oxide (PPO) [162]. 
Owing to the poor solubility of many compounds, in some supercritical fluid 
techniques, SCC02 has been used as an anti solvent where the compound is 
dissolved in a conventional organic solvent which will dissolve in SCC02. On 
introduction of SCC02 to the organic solvent, compound mixture will increase 
in density and therefore crystallization of the compound can take place. 
1.5.2.2 Rapid Expansion of Supercritical Fluid Solutions Method 
There has been development of a number of modified processes for the 
application of scC02• Rapid expansion of supercritical solutions (RESS) [163] 
utilises scC02 as a solvent (in which the compound is dissolved) and therefore 
the polymer must have a degree of solubility in SCC02. When the solution is 
depressurized through a nozzle, the temperature change decreases the solvent 
power, leading to precipitation of the solute. The governing principle of RESS 
is pressure induced phase separation [146]. RESS has previously been used in 
coatings [164, 165] and was first applied in the production of drug loaded 
microparticles in 1993 [166]. Since this time, RESS has been used to produce 
microstructures of a poly(styrene )-b-(poly(methyl methacrylate )-co-poly 
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(glycidyl methacrylate)) copolymer [167], poly (lactic acid) [168], polystyrene 
[169], and PGA [170]. It has also been used with encapsulation of drugs such 
as the non-steroidal anti-inflammatory drugs naproxen [168], and ibuprofen 
[171]. In the latter study, ATR-IR spectroscopy was used to study the films 
produced, with a molecular interaction between the ibuprofen and the 
polymeric matrix (poly (vinylpyrrolidone)) being revealed. This was 
confirmed using Raman spectroscopy. The proteins lipase [172] and BSA 
[173] have both been encapsulated using RESS with good sustained release of 
BSA over 24 h being achieved. 
A major drawback with the RESS method is that the drug and polymer must be 
soluble in scC02, which few compounds are, and therefore modifications to 
the process have emerged in an attempt to widen the scope of applications. Co-
solvents are a common addition to the process; suitable co-solvents include: 
ethanol [167], which allowed the processing of polymers such as 
poly(styrene )-h-(poly(methyl methacrylate )-co-poly (glycidyl methacrylate)) 
copolymer, PEG and PMMA. These polymers demonstrate poor solubility in 
C02 and ethanol but the two solvents combined allowed adequate processing 
into microparticles. Co-solvents such as acetone [174], chlorodifluoromethane 
[175], and methanol [176] have been used successfully to improve processing. 
However, the use of co-solvents introduces problems with drug stability for 
protein drugs, as well as solvent removal and residues in the final product. 
33 
Chapter 1 
1.5.2.3 Gas Anti-Solvent (GAS) Method 
Owing to the problems of processing biodegradable polymers, an alternative 
processes where scCOz is used as an anti-solvent has been developed. This 
system is more suitable for several polymers, as the process uses a 
conventional organic solvent in which the drug/polymer is dissolved, before 
scCOz is used to supersaturate the solvent. The GAS process recrystallizes 
solid compounds that are not soluble in supercritical fluids [177, 178]. It is 
therefore especially appropriate for polymers. 
GAS is the scCOz technique often used to encapsulate protein drugs [179, 180] 
but has also been applied in the production of carbamazepine loaded PEG 
particles [181], and hydrocortisonelPVP composites [182]. scCOz has been 
applied as an anti-solvent in the processing of poly(L-lactic acid) to create a 
porous scaffold [183]. In this case, the use of scCOz is particularly 
advantageous for the creation of pores, as they will simply occur from the 
dispelling COz from within the matrix on particle fonnation. 
scC02 can be used as an anti-solvent, and techniques utilising this include 
GAS, SAS, PCA, ASES and SEDS. All these techniques use a traditional 
organic solvent to dissolve the solute and then the scC02 is used to super-
saturate the solution and precipitate the solute. This works, as when the dense 
C02 is introduced to the organic solvent, the liquid phase is expanded and the 
solvent power of the solvent decreases, leading to particle fonnation. 
The choice of solvent for dissolving the drug/ polymer components must allow 
the drug and polymer to be dissolved, while simultaneously being soluble in 
scCOz itself. However, as with the application of a co-solvent in the RESS 
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technique, there are issues arising from the use of a conventional organic 
solvent. 
1.5.2.4 Supercritical Anti-solvent (SAS) Method 
This technique is similar to GAS, whereby the supercritical fluid acts as an 
anti-solvent for polymers. However, the contacting mechanism is different. It 
has been modified for both batch and continuous processes and used in the 
processing of explosives, polymers, and pharmaceutical products, 
superconductors and catalysts [184]. Rifampicin micro- and nano-particles 
have been produced, using DMSO as the organic solvent [185]. Similarly 
DMSO was the solvent of choice for the micronization of salbutamol [186]. 
The co-precipitation of PLA and paclitaxel used a modified SAS process, 
which introduces ultra-sonic vibrations for the production of more uniform 
particles with a narrower size distribution. Paclitaxel was encapsulated at 
83.5% and release was sustained over 30 days [187]. 
Similar techniques to SAS include aerosol solvent extraction system (ASES), 
where the scC02 flows in a counter current against the solution, or 
precipitation with a compressed anti solvent (peA). In this method, the 
polymer is dissolved in a liquid solvent, it is then sprayed into a chamber 
where the supercritical fluid antisolvent already exists. These two techniques 
have also been used in pharmaceutical processing [188, 189]. 
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1.5.2.5 Solution Enhanced Dispersion by Supercritical Fluids (SEDS) 
Method 
This is a similar technique to SAS, although the liquid solution and 
supercritical fluid are sprayed together using a specially designed coaxial 
nozzle [146]. The two high-speed streams of the solution and the supercritical 
fluid are able to generate a finely dispersed mixture and give particle 
precipitation. It is possible to use three processing components, such as two 
different supercritical fluids and one organic solvent which can convey 
versatility on the system. Advantages of this process include the ability to 
process aqueous solutions allowing the formation of particles from proteins 
and sugars. Biodegradable microparticles can be prepared using this system 
[190, 191]. 5-Fluorouracil was micronized and used to produced 
microparticles with PLA utilising dichloromethane as a solvent [192]. The 
preparation of particles without the use of organic solvent have been attempted 
using this technique, however, without an organic solvent the resultant product 
is wet with a suitable dry powder very difficult to obtain [193]. 
1.5.2.6 Particles from Gas Saturated Solutions (PGSS) Method 
The PGSS method differs from the above methods as SCC02 is not being relied 
upon as a solvent or an anti-solvent. The high solubility of C02 in some 
materials is exploited in this method and may lead to a gas saturated solution. 
It is often the case that the interaction of SCC02 with a polymer reduces the 
glass transition temperature, allowing plasticization to occur at more ambient 
temperatures [153]. A key advantage of this technique is that the polymer and 
drug do not need to be soluble in SCC02, but it does require the polymer to be 
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plasticized by the SCC02. The polymer and therapeutic agent are placed in a 
chamber where the temperature is increased and CO2 is pumped in up to a set 
pressure. As the temperature and pressure increase, the polymer will plasticise. 
The stirring of the polymer and drug particles creates a homogenous mixture 
which upon depressurisation will solidify trapping the drug particles. 
The PGSS method was originally developed for the production of powder 
coatings [194] and has also been applied in the food industry [195]. More 
recently the process has been used in the production of pharmaceutical 
products. The T g lowering effect of the scC02 in this process has enabled the 
encapsulation of protein drugs. Human growth hormone was encapsulated in 
PLGAIPLA microparticles with high encapsulation efficiencies and good 
sustained release over 14 days [196]. Ribonuclease A and lysozyme have also 
been incorporated into PLA microparticles[ 197] with no significant loss of 
protein activity. 
Porous scaffolds for applications in tissue engineering have been prepared 
using the PGSS technique [198, 199]. However, by implementing a spraying 
step in the process, various structures can be prepared. Fibres or microparticles 
can be manufactured by introducing a back pressure in the collection chamber 
[153]. The back pressure is usually created using nitrogen gas as it is relatively 
inert and will not plasticise polymers under the operating conditions allowing 
solidification. It also exerts control over product morphology, by regulating the 
diffusion of carbon dioxide out of the solidifying polymer. The viscosity of the 
polymer mixture can impact the atomisation step in this process [153,200]. 
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Benefits of this technique over the other methods of particle formation include 
the absence of conventional solvents during processing, by-passing the 
problems with toxic products in the dosage form. It also does not require the 
polymer or the drug to be soluble in SCC02, and so mild processing conditions 
are used. 
1.6 Project Aims 
The introduction of gastroretentive delivery systems have enabled more 
efficient delivery of candidate drugs which demonstrate narrow absorption 
windows in the upper GIT, however, very few systems have proven successful 
enough to reach the market. Although there has been poor in vitro-in vivo 
correlation with these systems, a combination of buoyancy and mucoadhesion 
may improve oral bioavailability. 
The supercritical fluid method, PGSS, is a novel polymer processing technique 
which enables the production of highly porous microparticles without the use 
of volatile organic solvents, or high temperatures. This thesis aims to apply the 
pass technique to the design of highly porous biodegradable polymeric 
particles capable of gastric retention. The process parameters, and specific 
particle properties required to achieve gastroretention thus improving oral 
delivery of 'problematic' drugs will be investigated. 
In vitro analysis, aims to establish a fundamental understanding of a 
correlation between the buoyancy of particles and their physicochemical 
properties (including size, density, and morphology). Buoyant particles will be 
loaded with suitable candidate drugs (furosemide, metformin, riboflavin) and 
the drug loading potential and release profile of the formulation will be 
determined and optimized to correlate with the potential gastric retention time. 
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The choice of these three therapeutics was justified as all three are 
characterised by narrow absorption windows in the upper small intestine. The 
three drugs exhibit differing solubilities enabling comparisons to be made of 
their release properties. The mucoadhesive polymer chitosan and its derivative 
chitosan-NAC will be introduced to the system with the aim of introducing 
mucoadhesive properties to the buoyant particles, potentially augmenting 
gastroretention. In vitro analysis of mucoadhesion will be investigated. 
The success of selected formulations will be evaluated in vivo and plasma 
concentration profiles prepared in order to allow conclusions to be drawn upon 
the success of the system as a potential new drug delivery system for the oral 
route. 
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Experimental Methods 
This chapter describes the general methods used throughout this thesis which 
cover the production and characterisation of PLGA particles produced using 
the PGSS method. Chapter specific methods will be described in the 
appropriate chapters. 
2.1 Particles from Gas Saturated Solutions Method 
Microparticles were prepared using the Particles from Gas Saturated Solutions 
system (PGSS) as described previously [1-3]. The basis of this process is the 
ability of supercritical carbon dioxide to decrease the glass transition 
temperature of many biodegradable polymers suitable for applications in drug 
delivery. Poly(lactic-co-glycolic acid) (PLGA) is a widely used polymer in 
drug delivery and is highly compatible with this process [4]. The components 
of the formulation and are mixed together before being introduced to a 10 ml 
cone shaped mixing chamber which is then attached to the head of the 
apparatus which contains the stirrer and sealed using a clamp and a viton 42 x 
2 mm o-ring. A schematic of the high pressure equipment can be found in 
Figure 2.1 along with a labelled photograph illustrating the main components 
(Figure 2.2). 
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Figure 2.1 Simplified diagram of the high pressure equipment used to 
fabricate particles 
Inlet pipe Stirrer 
Vent pipe 
M ixing chamber 
Collection chamber 
Figure 2.2 Labelled photograph of the mixing chamber attached to the 
collection chamber. 
2cvlinder 
The temperature is increased initially to 40°C by a heating band around the 
mixing chamber. CO2 is introduced to the system through the inlet port to a 
pressure of 140 bar and the mixing chamber is finally heated up to 60°C. At 
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this point the carbon dioxide is in the supercritical state and the PLGA will be 
molten. For a period of 50 mins the contents of the mixing chamber are stirred 
to allow the homogenous distribution of the materials throughout the now 
molten polymer matrix. During this soak period the pressure and temperature 
are monitored. After 50 mins the stirring is tenninated and the contents are left 
to stand for a further 10 mins. 
Collection of the product occurs through spraying the molten mixture through 
a 0.5 mm disc nozzle into a collection chamber. The disc nozzle sits on top of 
the collection chamber with a 15 x 2 mm o-ring, the ball valve is mounted on 
top of the disc nozzle, sealed using a 14 x 2 mm viton o-ring, between the ball 
valve mount and the mixing chamber there is a lOx 2 mm o-ring. This nozzle 
assembly is opened and closed using an air driven actuator. This 
depressurisation step is outlined in the steps below: 
1. Collection chamber is filled with N2 to a pressure of 50 bar. This 
provides some control over the depressurisation and the diffusion of 
CO2 gas from the solidifying polymer matrix 
2. The disc nozzle is opened for a period of 0.5 seconds allowing a spray 
of molten polymer to exit the mixing chamber to be deposited as solid 
sample in the collection chamber. 
3. The collection vessel is then depressurised . 
4. The process (steps 1-3) is repeated eight times before the product is 
collected from the collection chamber. 
The depressurisation is carried out eight times as it was found to facilitate the 
most efficient collection. The product is collected and ground (Cookworks 
coffee and herb grinder) before sieving through sieves of aperture size 2000 
54 
Chapter 2 
~ m , , 1 000 ~ m , , 800 ~ m , , 500 ~ , , 250 ~ m , , and 1 00 ~ ~ (Fisher Scientific) using 
a Retsch/Copley AS300 shaker to separate the different size fractions. Sieving 
was carried out for 30 mins at an amplitude of90 mm. 
2.2 Scanning Electron Microscopy 
The morphology of the particles was evaluated by scannmg electron 
microscopy (SEM) using a Jeol 6060L V (Tokyo, Japan) variable pressure 
instrument. Prior to analysis samples were mounted on aluminium stubs using 
adhesive double-sided carbon discs. A Balzers SCD030 gold sputter coater 
(AG, Liechtenstein) was used for coating the samples. Coating occurred in an 
argon atmosphere for 4 mins before the SEM analysis was carried out. Image 
analysis was carried out using the in-built SEM control and user interface 
software (version 6.57) and digital imaging system. 
2.3 X-ray Microtomography 
A detailed internal analysis of the particles was carried out using a SkyScan 
1174-V2 X-ray Microtomography System. Micro-computed tomography 
(micro-CT) is a non-invasive technique which creates 2D cross-sections of a 
3D object. It is then possible to reconstruct a 3D image of the object to allow a 
representation of the internal structure to be built. 
This technique found applications in drug delivery as it allows the relationship 
between delivery system structure and its function to be determined [5]. 
MicroCT enables visualisation and quantification of matrix porosity and 
density. Details such as pore size, shape, connectivity, and distribution can be 
revealed [5, 6]. Although microCT has established applications in 
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determination of porosity in polymeric scaffo lds for tissue engineering [7], 
microCT in matrix based drug delivery devices is less well reported [8]. 
In the present thesis particles were mounted on a carbon disc which wa 
attached to a small microCT holder (Figure 2.3) and placed in the scanner. 
Analysis of raw data was carried out using NRecon and CT AN. Scanning was 
carried out at 50 kV and 800 rnA current. Thresholding of the 2D Im ages 
allowed a distinction between polymeric matrix and porous space. 
l1li Particles 
arbon disc 
+---- Small holder 
Figure 2.3 Transmission image demonstrating how the particles are loaded 
into the microCT instrument. 
2.4 Fluorescent Microscopy 
Fluorescence microscopy provides images of a samp le ba ed on it fluorescent 
or phosphorescent properties. The microscope operate by illuminating a 
sample with light of a wavelength known to cau e excitati n of th 
fluorophores. This energy is manifested as emitted light which i much weak r 
and of a longer wavelength than the illumination light a llowing it to be 
distinguished and imaged. In this study particles were imaged u ing a x 
fluorescent microscope (GTVision) equipped with a QImaging Qi camera 
(Fast1394). Fluorescent materials were introduced to the samples for imaging 
in two different methods. Firstly, PLGA particles produced using the P S 
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method were loaded with coumarin 6 (0.5% w/w) during manufacture (with 
the same mass ofPLGA (Resomer, RG502H) being removed. Alternatively the 
mucoadhesive polymer chitosan was fluorescently modified through covalent 
attachment of fluorescein isothiocyanate (FITC) and used to coat the particles 
post processing (process described in Chapter 6). Following imaging analysis 
was carried out using QCapture (version 6). 
2.5 Particle Size Analysis 
The size of the particles was determined using a Sympatec IIELOS/BF particle 
size analyser. In this technique laser light interacts with the particles causing it 
to diffract and as there are different diffraction patterns for different size 
particles, it is possible to determine the size distribution of the sample being 
analysed. The pattern of diffraction can be described using the Fraunhofer 
theory which states that the diffraction angle for a small particle is larger than 
the diffraction angle for a larger particle. This is a result of the small particle 
having a relatively more curved surface. The angle at which the light is 
scattered is inversely proportional to the size of that particle. 
The light that is scattered from the particles is focused onto a detector by a 
lens. A photo-detector acquires an intensity distribution of the diffracted light. 
The data is compared to an optical model. 
In this thesis particles were mixed with 1 % Tween 20 and then added to a 
cuvette containing de-ionised water in the Sympatec lIELOS to be analysed. 
The cuvette is % filled with de-ionised water and 10 drops of tween20 1 %. The 
stirrer is switched on at 1200 rpm and the cuvette added to the laser diffracter. 
Approximately 50 mg of sample is mixed into a paste with tween20 1 %. The 
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surfactant is added in small amounts until the required consistency is reached. 
Using a small spatula the paste is added to the cuvette until the IIELOS 
detector elements box reads an obscuration percentage of 5-35%. The 
measurements are now taken. The instrument is set up to take 3 measurements 
and an average is taken and reported. 
2.6 Helium Air Pycnometery 
The density of the microparticles was measured usmg a Micromeritics 
AccuPyc 1330 helium pycnometer. The apparatus consists of two chambers, 
one is the sample chamber and the second is a standard chamber with a known 
internal volume. The equipment operates by detecting a pressure change 
resulting from the displacement of gas in the chamber by the solid sample. A 
sample of known mass is introduced to the sample chamber and helium gas is 
introduced up to a fixed pressure. The gas is then transferred to the reference 
chamber where the pressure is measured allowing the volume of the sample to 
be calculated using Boyle's law which states that for a confined gas pressure x 
volume is constant. The calculated volume is then used to determine density 
using the following equation: 
Density (g/em) = Mass particles (g) + Volume (em) 
The pycnometer was calibrated with an iron sphere of known volume and the 
method was validated prior to sample analysis. Approximately 0.7 g of the 
sample was loaded into the sample chamber. Each measurement involved 
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purging with helium 5 times up to a fill pressure of 19.5 psig at a rate of 0.05 
psig / min. Density analysis was carried out five times for each sample. 
2.7 In vitro Buoyancy Analysis of Porous Particles 
To determine how effective particles produced using the PGSS method are at 
remaining buoyant in a simulated gastric environment, in vitro buoyancy 
analysis was carried out. 10 mg of particles were weighed out and suspended 
on 10 ml simulated gastric fluid (SGF) (see Section 2.10) in a glass 
scintillation vial. The vials were then placed in a shaking water bath (Fisher 
Scientific) at 120 shakes / min and 37°C for 8 h. Following this time the vials 
were photographed (using a Nikon Coolpix S3000 compact camera) and any 
particles which remain floating on the surface of the media were removed and 
frozen in liquid nitrogen before freeze drying (Edwards Modulyo freeze drier) 
After 3 days dried particles were weighed allowing an approximate percentage 
for amount of particles which remain buoyant using the following equation: 
Percentage of buoyant particles (%) 
(
Mass of particles which remain bUOyant) 
= xl00 Initial mass of particles 
2.8 Differential Scanning Calorimetry 
Differential scanning calorimetry (DSC) measures heat flows associated with 
temperature-induced transitions in materials. It allows the determination of 
specific temperatures associated with thermal events, as when the sample 
undergoes a temperature related physical change more or less heat will need to 
flow to it than a calibrated standard in order to maintain the sample and 
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standard at the same temperature. Whether the heat flow increa es or decreases 
determines whether the change is endothermic or exothermic. 
As an amorphous substance is heated it undergoes a transition from a gla sy 
state to a rubbery state and this is known as a glass transition temperature (T g). 
Figure 2.4 illustrates the T g on a DSC trace as a downward step, indicating that 
it is an endothermic event. As it moves through its T g, a material dramatica ll y 
increases in viscosity and undergoes a transition from the hard and brittle 
' glassy' state to the elastic and flexible ' rubbery ' state. The second thermal 
event in Figure 2.4 is crystallisation. This exothermic event occurs when the 
molecules within a material undergo partial alignment into a crystalline form . 
The third and final peak on the DSC trace is the melting point (T m). As heating 
is continued the material will undergo a state change from solid to liquid thi s 
is an endothermic event. 
Exothermic 
i 
Heat Flow 
(mW) 
t 
Endothermic 
Glass Transition Meltiog Point 
Temperature (DC) 
Figure 2.4 Example of a DSC thermograph illllstrating a glass 
transition, a crystallisation, and a melting point. 
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In this study thermal events were analysed using a TA-Q2000 differential 
scanning calorimeter (TA Instruments), calibrated with an indium standard. 
Typically, 4-5 mg of particles were weighed into aluminium pans (Tzero DSC 
pans) and were hermitically sealed with a Tzero DSC lid using a Tzero press 
containing a Black Tzero lower die and a flat die. Samples were heated at 10°C 
per minute and temperature was ramped from O°C to 150°C followed by a 
cooling cycle back down to O°C the samples undergo two temperature ramp 
cycles. 
2.9 Determination of Drug Encapsulation Efficiency 
5mg of drug loaded porous particles were suspended in 10 ml 1M NaOn and 
left to dissolve completely. Following this the solutions were analysed using 
UVNIS spectrophotometery (Beckman coulter DU800) for absorbance at 450 
nm for riboflavin and 277 nm for furosemide. 300 III of sample was pipette 
into a Tm cuvette 14 mm high (Beckman instruments, inc. USA. Part number 
517481). 
Concentration of drug was determined against a standard curve. 
Drug loading was calculated as a percentage of drug using the following 
formula: 
D I . () (MaSs 0/ drug In particles (mg)) rug oadmg % = M / I l () x 100% ass 0 part c es mg 
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The encapsulation efficiency was then calculated using the following formula: 
(
Actual drug lOading) 
Encapsulation efficiency (%) = Th i II d x 100% 
eoret ca oa ing 
2.10 Preparation of Simulated Gastric Fluid 
Initial drug release studies were carried out in phosphate buffer solution (PBS) 
(Fisher Scientific PBS tablets made Up to 100 mUtablet) at p1I7.4 which allows 
a comparison of the drug release properties with similar systems already in the 
literature, however the system described in this thesis is destined for the GIT 
where conditions are not adequately replicated using PBS at p1I7.4. Therefore, 
a more physiologically relevant media was prepared and used for drug release 
studies. The composition of the gastric fluid (as described in detail in Section 
1.2.1 is highly variable and complex however a simplified 'simulated gastric 
fluid' (SGF) was prepared in line with the US pharmacopoeia [9] and consists 
of 2.0 g sodium chloride and 3.2 g pepsin dissolved in 7.0 ml hydrochloric 
acid (HCl) (5M) and sufficient deionised water to make 1000 ml. The final 
solution is made to pH1.2 using 5M Bel. 
2.11 Drug Release studies 
The release of the drugs furosemide, riboflavin, and metformin from the drug 
loaded particles was investigated over a period of 24 hours. 10 mg of drug 
loaded particles weighed out in triplicate were introduced to 20 ml scintillation 
vials. 10 ml of release media was added to the vials and they were placed in a 
shaking water bath (Fisher Scientific) at 37°C and 120 shakes / minute. Three 
different release media were prepared, phosphate buffer solution (pII7.4), 
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phosphate buffer solution adjusted to pH2.0 using 5M lIel, and Simulated 
Gastric Fluid (SGF) (Section 2.1 0). 5 0 0 ~ 1 1 samples were pipetted out of the 
release media and replaced with fresh media at 10, 20, 40, 80, 160, 320, 600, 
1440 mins. Each sample was analysed using UVNIS (as described above 
(Section 2.9» at the following wavelengths; furosemide loaded samples were 
analysed at 277 nm, riboflavin samples were analysed at 450 nm, and 
metformin samples at 233 nm. 
2.12 Time of Flight Secondary Ion Mass Spectrometry 
A surface analysis ofpartic1es was carried out using Time-of-Flight secondary 
ion mass spectrometry (ToF-SIMS) N instrument (ION-TOF GmbH Munster, 
Germany) equipped with a liquid metal ion gun (LMIG) with a Bi) + cluster 
primary ion source. This technique allows detailed analysis of the composition 
of the surface material in a sample, usually to a depth of approximately 1 nm 
[10], however the individual nature of samples makes it difficult to accurately 
estimate the depth of analysis. 
In this technique an area of the sample is bombarded with primary ions, in this 
case Bi) +, the impact of the primary ions on the sample surface results in the 
fragmentation of ion species from the surface material which, in tum, results in 
the emission of secondary ions (Figure 2.5). Both negative and positive 
secondary ions are emitted from the sample. The ions will then travel through 
an ultra-high vacuum towards a detector along an electric field of known 
strength which allows all ions of the same charge to have the same kinetic 
energy which is important as it is the mass of each ion which is of interest and 
at the same kinetic energy it is the mass/charge ratio which determines the 
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velocity of the ion so the heavier ions will travel more slowly and reach the 
analyser later. The time it takes to reach the detector and the known operating 
conditions make it possible to separate out the ions. 
The operating conditions involved primary ion energy of 25 kV and a pulsed 
target current of approximately 1.0 pA. Low energy electrons (20 eV) were 
used to compensate for surface charging which is a result of the primary ion 
bombardment on insulator surfaces. A raster area of typically 500 Ilm2 was 
analysed and data analysis was carried out using IonSpec and Ionlmage 
(version 4.1). 
• o 
o 
I e 
Figure 2.5 Schematic diagram of the ToF-SIMS process illustrating the 
liberation of secondary ions from the sample surface. 
ToF-SIMS has been applied in the analysis of controlled-drug d livery y terns 
[11] exposing the distribution of active pharmaceutical ingredient within a 
deli very system. 
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2.13 Depth Profiling 
As a surface technique ToF-SIMS does not provide information on any 
material below the initial layers. Depth profiling acquires this data by 
analysing the surface of the sample followed by erosion of the surface to reveal 
a new layer of material (Figure 2.6). The new surface layer is then analysed 
and the cycle is repeated. 
As described above, the ToF-SIMS technique detects secondary ions liberated 
from the sample following disruption of the surface by a primary ion beam, the 
technique itself is therefore causing disruption to the surface. Depth profiling 
exploits this and the relatively heavier ion C60+ is used in place of Bi3+ a the 
heavier ion is capable of a more efficient disruption of the surface. 
Figure 2.6 Diagram illustrating the depth profiling process. The analysis is 
. d b h B ·3+ · • . I h AO+ I' .r, carne out y tel pTlmary IOn !Vltrl teL · revea mg a new SllrJace 
layer. 
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Chapter 3 
Particle Manufacture and Optimisation for 
Gastroretention 
3.1 Introduction 
In the literature, floating fonnulations are separated into two distinct groups. 
The first being the effervescent systems, these produce gas on contact with the 
gastric media [1, 2]. The entrapment of produced gas within effervescent 
systems leads to a buoyancy effect through a decrease in density. As 
previously discussed (Chapter 1, Section 1.4.5), a major limitation of this type 
of delivery system is the lag time between the initial contact with the gastric 
media and the time the floating behaviour is exhibited. If this lag time is 
extended for too long there is the potential for the loss of the entire dose. The 
second group of floating systems includes those which do not effervesce, but 
posses characteristics which convey buoyancy in the gastric media. These 
characteristics include low density, with low density systems demonstrating 
good promise in the improvement of bioavailability of orally delivered drugs 
[3-5]. 
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Buoyant (low density) microparticulate systems can include porous 
microparticles [6] or hollow microspheres [7,8]. Instances where such systems 
have demonstrated promise in gastroretention include porous polypropylene 
microparticles loaded with ibuprofen, which were successfully optimised for 
gastroretention. The system achieved a time-dependant delivery for the 
treatment of arthritis symptoms [6]. Hollow polymeric microballoons of >500 
11m size, loaded with riboflavin (6% (w/w», possessed promising buoyancy 
following dispersal in a simulated gastric fluid [7] with 97% of the formulation 
remaining buoyant after 4 h. Riboflavin excretion half-life with the floating 
formulation was observed to correlate to the buoyancy of the system [7]. This 
correlation between buoyancy and extended urinary excretion indicated the 
importance of low density of the formulation. In another study, promising in 
vivo performance of rosiglitazone loaded Eudragit based multi-unit floating 
microparticles was reported [8]. The microparticles demonstrated 65-96% 
buoyancy following 24 h in SGF, in addition to high rosiglitazone entrapment 
efficiencies (78-97%) and sustained release behaviours over 12 h [8], this 
formulation demonstrated good glycaemic control in a rat model. The above 
studies confirm that low density systems improve therapeutic potential of 
formulations. This chapter focuses on the optimisation of a low density oral 
delivery system using a novel supercritical fluid technology. 
Multi-unit systems, such as microparticles, may have a greater potential for 
success in gastroretention when compared to their single unit counterparts. 
Single-unit systems are limited by an 'all or nothing' principle, whercby if the 
gastroretention effect fails, the therapeutic performance will be compromised 
[2]. The production of microparticles for a variety of drug delivery purposes 
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has been subjected to much research and has been reviewed previously [9-12]. 
The different techniques in particle production are discussed in further dctail in 
Chapter 1 (Section 1.5). 
Recently, supercritical fluid techniques have provided a solvent free route to 
the production of particulate formulations. Due to favourable critical 
conditions (Pc=73.9 bar Tc=31.l °C), as well as low cost, and low toxicity, 
SCC02 is often used in these techniques. There are several reviews in this area 
discussing the different approaches to particle development applying 
supercritical fluids, in particular COz [13-17] and have been discussed in this 
thesis in detail in Chapter 1 (Section 1.5). The PGSS technique in particular 
holds great promise in the preparation of particles for drug delivery, as it 
requires no organic solvent and it does not rely on the solvent or anti-solvent 
capabilities of SCC02 instead exploiting the ability of scCOz to act as a 
plasticiser [18-20] . 
The PGSS method was originally designed for powder coatings [21], however 
it has since been applied in the food industry [22] and, more recently, in the 
development of pharmaceutical products [23-27]. This technique utilises 
scCOz as a plasticiser for biodegradable polymers, by dissolving into materials 
and reducing their glass transition temperature (T g) to allow plasticisation to 
occur at relatively low temperatures and pressures. Drug, in the form of solid 
particles, can then be mixed into such a polymer melt. When plasticisation 
occurs at low temperatures (often more than lOoC below the polymcrs usual T g 
[28]) the method offers a possibility to encapsulate thermally unstable drugs, 
including proteins [27]. The homogenous mixture of liquefied polymer and 
drug particles is rapidly depressurised though a nozzle into a collection 
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chamber, upon depressurization the CO2 returns to the gaseou tate and the 
polymer solidifies producing drug encapsulated polymer particle . Thi 
process is illustrated in figure 3.1. 
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Figure 3.1 Schematic of the PGSS process f29} 
The depressurisation step is integral to the success of the P in fabricati n 
of gastroretentive systems. As the CO2 returns to th gaseou tate, it diffu 
out of the solidifying polymer leaving behind a porou , netw rk within th 
matrix. This property is behind the formation of porous scaffo ld aimed for 
ti ssue engineering applications [30] . This porous matrix may poss s 
decreased density properties, the fundamental characteri tic which nv y 
gastroretention. 
Biocompatible polymers such as PEG [26, 31] and PL A [27] ar oft n 
selected for processing in the PGSS method. These polymer arc appr ed ~ ~ r 
use in medical preparations such as drug delivery sy terns, implant and 
sutures. The selection of material used in PGSS proces ing ha a profound 
effect on the morphology of the product [32]. It has been reported that the 
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viscosity of the polymer melt impacts the morphology of the final product 
[33]. More viscous polymers undergo atomisation during the depressurisation 
less efficiently than less viscous polymers, resulting in little or no yield, or a 
fibrous product [34]. 
Size of delivery systems has previously demonstrated to impact gastric 
residence time, an increase in size up to 5 mm in diameter has been reported to 
increase gastric residence time [35], and solids may only empty from the 
stomach if they are smaller than 2 mm [36]. It has been reported that particles 
larger than this do not demonstrate any difference in gastric residence [37]. A 
comparison of the GI transit of small (0.5 mm) and large (4.75 mm) pellets 
was examined using gamma scintigraphy and although gastric emptying was 
found not to be affected by size, small intestinal residence time was prolonged 
by the larger pellets [38]. This chapter considers the effect of particle size on 
potential particle buoyancy enabling optimisation of gastroretention. 
3.2 Materials and Methods 
3.2.1 Materials 
PLGA (Resomer® RG502H -12KDa free carboxylic acid end group and 
RG503 -25KDa ester end group) was supplied by Boeringher Ingleheim. 
Myristic acid, SP AN80 was purchased from Sigma Aldrich. C02 
(pharmaceutical grade 99.9%) and Nitrogen were supplied by DOC. All 
reagents were used as received. All water used for the preparation of solutions, 
and subsequent dilutions, throughout this thesis was deionized and purified. 
Produced using an Elgastat system (Elga, High Wycombe, UK) (15 M!lcm 
resistivity). 
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3.2.2 Methods 
3.2.2.1 Particle Production 
Particles were prepared using the PGSS method as described in detail in 
Chapter 2 (Section 2.1). In this chapter no drug was introduced to the particles 
and each 2 g batch contained a combination (as described) of PLGA and 
processing aids. 
3.2.2.2 Scanning Electron Microscopy 
SEM was used to assess the morphology of particles as described in Chapter 2 
(Section 2.2). 
3.2.2.3 Particle Size Analysis 
Laser diffraction was used to determine the size distribution of the 
microparticles prepared. This method is described in detail in Section 2.5). 
3.2.2.4 Helium Air Pycnometry 
Density was determined using helium air pycnometry as described in Chapter 
2 (Section 2.6). The method allows the density to be assessed from a known 
mass of the sample and a determined volume of the sample. The volume of the 
sample is determined by the amount of space in a calibrated volume the sample 
occupies, with helium gas being used to make a comparison of space occupied 
in an empty sample holder and the holder containing the sample. 
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3.2.2.5 In vitro Buoyancy Analysis 
Ability of the different formulations to exhibit adequate buoyancy in a 
simulated gastric environment was carried out as described in Chapter 2 
(Section 2.7). 
3.2.2.6 X-ray Microtomography 
Porosity was determined both quantitatively and qualititatively using microCT 
as described in Chapter 2 (Section 2.3) 
3.3 Results 
3.3.1 Effect of Myristic Acid Content on Particle Morphology 
Particles were initially produced using PLGA (Resomer® RG5021I) with an 
approximate molecular weight of 12 KDa. This polymer has previously been 
well characterised in the PGSS method in the production of controlled release 
drug delivery particles [27]. Initially, processing 100% (2g) PLGA produced a 
very low yield (see Figure 3.2) and therefore the fatty acid, myristic acid, was 
incorporated into the formulation as a processing aid. The presence of myristic 
acid in the formulation was found to improve processing of the mixture. Figure 
3.1 confirms the increasing myristic acid content in the particles improves the 
yield with particles made solely of myristic acid having a yield of 65%. 
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Figure 3.2 Percentage yields of particles as myristic acid content increases. 
(n=J) 
The changing morphologies of particles, as the PLGA: myri tic acid ratio was 
investigated using SEM, are illustrated in Figure 3.3. With incr asing myri tic 
acid content the particles assume a more ' fluffy ' appearance and appear to 
form aggregates. Formulations possessing higher PLGA content r v al larger 
more discrete structures. 
The particle size analysis, using laser di ffraction a de crib d in ection 2.5 
does not appear to conclude a specific trend in PLGA content effect n particle 
size (Figure 3.4). SEM images (Figure 3.3) demon trate that myri ti ac id 
particles form aggregates and it is likely that aggregation f th particl 
containing myristic acid may confound the re ults. 
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Figure 3.3 SEM images of particles prepared with different ratios of PLGA: Myristic acid. Scale bars in 
and bottom row 100JJm 
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Figure 3.4 i) Cumulative Size distribution profile of particles prepared with 
various PLGA: myristic acid ratios ii) corresponding differential curve for 
the formulations 
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3.3.2 Effect of Myristic Acid Content on Gastroretentive Potential 
Following analysis of the morphology of the microparticles their uitab ility a 
gastroretentive systems was investigated. The density data (Figure 3.5) 
demonstrates the increase in PLGA polymer content lead to an iner a e in 
measured density of particles. 
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Figure 3.5 Density of particles produced with increasing PLGA polymer 
content. (n=6 ± SD) 
To evaluate whether this increase in density i refl ected by th floating 
behaviour of the particles an in vitro buoyancy te t wa mpl y d. 
Photographs confirm that particles prepared with variou ratio f PL A and 
myristic acid, have densities which are too high for buoyancy to b a hi 
the gastric media (Figure 3.6). The photograph how a large pr p rti n f 
particles remaining in suspension with the u pending buffer to appearing 
turbid. The images do show a fraction of particle at each formulation pr ent 
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towards the surface of the media this may be due to the surface ten ion and the 
hydrophobicity of the myristic acid component of the particles. 
0:100 25:75 50:50 75:25 100:0 
Figure 3.6 Photographs illustrating the behaviour o/partic/es witll 
different PLGA: myristic acid ratios 
3.3.3 Changing Formulation 
Following the poor buoyancy obtained with the PLGA: myri ti acid bl nd 
alternative processing aids and polymers were incorporat d into th 
formulation . The higher molecular weight PLGA (Re mer® R 50 ) wa 
introduced along with the myristic acid as the higher intrinsic vi c ity (0. 2-
0.44 dUg compared to 0.l6-0.24 dUg with the RG502H PL A) may re ult in a 
larger product capable of containing more pores. However th high vi sity 
reduces the like lihood that the mixture will be sprayed th ugh thc 0.5mm dis 
nozzle, this is confirmed in Table 3.1 and as a re ult a new proc ing aid 
SPAN™gO was introduced and various combinations of th e ipient wcr 
processed using PGSS and the density of any product collected cvaluat d. 
78 
IMAGING SERVICES NORTH 
Boston Spa l Wetherby 
West Yorkshire l LS23 7BQ 
www.bl,uk 
MISSING PRINT 
Table 3.1 Investigation ofpolymer blends and processing parameters in order to find a suitable ( 
gastroretention using particle density values obtained from helium air pycno, 
Polymer %(w/w) of Processing aid % (w/w) of Processing aid Temperature (OC) 
pOlymer 
RG503 50 Myristic acid 50 40 
RG503 58 SPAN80 42 40 
RG503 75 SPAN80 25 40 
RG502H 50 SPAN80 50 40 
RG502H 80 SPAN80 20 40 
RG502H 85 SPAN81 15 40 
RG502H 1 RG503 65% 110% Myristic acid 25 40 
RG502H 1 RG503 70%1 25% SPAN80 5 40 
RG502H 1 RG503 50%/20% Myristic Acid 30 60 
RG502H 1 RG503 55%1 30% SPAN80 15 60 
RG502H 1 RG503 65% 110% SPAN80 25 60 
RG502H 1 RG503 75%/20% SPAN80 5 60 
79 
hapler 3 
3.3.4 Effect of Particle Size on Potential Gastroretentive Behaviour 
A fonnulation was selected based on yield and density, and was sieved to 
produce discrete size fractions from 100 )lm to 2000 )lm. These part icle wer 
then analysed for morphology, density, and porosity. The effect of s ize on 
porosity and subsequent density was assessed. 
d) 
Figure 3. 7 SEM images showing particles prepared witll PLGA (/2KDa): 
PLGA (5KDa):SP AN80 (ratio 70:25:5) of different size fractions a) 1 111111 
(scale bar 200 11m) b) 800/-lm (scale bar 200 11m) c) 500 pm (scale bar 500 
11m) d) 250/-lm (scale bar 200 11m) e) 100 pm (scale bar JOO 11111). 
The SEM (Figure 3.7) images provide evidence for the urfa morph logy f 
particles; x-ray microtomography (micro T) allowed a more detailed 
exploration of the microarchitecture of the particle to be arri d out. 
Figure 3.8 shows the porosity (given as a percentage of total particle pace) ~ ~ r 
the different size ranges from 100 )lm up to 2000 /lm a determined u ing 
microCT. The profile shows that the larger particles have a gr ater percentage 
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porosity and there appears to be a large jump between tho e particle <500 /lm 
and those which are >500 /lm. The larger sized particles express extremely 
high porosity values of around 60%. 
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Figure 3.8 Porosity o/microparticles with increasing size as measured 
using microCT (n=6 ± SD) 
Both density data and in vitro buoyancy data are presented in F igur 3. 
confirming that the smaller, less porous (as determined by micro T) part icle 
possess higher densities and subsequently demon trate poorer p rformanc 111 
the in vitro buoyancy investigation. Photograph w re tak n of the parti Ie 
following 6 h suspension in SGF and are presented in Figur 3.10. h 
photographs confirm the conclusion provid d by Figur and a 
particles larger than 500 11m remain buoyant fo llowing 6 h exp ur 
simulated gastric media. However particles smaller than 500 11m b gin to I e 
buoyancy and particles smaller than 250 11m do not demon trate u ce fu l 
buoyancy over the time period (6 h). 
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Figure 3.9 The relationship between particle density (n=6 ±SD (blue)) and in 
vitro buoyancy (n=3 ±SD) (red) behaviour for a range of particles sizes. 
Density determined as described in section 3.2.2.4 and buoyancy determined 
as described in section 3.2.2.5 
i) ii) iii) iv) v) vi) 
Figure 3.10 In vitro buoyancy test f or different sized particles i) 100 IJ In ii) 
250 IJm iii) 500 IJm iv) 800 IJm v) 1000 IJm vi) 2000 IJIIl in a simulated gastric 
medium. 
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3.4 Discussion 
Many materials have demonstrated processability in the PGSS, and similar 
supercritical fluid based processes, including polyolefins, fluoropolymers, poly 
amides and biopolymers, these have previously been reviewed [32]. The PGSS 
process requires the polymer matrix to be liquefied in the mixing chamber to 
allow the supercritical C02 to dissolve into the polymer where it acts as a 
plasticiser decreasing the Tg of the polymer. Including processing aids in the 
formulation may decrease the viscosity of the melt and allow more efficient 
mixing and spraying. 
PLGA has previously been well characterised in the PGSS method and has 
been shown to produce microparticles suitable for controlled release drug 
delivery [27]. PLGA was therefore selected as the polymer in this study to 
form the microparticle matrix. However, the high viscosity of the PLGA 
(inherent viscosity 0.16-0.24 dl/g) led to processing difficulties and relatively 
low yields of 35% (Figure 3.2) and irregular fibrous structures (Figure 3.3) 
being obtained. As a consequence to the low yields achieved with formulations 
containing 100% PLGA the fatty acid myristic acid was incorporated with the 
intention of lowering the viscosity of the polymer melt allowing for easier 
processing and the production of higher yields. 
The changing morphologies of particles as the PLGA: myristic acid ratio is 
altered as revealed by SEM imaging is shown in Figure 3.3. The presence of 
myristic acid resulted in particles which appeared smaller, with an increased 
tendency to form aggregates with an almost 'fluffy' morphology. The usc of 
fatty acids has previously been reviewed in the production of solid lipid 
nanoparticles [39]. Specifically, myristic acid has been successfully processed 
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using the PGSS method as the supercritical conditions depress the melting 
point of myristic acid from 54.3°C to 39-40°C [40]. As the ratio ofPLGA in 
the formulation increases the particles become more discrete and appear larger. 
On scrutiny of the SEM images porosity is also apparent in the particles. 
Particle yield data presented in Figure 3.2 demonstrates that although 
increasing the myristic acid content in the particles the yield can be improved 
from 35% to 65%. However as the myristic acid content increases other 
properties of the system such as controlled release may be compromised. The 
myristic acid may act as a processing aid improving yield in a similar way to 
poloxamer 407 and 188 and Solutol liS 15 which have been introduced as 
processing aids in the PGSS method [27]. These processing aids were 
employed to improve the drug release characteristics of human growth 
hormone (hGH) loaded PLGA microparticles which demonstrated maintenance 
of hGlI in rat serum for 3 days. The addition of PEG to PLA in the pass 
process has been observed to decrease the viscosity of the melt. A decrease in 
viscosity was measured as the two materials became increasingly miscible. 
This miscibility was also found to have a direct effect on the processing of the 
blend of the two polymers [28]. In the present work, myristic acid may be 
acting in a similar way improving particle production though a decrease in 
viscosity of the polymer melt. 
As the PLGA content increases relative to myristic acid the density of the 
microparticles was found to increase (Figure 3.5). Helium air pycnomctry was 
selected to measure density as it allows a measure of the true volume of the 
system to be determined, taking into account the porous space. Due to its small 
size, helium gas is used to diffuse into the smallest pores and may also diffuse 
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between the polymer chains. This provides a true measure of the exact volume 
of polymer matrix which is then used along with a known mass to determine 
density of the particles. The results conflrmed that the lowest densities found 
in particles prepared with 100% myristic acid exhibit densities higher than 1 
gcm-3• The reported density of myristic acid as a pure material is 0.8622 gcm-3 
indicating that during processing the density of myristic acid actually may 
increase. This is not the case for PLOA as the pre-processing density was 
measured as 1.4793(±0.0199) gcm-3 with a decrease to 1.2611(±0.0016) gcm-3 
being measured following processing. 
Reports in the literature state that the density of the gastric fluid is in the 
region of 1.004 gcm-3 [41] therefore a system suitable for gastroretention in 
this environment must demonstrate a density of less than this value. Figure 3.5 
shows photographs of the particles in suspension in a simulated gastric fluid 
offering an illustration as to how successful these particles will be as floating 
drug delivery systems. Whilst all formulations show a fraction of particles 
appear to remain buoyant the majority of the particles are in suspension or 
simply sink to the bottom of the vial suggesting these formulations may not be 
appropriate for gastroretention. Nevertheless the decrease in PLOA density 
following processing indicates the potential of the POSS method to reduce 
density of starting materials and therefore produce particles with low densities. 
Porosity data, as measured using microCT (Figure 3.8) reveals porosity can 
exceed 50% supporting the claim that the POSS method has the capacity to 
produce a highly porous product. In order to achieve the appropriate low 
densities a highly porous product must be fabricated. In the POSS method the 
pores are formed during the depressurization step, the supercritical carbon 
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dioxide is dissolved into the plasticised polymer which on depressurisation will 
return to the gaseous state and diffuse out. Simultaneously the plasticised 
polymer will be solidifying and therefore the gaseous carbon dioxide will leave 
behind open spaces the introduction of a nitrogen back pressure enables this 
step to be controlled as the presence of a back pressure slows down the 
diffusion of C02 from the product allowing the production of microparticles 
[34]. 
Due to the high densities of particles produced with the PLGA / myristic acid 
blend these particles were deemed to be unsuitable for gastroretention (Figure 
3.5 and Figure 3.6) subsequently other materials were investigated with the 
aim of producing particles with lower densities. Table 3.1 demonstrates the 
various formulations attempted in the pursuit to produce particles with high 
yields and low densities. Initially, the surfactant SP AN™80 was introduced in 
place of myristic acid; by changing the processing aid the particles produced 
may be more suitable in terms of yield and density for the aims of this project. 
The SPANTM80 has a lower melting point than myristic acid (-20.3°C 
compared to 54.4°C) and demonstrates a lower viscosity than myristic acid. 
Such properties may enhance the processing aids ability to improve PLGA 
processing. Nevertheless, the particles containing SPANTM80 and PLGA did 
not produce high yields and any product was soft and adhesive at room 
temperature and therefore could not be collected. As a next step a higher 
molecular weight PLGA polymer, which maintains the 50:50 lactide: glycolidc 
ratio but has an approximate molecular weight of ...... 25 kDa was included. This 
polymer is more viscous, with an inherent viscosity of 0.32-0.44 dVg compared 
to 0.16-0.24 dVg of the PLGA with a lower molecular weight. As a result of 
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this increased viscosity this polymer does not produce any product following 
PGSS processing, however in combination with a processing aid such as 
SP AWM80 it is possible to produce a product with a yield of around 60% 
(Table 3.1). 
The formulation demonstrating good yields (61.4% ± 3.S), with a highly 
porous product and the potential for buoyancy in the gastric medium has a 
composition of RGS02H 7S%, RGS03 20%, SPAN 80 S%. This formulation 
was processed, and the product ground to produce a particulate product which 
was sieved into various size fractions. 
Previously it has been reported that larger particles demonstrate longer gastric 
residence times [42], as the smaller particles are likely to get emptied from the 
stomach along with food particles during digestive processes. In the present 
work a wide range of size fractions were considered and analysed for 
prospective use as gastroretentive systems. The SEM images in Figure 3.7 
show the morphologies of the different size fractions. Although the particles 
are irregular in shape the presence of pores at the surface appears to be 
conserved in all size fractions. 
The density of the various size fractions was investigated using helium air 
pycnometry. As previously discussed, the density of a system suitable for 
gastroretention is <1.004 gcm-3• The relationship between size, density, and 
buoyancy was investigated with particles larger than 2S0 J.lm being revealed to 
remain buoyant in the gastric environment. This was verified using an in vitro 
buoyancy analysis in which the > 1 00 J.lm size fraction did not demonstrate 
adequate buoyancy and as the size is increased the percentage of particles 
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which remain buoyant also increased (Figure 3.8) . In order to better under tand 
the fundamental differences between particles of different size which may 
contribute to the changes in density, the detailed microarchitecture of th 
particles was examined using microCT. This data demon trate that a the 
particle size increased the percentage porosity also increa ed, (Figure 3.10) thi 
decreased the density of the particles. The presence of pore in the product i a 
result of the phase changes of the CO2 and the polymer on depr suri at ion and 
is therefore difficult to control. The grinding of the product may be the ba i 
of the decreased porosity of the smaller particles. Grinding and milling are 
common processes in many industries, in the food industry air hole pr ent in 
material has been found to provide cleavage tep [43] influ ncing particle 
shape following milling. Fracturing is more likely to occur along line of 
weakness, this would include existing pore . Smaller particle will conta in 
fewer pores and the larger particles are able to harbour more and larger pore 
this concept is illustrated below in Figure 3.11. 
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Figure 3.11 Illustration of how the grinding procedure results in a number 
of smaller particles (b)) with lower porosity than the original larger particle 
(a)). 
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3.5 Conclusions 
The effect of material on the yield and morphology of the product was initially 
investigated, with the choice of polymer and the composition of the 
formulation being found to affect the yield and morphology of the product. 
Initially, particles prepared using PLGA and myristic acid were investigated, 
however helium air pycnometry quantitatively revealed that the density of 
these particles was not acceptable for gastroretention. Conclusions drawn from 
the density data was verified by investigating the floating ability of the 
particles in a simulated gastric fluid at 37°C under constant agitation in a 
shaking water bath for 6 h. This confirmed that none of the PLGN myristic 
acid formulations were suitable for gastroretention. New formulations were 
explored in an attempt to produce particles with lower densities. The most 
porous formulation tested was 75% RG50211 (PLGA 12 kDa 505:50 LA:GA 
ratio) 20% RG503 (PLGA 24 kDa 50:50 LA: GA ratio) 5% SPAN80 and 
following production the product was ground and sieved to produce discrete 
size fractions. 
The size of the microparticles was found to affect the capacity of the system to 
demonstrate adequate floating behaviour in the gastric fluid. SEM images 
confirmed that porosity is evident in all size fractions, and microCT provided a 
more detailed insight into the nature of the internal porosity of the 
microparticles. Pores were found to exist at all size fractions, however, the 
larger particles were found to be more porous than the smaller particles. The 
porosity data along with the in vitro buoyancy studies confirmed those size 
fractions which are suitable candidates for gastroretention are the particles 
>500 Jlm. 
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Large porous structures have previously been prepared using supcrcritical 
fluids in the area of tissue engineering, however the production of large, 
porous micropartic1es for gastroretention using this method, has not as far as 
the authors are aware previously been investigated. 
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Chapter 4 
Incorporation of Active Pharmaceutical Ingredient into 
Particles Produced using the PGSS Method 
4.1 Introduction 
Oral administration for therapeutics in many cases is highly desirable from the 
point of view of the patient and health care professional alike, however 
limitations of these systems often lie with poor bioavailability [1, 2]. The low 
bioavailability of drugs administered via the oral route can be a result of the 
barriers the drug must overcome from the intestinal lumen in order to reach the 
systemic circulation. In order to reach the circulation this journey involves the 
absorption through the intestinal wall. For many drugs, including furosemide, 
riboflavin, acyclovir, captopril, levodopa and metformin [3], the absorption 
occurs at a relatively narrow area of the upper small intestine, within a so 
called absorption window (as discussed in Section 1.2.2.3). This presents a 
problem when considering relatively rapid gastric transit times. The 'house 
keeper' wave (discussed in more detail in Section 1.2.2.2) occurs every 1-2 h 
in the fasted state [4] and serves to remove debris from within the stomach. 
Such peristaltic waves usually carry the delivery system past the absorption 
window. For instance, ranitidine has been reported to exhibit absorption in the 
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upper part of the small intestine and demonstrates an oral bioavailability of 
50% of the administered dose [5]. Although 50% is considered an adequate 
value for oral bioavailability, the oral bioavailability has been improved 2.4 
times using a gastroretentive floating formulation [6]. Similarly, an 
approximate 210% increase in oral bioavailability for riboflavin has been 
reported for a gastroretentive system, relative to a 'classical' immediate release 
formulation [7]. This was achieved through gastroretention over a period of 
approximately 10 h. The diuretic drug furosemide has a reported oral 
bioavailability of 40-60% [8]. This has been increased by a mucoadhesive 
formulation which demonstrated an AVe value 1.8 times larger in comparison 
with a non-adhesive formulation [3], once again indicating an improvement in 
bioavailability through gastroretention. These studies illustrate the potential 
that novel formulations may hold in improving oral bioavailability. 
Gastroretentive delivery systems potentially increase drug bioavailability by 
retaining the delivery system in the stomach, above the drug absorption 
window, typically located in the upper small intestine. If the system is in the 
same time capable of exhibiting controlled release of the drug, it would 
provide a 'stable' supply of drug to the absorption window. Examples of 
gastroretentive delivery systems have been recently reviewed [9]. Although 
good success has been reported with different gastroretentive formulations, 
there are many factors that need to be considered for a formulation to be 
effective. 
Gastrointestinal transit is a major factor when developing gastroretentive 
systems; it is the motility along the GIT which must be overcome in order for 
the delivery formulation to remain in the stomach. In an average human, the 
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time taken for stomach contents to pass into the intestines is around 4 h [10], 
although this value is highly variable and may be as fast as 10-15 mins for 
water or up to 6 h for a barium meat meal 
A recent publication demonstrated a mean gastric retention period of 5.5 ± 0.8 
h for a controlled release floating tablet [11]. A comparable period of gastric 
retention (5.50±0.77 h) was reported for effervescent floating matrix tablets 
containing baclofen [12]. Other gastric-floating drug delivery systems based on 
bilayer tablets have reported gastric residence times of 6 h [13], and values in 
excess of 8 h have been reported for floating matrices of metronidazole [14]. 
However high intersubject variability in gastric residence times has been 
observed as well as day-day intrasubject variability [15, 16]. Physiological 
factors such as composition and volume of stomach content, gastric content 
transit times, pH levels, presence of food along with the specific composition 
of consumed material, gender and age all influence gastric emptying [17]. The 
presence of food in the stomach affects gastric transit time and therefore exerts 
an impact on drug bioavailability [18, 19] by influencing drug solubility, 
gastric transit, and delivery system disintegration. 
Gastric pH is another important factor, which can impact both, the solubility of 
the drug and the stability of the delivery system [20, 21]; this is a particular 
concern with gastroretentive systems which remain resident in the stomach at a 
low pH for prolonged periods. 
This chapter focuses on the development of the system previously described in 
Chapter 3 as a drug delivery system for the sustained release of active 
pharmaceutical compounds over the period of time the system will remain 
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resident in the stomach (- 6 h). The model drugs selected for in vitro release 
studies, furosemide and riboflavin (chemical structures are presented in Fig. 
4.2), both demonstrate narrow absorption windows in the upper small intestine 
and therefore could benefit from gastroretentive technology. Furosemide is a 
highly potent diuretic which inhibits chloride reabsorption in the loop of 
Henley in the kidney; this in turn prevents sodium reabsorption. It is used in 
the treatment of congestive heart failure and oedema. Various sustained release 
formulations for furosemide include hydroxypropylmethyl cellulose (IIPMC) 
matrix tablets [22] which demonstrate good sustained release properties, 
however, as furosemide is absorbed in the upper small intestine, sustained 
release formulation is not an ideal solution, unless coupled with 
gastroretention. A prolonged release unfolding gastroretentive formulation of 
furosemide has shown improvements in pharmacokinetics in humans 
compared with immediate release, unfolding, counterpart [23]. Floating 
formulations of furosemide, based on gas generating sodium bicarbonate and 
an outer layer of polymethacrylates, have demonstrated sustained rc1ease over 
10 h and a gastric residence time of 6 h [24]. 
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Figure. 4.1 Chemical structures for a) Furosemide and b) Riboflavin. 
Solubilities 0.006 and 0.01 mg/ml respectively 
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Riboflavin, also known as vitamin B2, plays a key role in energy metabolism. 
Riboflavin is often used as a model drug for gastroretentive formulation 
development, as it is a suitable candidate with known absorption window and 
relative safety. Enhancement of bioavailability of riboflavin has been 
demonstrated in dogs [25], as well as humans [7], through the use of 
gastroretentive systems based on an unfolding formulation. Floating 
microballoons containing riboflavin have demonstrated good gastroretention in 
man [26] although this was found to be dependent on filling state of the 
stomach. 
The release of the drug from a gastroretentive formulation should ideally be 
sustained for the duration of the formulation's presence above the absorption 
site in the intestinal tract for that particular drug. In vitro investigations into 
the release profiles of drugs from gastroretentive formulations have reported 
sustained release for approximately 9 [27], 8 [28], or up to 24 [29] h. These 
periods should correlate with the expected time the system will be resident in 
the stomach/above the absorption window. Otherwise, any subsequent release 
of the drug will not contribute to the absorptionlbioavailability. 
Regarding the drug release, the size of delivery formulation has been found to 
impact the release of drugs from PLGA microparticles [30]. For instance, the 
release of dexamethasone from PLGA microspheres of two different sizes, 1 
Ilm and 20 Ilffi, showed that, although the burst release from the smaller 
microspheres was high (around 20% of the encapsulated dose), the cumulative 
release over the course of the study (550 h) was only 30%. In contrast, 20 11m 
microspheres demonstrated an almost linear drug release up to 90% over 550 h 
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with very little initial burst [31]. 5-Fluorouracil-loaded, poly(lactic-co-glycolic 
acid)-based microparticles also demonstrated a trend for slower release with 
smaller particle sizes [32]. Although at the final time point (21 h) the release 
from all size fractions was at 100% the smaller particles «36 J..lm) 
demonstrated a slower rate with only 50% released after 7 h, whereas the 
larger particles (125-72 J..lm) revealed approximately 80% release after 7 h. 
The faster release rate from the larger particles in the above examples may be 
surprising as it is more common for PLGA microparticles to demonstrate a 
decrease in drug release rate with larger particles [33]. This decrease does not 
appear as pronounced in microparticles demonstrating high porosities [30]. In 
order to explain this release behaviour, changes in T g of the small and large 
particles over the course of the release study were assessed. T g decreased faster 
with time for the larger particles (reduction to 25°C for 73 J..lm particles and 
45°C for 7.3 J..lm particles over 30 days) which may indicate an increased rate 
of polymer degradation in the larger particles. This increase in PLGA 
degradation rate in larger particles has been reported previously [34]. With the 
rate of drug release being influenced by the size of particle, this presents a 
parameter which should not be overlooked when optimising release rate from a 
novel system. 
The release profiles of the two model drugs from particles of various sizes 
(prepared as detailed in Chapter 3) will be investigated in this chapter. The 
release profile will be discussed in the context of the morphological changes of 
the particles following exposure to the release media at different pH levels, 
PBS (at pH 7.4) and SGF (at pH 1.2). 
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4.2 Materials and methods 
4.2.1 Materials 
Furosemide was obtained from VWR International ltd, and riboflavin was 
obtained from Calibochem®. Sodium chloride, pepsin, and 5M IICI to prepare 
the simulated gastric fluid was obtained from Fisher Scientific. The phosphate 
buffer solution was obtained from Fisher Scientific as tablets and prepared as 
per manufacturer instructions. Sodium hydroxide pellets were obtained from 
Fisher Scientific. Other materials used in particle preparation are described in 
Chapter 3 (Section 3.2.1). 
4.2.2 Methods 
4.2.2.1 Incorporation of Active Pharmaceutical Ingredient into Particulate 
Formulation 
Initial drug loading for both drugs was 5 % (w/w) of the 2 g batch introduced 
to the PGSS apparatus. The following formulation was selected as it 
demonstrated the most appropriate characteristics for gastroretcntion, it 
consisted of: 
~ ~ PLGA (RG502H -12KDa) 70% (w/w) 
~ ~ PLGA (RG503 -25KDa) 20% (w/w) 
~ ~ SPANTM 80 5% (w/w) 
~ ~ Active pharmaceutical ingredient 5% (w/w) 
The materials were weighed out, introduced to the POSS apparatus and 
formulations prepared as described in detail in Chapter 2 (Section 2.1). 
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4.2.2.2 Encapsulation Efficiency and In Vitro Drug Release 
The encapsulation efficiency of drug loaded particles and the subsequent 
release patterns in both simulated gastric fluid (SGF) (preparation detailed in 
Chapter 2 Section 2.10) at pH 1.2 and in PBS at pH 7.4 was carried using 
UVNIS as described in detail in Chapter 2 (Section 2.9). 
4.2.2.3 Time-of-Flight Secondary Ion Mass Spectrometry (ToF-SIMS) 
ToF-SIMS surface analysis was carried out to detennine the distribution of 
drug related ionic species across the surface of the sample as described in 
detail in Chapter 2 (Section 2.12) 
4.2.2.4 Scanning Electron Microscopy (SEM) 
To assess the morphological characteristics of the particles prior to and 
following release studies SEM was carried out as described in Chapter 2 
(Section 2.2) 
4.2.2.5 Freeze Drying of Particles 
In order to carry out microCT and SEM analysis of the particles following 
exposure to the release media the particles were filtered from the media and 
frozen in liquid nitrogen. The particles were then lyophilised in the freeze drier 
(Edwards Modulyo) for a period of 3 days. 
4.2.2.6 X-ray Microtomography (microCT) 
microCT was carried out to detennine the porosity and internal morphology of 
the particles prior to and following the release study as described in detail in 
Chapter 2 (Section 2.3). 
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4.2.2.7 Differential Scanning Calorimetry (DSC) 
Thermal analysis of particles was carried out as described in detail in Chapter 2 
(Section 2.8). 
4.3 Results 
4.3.1 Encapsulation of Active Pharmaceutical Ingredients 
Riboflavin, or furosemide, were introduced to the formulation at a 'theoretical 
loading' of 5% (w/w). Both drugs were encapsulated with high efficiencie of 
over 80% for all size fractions (Figure 4.2). A two-way ANOV A analysi 
carried out on the encapsulation data, confirm that there is no ignificant 
effect of particle size on encapsulation efficiency (P=0.0671), and that there is 
also no significant difference in the encapsulation efficiency between the two 
drugs (P=0.0539). 
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Figure 4.2. Encapsulation efficiency of furosemide and riboflavin for 
different size fractions of the PLGA particles, prepared by the PGSS method 
(n=3±SD) 
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4.3.2 Surface Analysis of Drug Loaded Particles 
ToF-SIMS surface analysis was applied to assess the distribution of the drug 
on the particles surface. Figure 4.3 a) shows the mass spectrum of the SN021r 
and SN02H2- peaks, which are characteristic of furosemide, in a furosemide 
loaded formulation, a blank PLGA formulation and furosemide powder. These 
peaks were selected to illustrate the presence of the drug due to the 
characteristic sulphur atom which is not found in other components of the 
formulation, enabling drug molecules to be distinguished from the other 
materials present. These peaks are higher in the furosemide powder sample 
than the formulation containing furosemide, which is expected due to the 
relatively higher amount of furosemide. The presence of the peaks in the 
furosemide loaded samples confirms that there is successful encapsulation 
within these particles. There is no 'contamination' with the drug of the control 
particles. The SN02H- peak was used to prepare the ion images presented in 
Figure 4.3 b). The images illustrate that furosemide is distributed across the 
surface of the sample. Although there are brighter areas indicating a relatively 
higher concentration of furosemide, compared to the darker areas the drug is 
present across the entire sample area. 
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Figure 4.3 a) ToF-SIMS mass spectrum revealing the intensity of the 
SN02H (mass= 329) and SN02H 2 (mass= 330) peaks in i) drug loaded 
microparticies ii) blank microparticies and iii) furosemide powder. b) The 
corresponding ion distribution images which illustrate the distribution of the 
S N O ~ ~ ion in i) drug loaded particles and ii) blank microparticies. 
An application of ToF-SlMS known as depth profiling (explained in detail in 
section 2.13), allows the intensity of a specific ion fragment to be traccd 
through a certain depth of a sample. Thi is, in e ence, achieved by th ampl 
surface being repeatedly 'fired' between the data acqui ition with h avy 0 
ions which destroy a thin layer of ions clo e to the surface revea ling a n w 
layer below. This cycle of analysis followed by disruption of the urface wa 
carried out every second for 500 seconds. Intensitie for every ten e nd 
were averaged and plotted against time to explore any potential trend thr ugh 
the depth of the sample (Figure 4.4). 
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Figure 4.4 ToF-SIMS depth profile analysis demonstrating the intensity of 
the SN02H ion as it is found through the 'layers' of the furosemide loaded 
particle. The intensity is plotted over time with each time point representing a 
new layer through the sample. The average of intensity for every 10 seconds 
was calculated and averaged. 
The depth profile appears to demonstrate that there is a higher inten ity of 
furosemide originated ions on the very surface of the particles followed by a 
decrease between the 10 and 20 second analyses. Penetrating deeper into the 
sample shows that the intensity generally remains about the arne level, with a 
very shallow decrease in the intensity towards the deeper layers (300-500 
seconds analyses). 
4.3.3 Release ProfLIe of Furosemide and Riboflavin from Different ize 
PLGA Particles in PBS Medium at pH7.4 
The cumulative drug release profiles for furosemide and riboflavin from the 
PLGA formulation in in vitro conditions using PBS pH 7.4 as relea e medium 
are shown in Figure 4.5 a) and b). The release profiles do not reveal ignificant 
burst release of incorporated drugs, with gradual release up to approximately 5 
104 
Chapter 4 
h. Beyond 5 h, it appears that drug release rate for both drugs is faster from 
larger particles relative to the smaller particles. A two-way ANOV A statistical 
analysis was carried out on the data, the size of particle was found to have a 
statistically relevant affect over release for riboflavin containing particles (F 
(5, 84) =27.7 p=<O.OOl) as well as for furosemide containing particles (F (5, 
84) =9.92 p=<O.OOl). A closer look at the Bonferroni post test comparisons of 
each size fraction reveals no significant differences in release rate between the 
various size fractions at the 0-3 h time points. A statistically significant 
difference in release is shown between 3 and 24 h. 
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Figure 4.5 Cumulative release of a) riboflavin and b) furosemide frolll 
different sized microparticies using PBS pH7.4 as the release medium 
(n=3±SEM) 
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4.3.4 Release Profile of Riboflavin and Furosemide from Different Sized 
Particle Fractions in SGF Medium (pH1.2) 
The previous section (4.2.3) describes the release studies using PBS as the 
release medium. This buffer is often used to simulate physiological conditions 
in drug release studies; however, it is not representative of the conditions in the 
stomach. Consequently release studies of an oral formulation need to be 
conducted in a more appropriate medium. The release studies were hence 
performed using particles with size of 1 000 ~ m m and 250-500 ~ m m in a simulated 
gastric fluid (SGF) at pH 1.2 (Figure 4.6). The release profiles demonstrate 
that rate of drug release decreases in SGF medium relative to in PBS medium, 
with cumulative release not exceeding 20% for the two analysed size fractions 
over the course of 24 h. Statistical analysis of the data confirms a decrease in 
release rate in SGF, compared to in PBS at all time points for furosemide 
loaded particles sized 1000 Jlm (p=<O.OOOl) and at time points after 5 h for 
riboflavin loaded particles of the same size (p=O.OO 1). 
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Figure 4.6 Cumulative release of a) riboflavin and b) furosemide from 
PLGA particle fractions sized 1000 Jun and 250 lAm in SGF. (n=3 ±SEM) 
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4.3.5 Morphology of Particles Following Exposure to Release Media 
Morphological analysis of formulations applying SEM and microCT was 
employed to determine possible changes in microarchitecture of the PLGA 
matrix following the in vitro release studies. Morphology of the formulation 
following the release study appears to be dependent on the medium used; for 
PBS pH 7.4 medium surface erosion is evident as per increased appearance of 
surface pores and sponge like structures (Figure 4.7), relative to the initial 
particles morphology. This contrasts with the morphology seen following 
exposure to SGF pH 1.2 (Figure 4.8) where the particles demonstrate smother 
surfaces than is seen following exposure to PBS. This difference in 
morphology is complemented by the microCT analysis. The 3D models 
reconstructed from the data collected (Figure 4.9) show both the space 
occupied by polymeric matrix and the space within the particle which is 'open 
pore' space. Particles exposed to the low pH SGF show a decrease in porosity 
relative to their original porosity (Figure 4.9). 
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Figure 4.7 SEM images of different size fractions of PLGA particles loaded 
with riboflavin following 24 h exposure to PBS pH7.4. Particle sizes and 
scale bars indicated on individual images (scale bar values i), ii) 500 pill iii), 
iv), v) 200 pm, and vi) 100 pm) 
Figu re 4.8 SEM images of different size fractions of PLGA parli les l(Jaded 
with riboflavin following 24 h exposure to SGF pH 1.2. Parlicl ' siz ' ami 
scale bars indicated on individual images (scale bar values i),ii),v) 500/1'" 
and iii) and iv) 20011111 
(a) i) ii) (b) i) ii) (c) i) ii) 
Figure 4.9 3D reconstruction ofmicroCT data 1000 lUll sized parli les: 
following production and prior to the exposure (a) following ' (pOSllr ~ ~ to 
PBS (b) andfollowing exposure to SGF (c). In each case i) repres ' llts til 
polymer matrix, ii) represents the open pore space witlti" tlte matrix allolVillg 
a visual comparison of the porosity to be made. 
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4.3.6 Thermal Analysis of Particles Following Exposure to Release 
Media 
DSC analysis was carried out to detennine the thennal characteristi cs of the 
PLGA particles loaded with riboflavin before and following the release 
studies. The thennograph (Figure 4.10) exposes a new thennal event following 
exposure of the fonnulations to both release media and somewhat decreased T g 
temperatures fo llowing exposure to both PBS and SGF. 
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Figure 4.10 DSC thermograph of PLGA particles before exposure to release 
media (green) and following exposure to PBS (blue) and SGF (rell). 
4.3.7 Analysis of Mechanism of Drug Release 
The release data obtained in section 4.4 and 4.5 were analysed by fittin g the 24 
h data obtained for the riboflavin release from I 000 ~ m m sized parti cles fraction 
in PBS and SGF to typically used kinetic models (Table 4. 1). Data 
demonstrated the best linearity with the Higuchi model. Hence release data fo r 
all size fractions of both the riboflavin and furosemide fonnul ations were 
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subsequently fitted to the H iguchi model (F igure 4. 11). Good linear regrc Ion 
is gained for all formulations. 
Table 4.1 Regression parameters obtainedfor PLGA particles sized lmm 
loaded with riboflavin in PBS for the different kinetic models. 
Sample Zero-order First-order Higuchi Korsemcycr-Pcppas 
r Z KOW1) r Z K1(h-1) r2 KHW172) r2 n 
No PEG 0.9392 0.0162 0.6834 0.0463 0.9720 0.0868 0.8400 0.3026 
PBS 
No PEG 0.4303 0.0028 0.2950 0.0244 0.6556 0.0 182 1 0.4657 0. 174 1 
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4.4 Discussion 
Two candidate drugs for gastroretentive formulations, furosemide and 
riboflavin, were incorporated into the PLGA based matrices. The high 
encapsulation efficiency was achieved for all size fractions of the matrices, 
with values between 80 and 100%. These values are favourably comparable 
with conventional methods of small molecular drug encapsulation within 
PLGA microparticles where values may vary between 20 and 70% [35]. For 
instance, the encapsulation efficiency of rhodamine in PLG microparticles 
prepared by an acoustic excitation method (which involes spraying of the 
polymer mixture through a nozzle whilst an ultrasonic generator allows 
ultrasonic excitation to produce uniform droplets) was found to be around 63% 
for 20 ~ m m particles and similar values of 61 % were reported for larger particles 
of 65 ~ m m [36]. Previously reported data from this group for incorporation of 
human growth hormone into PLGA based microparticles prepared by the 
PGSS method was 100% [37] this suggests that the pass method for drug 
encapSUlation is comparable, and indeed favourable to other methods. 
The mixing of the drug within the PLGA polymer matrix occurs during the 
soak period of the fabrication process (described in Section 2.1), where a 
stirrer enables the mixing of the solid drug particles within the plasticized 
polymer matrix under supercritical conditions [38, 39]. In the next stage of the 
process the mixture formed is sprayed through the nozzle from the mixing 
chamber into a collection chamber where conditions are no longer 
supercritical. The PLGA polymer rapidly solidifies, physically entrapping the 
drug particles within the polymeric matrix. Following production, the particles 
were analysed using ToF-SIMS to assess if the process provides a relatively 
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homogenous distribution of drug particles throughout the matrix, as this could 
have an impact on subsequent drug release profile. ToF-SIMS has recently 
been applied in the pharmaceutical sciences to allow detailed surface chemical 
analysis of carrier systems as well as providing an insight into the distribution 
of drugs within a certain depth of the carrier system [40, 41]. 
The ion images in Figure 4.3 b) show the intensity of the SN021I ion, 
representative of furosemide in drug loaded and blank samples. The relative 
homogeneity of intensity (or lack of extremely high and low intensity regions) 
confirms that the mixing of drug and polymer during the soak period creates a 
reasonably homogenous mixture of drug particles in the plasticised polymer 
melt. The distribution of drug particles in the polymer matrix is important 
when considering its release. Typically a uniform distribution of drug particles 
throughout the matrix will support sustained release while a heterogeneous 
distribution can lead to a pronounced burst release [42]. 
ToF-SIMS is a technique which provides molecular analysis of materials 
present in the shallow surface layers of a sample, and it should be noted that 
this data cannot be representative throughout the entire particle. PLGA based 
microparticulate systems have been reported to possess a relatively larger 
amount of drug present on the surface of the particles [43]. This surface bound 
drug contributes to the high burst release frequently reported for these systems 
[42, 44]. Unlike these reports, the release profiles for PLGA micropartic1es 
reported in this study (Figure 4.6) do not reveal any significant burst release; 
this may be explained by data obtained by ToF-SIMS depth profiling. Depth 
profiling allows the surface analysis to be continued through the 'layers' of the 
sample with the region of interest being 'deepened' between each analysis. 
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Conclusions can then be drawn upon the drug distribution through the certain 
depth of the system. The depth profile illustrates that there is a somewhat 
higher intensity of drug originated ions on the upper sub-micron layers of the 
particles (Figure 4.4), followed by a slight decrease moving through the 
sample. This demonstrates that the intensity generally remains at similar levels 
throughout the sample, again supporting PGSS process capabilities in the 
production of particles with a homogenous distribution of a therapeutic agent 
and potentially facilitating sustained release. 
It has been reported that, although porous particles release drug rapidly and 
with a high burst release, it is possible, by closing these pores, to sustain 
release over a period of about a month [45]. The microCT data described in 
Chapter 3 (Figure 3.8) illustrates that the larger particles are more porous than 
smaller particles, which may explain the faster release from larger relative to 
smaller particle fraction (Figure 4.5) . However, within all size fractions there 
are areas of solid matrix between the pores. In the larger particles these areas 
of solid matrix space can be larger in size than the smaller particles 
themselves. It is therefore surprising that the larger particles would exhibit 
faster release (provided that the drug is reasonably homogenously distributed 
within these regions). 
Release of drug from PLGA microparticulate systems has frequently been 
reported to be governed by Fickian diffusion [46-48], whereby the expected 
trend would be for large particles to release drug more slowly due to increased 
diffusion distances [36, 49]. However the majority of studies in the literature 
deal with particles in the micrometer / nanometre size range leaving it difficult 
to make direct comparisons with the far larger particles studied in this work. 
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The effect of longer diffusion pathway has been shown to be compensated for 
by the effect of 'auto-catalysis' of larger PLGA matrices [30]. This is the 
phenomenon whereby hydrolytic degradation of the ester bonds in the PLGA 
produces the acidic oligomers lactic acid and glycolic acid. The build up of 
these oligomers within the microparticles decreases pH [50]. As the rate of this 
hydrolysis is higher at lower pH, the build up of oligomers results in an 
increase in rate of degradation. This effect of auto-catalysis has been shown to 
be more profound in larger particles [51] and therefore may compensate for the 
increased diffusion distance in these systems. There is much literature on the 
effect of auto-catalysis [52, 53], however, the time scale for such experiments 
has previously been over a time scale far greater (around 35 days) than 
reported in the present study (24 h) [54, 55]. Autocatalysis is unlikely to have a 
great effect on release in this study due to the short time frame. Park 1994 [56] 
quantitated the decrease in molecular weight of PLGA of various lactic acid: 
glycolic acid ratios, the study revealed a sharp decrease in molecular weight of 
the 50:50 PLGA in the first couple of days therefore this hydrolytic breakdown 
of PLGA chains may impact release in the present work. 
Another factor contributing to the release profile via its effect on the matrix 
degradation is the molecular weight of the PLGA material [57, 58]. DSC data 
(Figure 4.10) indicates that during the 24 h period of the in vitro release study 
some degradation of the PLGA polymer had occurred, with a decrease in T a 
being apparent. 
It has been demonstrated that the degradation of PLGA microspheres occurs 
more rapidly at low pH levels as a result of the catalytic effect of low pI I on 
ester bond hydrolysis [59]. The increase in the rate of degradation of PLGA at 
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low pH is often followed by an increase in the rate of release, with the 
morphological analysis over the course of the release study confirming 
morphological changes [59]. The present study also reports on the effects of 
particles exposure to a release medium on their morphology and drug release 
(Figures 4.6 and 4.7), however the results are somewhat contradictory to the 
literature. Exposure of the particles to PBS pH 7.4 medium results in the 
emergence of surface erosion and increased surface porosity, whereas at pH 
1.2 smooth polymeric matrix dominated. This was accompanied with 
significantly decreased drug release in SGF medium at pH 1.2 compared to 
release in PBS pH 7.4 (Figure 4.6). 
A potential explanation for this phenomenon may be arising from the SEM and 
microCT data in Figures 4.7 and 4.8 which clearly show the presence of 
smooth almost pore-less surfaces following exposure to acidic release medium, 
and evidence of pores and surface pitting in the PLGA matrices after 
exposure to PBS pH 7.4 release medium. Similar pH dependent matrix 
morphology has previously been reported [21, 59]. As the release media moves 
into the porous microparticles it results in the hydrolytic degradation of PLGA 
chains and the build up of acidic oligomers, these oligomers contribute to the 
decrease in pH levels within the microparticlc in what has been described as a 
pH 'microclimate' [50, 60]. At low pH (such as SGF) the oligomers are not 
soluble, whereas at more neutral pH (PBS) the oligomers will dissolve 
resulting in the emergence of porous channels explaining the emergence of 
surface porosity following exposure to PBS (P117.4). 
The time course of release profile obtained by gastroretentive delivery systems 
must complement the period of time the system will spend proximal to the 
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drug's absorption site. Previously reported systems are achieving gastric 
residence times of around 6-8 h [61,62]. The amount of drug release over the 
period of 8 h for the largest size fraction is approximately only 50% in PBS 
medium (Figure 4.5). It was therefore important to modulate the release profile 
to enable optimal drug release over the period of gastric residence. 
4.5 Conclusions 
This chapter describes the potential of the gastroretentive particles investigated 
in Chapter 3 as sustained release systems. The release of two drugs, 
furosemide and riboflavin was explored in both PBS and SGF. These drugs 
were selected as potential candidates for gastroretentive systems as they both 
demonstrate narrow absorption windows in the upper small intestine, and both 
have demonstrated different levels of solubility in both the PBS (pH 7.4) and 
the SGF (pH1.2) and therefore allows an insight into the effect of the drug 
solubility can be obtained. The encapsulation efficiencies obtained by the 
PGSS process has been shown to be reproducibly high and favourable 
compared to other conventional methods of drug encapsulation. 
Chapter 3 concluded the larger particles are more suitable for gastroretcntion 
as they are more inherently buoyant due to their low densities. This chapter 
looked at the different release profiles found with different size fractions. The 
larger particles demonstrated the fastest rate of drug release. IIowever, taking 
into account that previously reported systems are achieving gastric residence 
times of around 8 h, the amount of drug release in this period even for the 
largest size fraction is approximately 50%. In the next chapter improvements 
in the rate of release are explored in order to improve potential bioavailability. 
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Chapter 5 
Modulation of Release Rate by the Incorporation of a 
Hydrophilic Excipient. 
5.1 Introduction 
The objective of gastroretentive drug delivery systems is to retain and deliver 
drug proximal to the absorption window where the drug will be released in a 
sustained manner and in this way allow for improved bioavailability and 
reduced dosing frequency. 
PLGA based polymers have been widely and successfully used in production 
of controlled release formulations [1-3]. These systems often explore 
variations in molecular weight [4, 5], as well as lactide : glycolidc ratio [6] in 
the optimisation of the release rate. Polymer blending has also been 
investigated as a means to improve or tailor formulation characteristics such as 
microparticle degradation properties [7, 8] and drug release rates [9, 10]. 
Hydrophilic excipients in particular, such as poly (ethylene glycol), have 
demonstrated potential in the improvement of drug loading as well as release 
rates in PLGA based microparticulate systems [11-13]. The hydrophilicity of 
the PEG is considered to improve the hydration of the matrix, in tum 
enhancing the penetration of release medium into matrix and consequently the 
diffusion of the drug into the medium. In the case of PEG, its presence not 
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only improves hydration of the microparticles but its high solubility in water 
results in the production of pores as the PEG dissolves, leaving behind an 
extensive network of water channels which enhance the diffusion of the drug 
out of the system. Other water soluble materials can be applied in this way to 
produce diffusion channels within a polymeric matrix, including sodium 
chloride, and sucrose [14]. These materials are typically introduced during the 
production of intended formulations and are subsequently extracted by 
dissolving in water. This pore formation has been reported to be followed by 
an increase in drug diffusion coefficients for vitamin Bl2 and proxyphyline 
[14]. PEG has also been applied as a porogen where the porosity will enhance 
not only the diffusion of therapeutic materials from within the system but also 
the movement of materials into the interior of systems [14]. 
This chapter describes the addition of hydrophilic PEG of different molecular 
weights into the PGSS processing of PLGA particles in ordcr to exert control 
over the drug release. Moreover, the chapter explores the relationship bctween 
particles micro-architecture and rate of drug release. 
5.2 Materials and methods 
5.2.1 Materials 
Poly (ethylene glycol) of molecular weights 1 KDa, 3 KDa, 6 KDa, and 35 
KDa were obtained from Sigma Aldrich. Other materials used in the 
preparation ofPLGA particles are described in Chapter 3. 
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5.2.2 Methods 
5.2.2.1 Production of Riboflavin Loaded Particles Containing Various 
Molecular Weights of PEG 
Particles were produced using the PGSS method as described in detail in 
Chapter 2 (Section 2.1). PEG was introduced to the formulation described in 
Chapter 4 at a loading of 10% (w/w) with the formulation containing: 
~ ~ PLGA (RG502H -12 KDa) 60% (w/w) 
~ ~ PLGA (RG503 - 25 KDa) 20% (w/w) 
~ ~ PEG 10% (w/w) 
~ ~ SPANTM80 5% (w/w) 
~ ~ Riboflavin 5% (w/w) 
5.2.2.2 In vitro Drug Release from Various Formulations 
Drug release studies were carried out as described in detail in Chapter 2 
(Section 2.11). Quantification of drug release was carried out using UVNis 
analysis (Section 2.9). 
5.2.2.3 Scanning Electron Microscopy (SEM) 
SEM was carried out to determine morphological characteristics as described 
in detail in Chapter 2 (Section 2.2). 
5.2.2.4 X-ray Microtomography (microCT) 
The internal morphology was evaluated using microCT as described in detail 
in Chapter 2 (Section 2.3). 
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5.3 . Results 
5.3.1 Release of Drug from PEG Modified Particles into PBS Medium 
Poly (ethylene glycol) of various molecular weights, at a theoretical loading of 
10% (w/w), was incorporated into the formulation (To maintain overall batch 
mass the same, 10% (w/w) of PLGA was removed from the formulation 
described in Chapter 4). Microparticles of the size fractions 1000-2000 J.lm and 
250-500 J.lm were selected for release studies in PBS pH 7.4 medium (Figure 
5.1). 
Statistical analysis applying two way ANDV A was carried out on the release 
data over the initial 4 h of the study. This indicated that at these early time 
points there is (i) no significant difference in the drug release on the addition of 
PEG and (ii) there is no significant effect on the release of different PEG 
molecular weights. However, statistical analysis carried out over the 24 h 
reveals that the overall effect of PEG incorporation is a statistically significant 
increase in the drug release rate with the exception of PEG 1 KDa. Moreover, 
the effect of molecular weight was found to be significant for both the larger 
particles (F(4, 70) =202.2p=<0.0001) (Figure 5.1) and the smaller particles (F 
(4, 70= 55.42) p=<O.OOOl) (Figure 5.2). 
Interestingly, PEG of 3 KDa molecular weight demonstrates the greatest 
increase in drug release in both size fractions tested. Unlike the higher 
molecular weight PEGs, PEG of 1 KDa does not increase rate of release for 
either size fraction; quite the contrary, for larger particles (1000 11m) 
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introducing PEG 1 KDa statistically decreases amount of released drug at the 
later time points. 
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Figure 5.1. Release of riboflavin from the 1000 11m size fraction of PLGA 
particle incorporating 10% PEG of various molecular weight PBS pH 7.4 
used as the release medium. (n=3 ±SD) 
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Figure 5.2. Release of riboflavin from 250 J.lm size fra ction of PLGA 
particles incorporating 10% PEG of various molecular weights. PBS pH 7.4 
llsed as the release medium (n=3 ±SD) 
5.3.2 Release of Drug from PEG Mod ified Particles in GF Medium 
As in chapter 4, the release studies were al 0 conduct d in F m dium, a it 
is generally considered more repr sentative of the ga tr ic flui d [ I - 17]. In 
addition, a comparison of the release profi le in di fferent m dia may PI' vid 
some insight into the detailed mechani m of relca c. 
In SGF pH 1.2 the release trend di ffers to that een in PH plJ 7.4. Th 
release of incorporated riboflavin within 24 h experimcnt i 111 just 
over 30% for the highest performing sy tem, relativc to thc rt d ~ ~ r 
release in PBS at around 70%. In SGF the two way AN V tati sti al 
129 
hapter 5 
analysis provided evidence to confirm that PEG has an ov rail significant 
effect for the larger (F (4,70)=28.15, p= <0.0001) (F igure 5.3) particle 111 
which case the effect is negative and actually decreases release. There i al 0 a 
significant effect of PEG introduction to increase relea e from the sma ll er 
particles (F (4, 70) =28.39 p=<O.OOOl) (Figure 5.3). 
-c;e. 40 
-CD 
en 
co 
CD 30 
CD 
l-
t]) 
2 20 
"C 
CD 
> 
10 10 
::J 
E 
::J 
o 0 
0 
~ ~
---
5 10 15 
Time (hours) 
No PEG -.- PEG 3k 
PEG 1k ~ ~ PEG 6k 
20 25 
-+- PEG 35k 
Figure 5.3 Release of riboflavin from J 000 J.l1II size fra ction of PL ,A 
particles incorporating 10% PEG of various molecular weights. GI< 1'1/ 1.2 
IIsed as the release medium (n=3 ±SD) 
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Figure 5.4 Release of riboflavin from 250 J.lm size fraction of PLGA particles 
incorporating 10% PEG of various molecular weigh ts. SGF pH 1.2 IIsed as 
the release medium (n=3 ±SD) 
5.3.3 Morphological Examination Following Exposure of PLGA Particl s 
to Release Media 
Following 24 h exposure to PBS or SGF reI a e media, PL parti I s w re 
collected and freeze dried for microCT analysis. Thi data wa c mpared v ith 
that of the particles before exposure to the release media with th aim r 
investigating the relationship between potential morphological hang . and th 
drug release. Although the quantitative micro T data for POro ity ( 1 ur .5) 
does not provide any statistically significant finding the corr p nding D 
models along with the SEM images (Figure 5.6) illustrate that xp ure t til 
different release media indeed affect morphology at the urface f the parti 
Interestingly, comparing models for the open pore pace in the 1111 ro T 
models (Figure 5.5) for PEG MW > 3 KDa reveals a decrea e in p ro ity n 
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introduction of PEG into the matrix. This, however following particles 
exposure to the PBS as the release media increases. This is likely due to the 
PEG solubilisation and diffusion out of the matrix which created a porous 
network. Particles containing PEG 1 KDa do not show such pronounced 
increases in porosity. Comparing the open pore space models for exposure to 
SGF with exposure to PBS media indicated that following exposure to the SGF 
the open space is typically less than in with PBS exposure. 
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Figure 5.5 Porosity data obtained by microCT analysis Bille-prior to 
exposure, Red- following exposure to PBS pH 7.4, Greell- fol/olVin T 
exposure to SGF pH 1.2 (n=6±SD) Corresponding 3D reconstruction 
'models' shown as images next to the bar. The image on the left illilstrates 
the matrix space within the particle and the image on the right illustrates 
open pore space. 
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Figure 5.6 Scanning Electron Microscopy micrographs showi,,!: til 
appearance of the microparticles with incorporation of diffi r lit 1110/ 1 II/ar 
weight PEGs before and following the completion of the r / as stlltli.\' i .. 
exposure to PBS pH 7.4 of SGF pH 1.2. 
SEM images (Figure 5.6) provide further eviden ~ ~ r th m rphol Ii al 
changes at the surface following exposure to the difi:i rent m diu . 
Exposure to the two release media re ult in very diffl r nt m rph 10 Ii',. 
Following exposure to PBS the particles show an in r a in urfa 
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with a breakdown in matrix integrity, which contrasts greatly to the 
morphology revealed following exposure to SGF where there is evidence of 
surface porosity but the surfaces are generally smoother and there is far less 
surface porosity. 
5.3.4 Mechanism of Drug Release from Particles 
In order to understand the mechanism of release of the drug from the system, 
release data was fitted to several typically used kinetic models [18], as 
outlined below. 
1) Zero Order: 
Qt = Qo + Kot 
Where Qt is the amount of drug dissolved at time I, Qo is the initial amount of 
drug in solution and Ko is the zero order release constant. The zero order rate 
equation describes situations where the release rate is independent of 
concentration. 
2) First Order: 
Kt 
Q = log Co - 2.303 
Where Co is the initial concentration of drug, K is the release constant and I is 
time. First order release is concentration dependant. 
3) Higuchi: 
Q=K.fi 
Where K is the rate constant. The Higuchi model describes the rate of release 
based on Fickian diffusion of a dissolved drug through an insoluble matrix 
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4) Korsemeyer-Peppas: 
Where M t / Moo is a fraction of drug released at time t and K is the release 
constant and n is the release exponent. 
The regression parameters obtained for the release data in PBS and SGF 
following fitting to the various kinetic models are presented in Tables 5.1 and 
5.2. The release data demonstrates the best fit with the Higuchi model for both 
release media (Tables 5.1 and 5.2). 
Release data for> 1000 J..lIl1 and 250 J.lm-500 J.lm sized particles containing the 
various molecular weights of PEG in both release media were fitted to the 
Higuchi release model with consistently good linearity at all time points 
(Figure 5.7 and 5.8). 
Table 5.1 The regression parameters lor the different It.inetic model.1i 
obtained/or release o/riboflavin/rom PLGA particles with v a r i o u . ~ ~ PEG 
molecular weights. Size fraction 0/1 mm was U!led in PBS pll 7.4. 
Sample Zero-order }'irst-order Higuchi Korsemeyer-
Pt'ppus 
rl Ko(h,J) rl KI(h,l) r2 K/I(h" rl n 
Ill) 
No PEG 0.8214 2.3101 0.5983 0.0321 0.9865 0.0470 0.7737 0.3244 
PEG 1 KDa 0.8166 0.915 0.5786 0.0298 0.9625 0.0274 0.7944 0.1931 
PEG3 KDa 0.8511 2.3009 0.6201 0.0332 0.9821 0.0650 0.8355 0.2028 
PEG6KDa 0.8538 1.8252 0.6431 0.0317 0.9803 0.0515 0.8545 0.1926 
PEG35 0.8538 1.85252 0.6141 0.036 0.9882 0.0604 0.8294 0.2201 
KDa 
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Table 5.2 The regression parameters for the different kinetic models 
obtainedfor release of riboflavin from PLGA particles with various PEG 
molecular weights. Sizefraction of Imm was used in SGF pH 1.2 as the 
release medium. 
Sample Zero-order First-order Higuchi Korsemeyer-
Ko(h-1) rl K1(h-l ) 
P e ~ ~ a s s
rl rl KH(h-112) rl n 
No PEG 0.8626 1.3355 0.4551 0.0561 0.9831 0.0375 0.6839 0.3309 
PEG! 0.7241 0.7059 0.3241 0.054 0.9058 0.0209 0.5941 0.2713 
KDa 
PEG 3 0.7865 1.1882 0.468 0.0509 0.9286 0.0344 0.6376 0.2872 
KDa 
PEG6 0.8533 0.6871 0.478 0.0589 0.9469 0.0194 0.7090 0.2946 
KDa 
PEG 35 0.8089 0.7758 0.4431 0.0432 0.9579 0.0223 0.6188 0.2826 
KDa 
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Figure 5.7 Data for the release of riboflavin from PLGA particles with 
various PEG molecular weights fitted to the Higuchi kinetic model for 
release data in PBS pH 7.4 for i) 1 mm sized and ii) 250 pm sizeel particles 
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Figure 5.8 Datafor the release of ribofla vin from PLGA particles with 
various PEG molecular weights fitted to the Higuchi kinetic modelfor 
release data in SGF pH 1.2 for i) 1 mm sized and ii) 250 pm sized particles 
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5.4 Discussion 
In this thesis, porous microparticles have been successfully produced and 
loaded with model therapeutic agents using the novel supercritical fluid 
method, Particles from Gas Saturated Solutions. The potential for controlled 
release of a therapeutic agent has been confinned and the modulation of this 
release to suit the aimed gastroretentive application was investigated by 
incorporation of the hydrophilic excipient PEG. This chapter presents a 
systematic study correlating drug release profiles in different media with a 
detailed insight into the matrix morphology provided by microCT and SEM. 
Previously, it has been demonstrated that the morphology of microparticles 
prepared with poly (lactic acid) has an influence over somatostatin drug release 
[19]. The effect of porosity on somatostatin release was found to be greatest at 
the early time points, whereby, the release from porous matrices was faster. 
Similarly, a comparison of lidocine release from porous and non-porous 
PLGA microparticles indicated an increase in drug motility in porous particles 
fundamentally changing the release profile and resulting in an increase in 
release rate [20]. 
The contrast between the rapid drug movement through fluid-filled pores and 
relatively slower movement through polymeric matrix is the root of these 
changes in release rate. In Chapter 4 the size of PLGA particles was found to 
affect rate of release. The microCT data (refer to Figure 3.8) indicated porosity 
within the PLGA particles is dependent upon the size of particle. The present 
chapter introduced the effect of PEG on the porosity of the particles and 
discusses the consequent effects on the drug release rate. 
140 
ChapterS 
The introduction of PEG in the particles formulation was accompanied by an 
overall decrease in percentage porosity, typically decreasing from 53% for 
formulations with no PEG to as low as 11 % on the addition of PEG 35 KDa 
(10% w/w) for similarly sized particles (Figure 5.5). This marked decrease is 
illustrated further by the 3D models, which additionally provide an insight into 
how this porosity is distributed through the particle. The decrease in porosity is 
in contrast to other methods of particle production where PEG or other 
hydrophilic materials are often used as porogens [21-23]. However, the 
mechanism of pore production in the PGSS method differs to that with 
conventional methods. On depressurisation of the plasticised mixture, the CO2 
gas leaves the rapidly solidifying matrix leaving behind an open pore network 
in its place. PEG is a crystalline polymer and supercritieal CO2 has been 
reported to infiltrate the polymer with more difficulty [24]. A smaller amount 
of C02 in the matrix will result in a decreased number of pore channels in the 
product. 
Despite the decrease in initial porosity, the introduction of PEG to the system 
generally increases the rate of release (Figure 5.1 and 5.2). Introducing PEG 
into the system statistically increases release of riboflavin in PIlS for PEG 
molecular weights greater than 3 KDa (p=<O.OO 1), there is no specific trend 
seen in the molecular weight of the PEGs. In contrast, the PEG 1 KDa 
incorporation results in a decrease in release rate. Statistical analysis on the 
drug release data reports that in the 1 mm particles the presence of PEG has a 
statistically significant effect on the rate of drug release (F (4, 70) =28.15, p= 
<0.0001). Similarly in the case of the 250 ~ m m particles it was revealed that the 
presence of PEG had a statistically significant effect on rate of release (F (4, 
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70) =28.39 p=<O.OOOl). In Chapter 4 it was established that there is little burst 
release observed at the early time points for the PLGA particles of different 
size fractions. This is particularly surprising given the high porosity of the 
particles (up to 50% for particles with no incorporated PEG and 20% upon the 
incorporation of PEG). The inclusion of PEG in the formulation results in a 
somewhat increase in release at the early time points (0-3 h), although this is 
not a statistically significantly increase compared to particles with no PEG. 
Beyond 3 h, this is a different story with PEG mw greater than 3 KDa 
increasing the rate of release in PBS compared to particles of the same size 
with no PEG. 
Typically, drug release from PLGA based microparticles demonstrates 
extensive burst release [25]. ToF-SIMS exposed the homogenous distribution 
of drug throughout the particle with relatively little, preferentially surface 
bound drug (refer to Figure 4.2 Chapter 4). This could explain the low burst 
release. 
The shape of the release curves do not show any dramatic changes between 
particles with PEG and those without, it was therefore unlikely that there 
would be any change in mechanism of release and this was confirmed through 
the application of various kinetic models the release data (Tables 5.1 and 5.2). 
The Higuchi model demonstrates the best correlation with the drug release data 
(Figure 5.8) indicating that the release is diffusion dependent for all 
formulations, and further demonstrating that the mechanism of release docs not 
change on the addition of PEG. 
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The pH of SGP (PH 1.2) significantly slows the release rate relative to release 
in PBS (pH 7.4) at all time points for particles prepared with PEG with 
molecular weight >3000 KDa (p=<O.OOOl). Chapter 4 reported a decrease in 
release rate for the different size fractions (1000 ~ ~ and 250 11m) in SGF 
relative to in PBS (Figures 4.4 and 4.5). A decrease in release rate at lower pI I 
levels has been reported to be a result of a decrease in glass transition 
temperature for the PLGA polymer at the lower pH [26]. On contact with SOF 
medium the polymer moves through the transition of the glassy to rubbery 
state, the structure of the particles will consequently become compromised and 
there will be an element of breakdown in the porous network. Following this 
the polymer chains may reorganise to become more tightly packed resulting in 
the smoother particles shown in Figure 5.6. Particles prepared with no PEG 
and PEG 1 KDa do not show any statistically significant difference in release 
rate until the fmal time points where the rate is significantly decreased in SGF 
at 24 h (p=<O.OOOl). The significantly increased rate of drug release on PEG 
incorporation in PBS is in marked contrast to its effect in SOP. 
Quantitative data corresponding to the porosity before and after the release 
along with the 3D reconstruction models allows a detailed look at this 
microstructure within the particles (Figure 5.5). The microCT data was 
subjected to a two-way ANDV A statistical analysis which revealed that the 
addition of PEG to the formulation significantly decreased porosity at all 
molecular weights (p=<O.OOl). Following exposure to PBS the porosity is also 
significantly higher in the case of particles with no PEG (p=<O.OO 1). As 
previously stated, it is the diffusion of CO2 from within the polymer matrix 
which results in the intricate porous network found in particles produced using 
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the PGSS process [27] and if less CO2 is 'dissolved' in the material during 
PGSS [24] the porosity will be decreased when PEG is introduced to the 
matrix. 
Following exposure to PBS the change in porosity was not found to be 
significant at any of the formulations. Although there appears to be a general 
trend for exposure to PBS to increase porosity (PEG 1 KDa being the 
exception to this) the variations between porosity measurements between the 
samples are too great to gain statistically significant difference. The 
mechanism of pore formation in the PGSS process is the result of the gaseous 
C02 diffusing from within the solidifying polymeric matrix, as these bubbles 
of gaseous C02 move around they will coalesce creating larger bubbles which 
leave behind large pore spaces. Variations in porosity are too great to fonn any 
statistically significant conclusions. The large variations may be because the 
sample size selected was far too small with only 10 particles being selected 
from each batch. 
Exposure to the low pH of SGF does not reveal any significant changes in 
porosity. Never-the-Iess, a general trend in porosity may provide some 
information with regards to the differences in this microarchitecture following 
exposure to different release media. PBS, particularly for particles containing 
PEG, appears to increase surface porosity, whereas SGF appears to decrease 
porosity. A comparison of the microCT data with the SEM images confirms 
this trend. This microCT data is verified further by the SEM images which 
provide additional evidence to suggest an increase in porosity and surface 
degradation in particles containing PEG, this was anticipated considering the 
presence of PEG is known to improve the hydration of the matrix and has 
144 
ChapterS 
previously been reported to fonn channels through the matrix [28]. Following 
production SEM images reveal irregular shaped particles with some surface 
roughness and porosity (Figure 5.6), following exposure to PBS there is an 
increase in this surface porosity with surface pitting becoming evident and 
some indication of degradation of structure at the surface. In the lower pI I SGF 
the resultant morphology is very different, with SEM images demonstrating 
smoother surfaces without the extensive surface pitting and appearance of 
surface pores (Figure 5.6). The surface porosity seen in the particles following 
production is no longer present. Corresponding to the SEM images 3D 
reconstructions were prepared using the microCT data and illustrate how the 
internal porosity changes. With SGF, in contrast to the extensive pore network 
present following exposure to PBS, the 3D models show more discrete pores 
within the polymer matrix. The contrasting morphologies following exposure 
to media of different pH levels was reported previously by Zolnik et al [29] 
where the pH level did not appear to affect the mechanism of release, therefore 
the shape of the release profile remained the same it was moved down on the 
release plot, a similar phenomenon was revealed in this study with the release 
data both in PBS and in SGF fitting well to the I Iiguchi model. Previous 
studies however have found that altering the pH level of the media has an 
impact on the fundamental mechanism of release [30] this study investigated a 
range of pH levels from 10.8 to 1.3 and little difference in release profile shape 
was seen between low pH levels and those nearer neutral. 
The smooth appearance of particles has been reported to be a result of 
homogeneity of pH levels within the particle as the diffusion of media into the 
particles results in degradation of the PLGA chains and a build up of oligomers 
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occurs. During release in PBS the acidic oligomers create a microclimate 
within the particles where the pH is low in comparison to the surrounding 
medium [31] this results in a heterogeneity in pI I levels inside the particle and 
it is this which leads to the production of pores. In contrast, if the media has a 
low pH, then the presence of the oligomers will not alter the microclimate as 
significantly and the pH level within the microparticle remains homogenous. 
Thermal analysis in previous studies has demonstrated the difference in state 
of the polymer in the different pH levels which may provide an explanation for 
the difference in release [26] at low pH levels the polymer is in the glassy state 
whereas at more neutral pH levels the polymer is in the rubbery state. In the 
rubbery state the chains of the polymer are more mobile improving the motility 
of the drug particles within the polymer matrix. 
The decrease in porosity and thus release rate from particles containing PEG 1 
KDa may be a result of the melting temperature of PEG 1 KDa. This is 
approximately 35°C and it is unique amongst the PEGs selected for this study 
as this temperature is below that of the release media (37°C). This may have 
structural implications for the microparticles causing the intricate pore network 
to breakdown when the PEG 1 KDa becomes molten. 
Polymer blends have previously been employed to modify characteristics of 
delivery systems, in particular in the modification of release rate. Mallardc et 
al [13] reported the release ofteverelix from PLGA particles to be significantly 
increased when using a PLGA-PEG copolymer with the actions of PEG in the 
particles being described as a 'water-pump' inducing drug release. Reports of 
the enhancing effect of PEG on drug release are many in the literature [28] 
however this study has demonstrated that although the presence of PEG does 
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have an effect on the rate of release in this case, it is the impact PEG has on 
morphology which governs this. 
5.5 Conclusions 
The PGSS method was successfully applied in the preparation of large porous 
particles for application in controlled, gastroretentive drug release. Particles in 
the size range 2000 Ilm-lOO Ilm were produced using a blend ofPLGA (50:50) 
of two molecular weights (-12 KDa and -25KDa) and 10% (w/w) PEG of 
various molecular weights (1-35 KDa). It is reported here that the presence of 
PEG of molecular weight ~ 3 3 KDa increases rate of drug release over 24 h, this 
increase relates to the hydrophilicity of PEG and this polymer's actions as a 
porogen during the course of the release study. Although the particles prepared 
with no PEG incorporation demonstrated higher initial porosity, there is a 
markedly greater increase in porosity following exposure to PBS in particles 
with PEG, relative to the increase in particles with no PEG, which results in an 
increase in drug release for these particles. 
PEG 1 KDa did not demonstrate a similar effect as the higher molecular 
weight PEGs although the explanation for this remains unclear it is likcly to be 
a result of the lower melting temperature of PEG 1 KDa compared with PEG 3 
KDa and above. 
The data presented in this chapter demonstrates that modulation of drug release 
properties is possible through altering formulation parametcrs. 
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Chapter 6 
Surface Modification for the Introduction of Novel 
Properties 
6.1 Introduction 
The introduction of bioadhesive properties to drug delivery systems is a an 
intensively studied area for mucosal routes of drug delivery including oral, 
buccal, nasal and vaginal [1]. Mucosal surfaces are covering areas exposed to 
the external environment and provide both defences against external factors 
and are also involved in secretion and absorption. Features of mucosal surfaces 
such as the high surface area offer ideal conditions for localised site-specific 
delivery, and may enhance retention of the delivery system at the relevant site 
for optimal drug absorption. 
Bioadhesion may be defined as 'the state in which two materials, at least one 
of which is of a biological nature, are held together for an extended period of 
time by interfacial forces' [2]. In the field of drug delivery this concept has 
been applied to the adhesion of a drug carrier system to a mucosal surface and 
the more specific term 'mucoadhesion' was coined. During the last two 
decades mucoadhesion concept has provided evidence for improved 
bioavailability of drugs from formulations applied to the buccal [3], nasal [4], 
respiratory [5], and intestinal [6] mucosa. Drug delivery to the oral cavity has 
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gained much interest due to the convenience of oral dosing. The introduction 
of mucoadhesive properties to oral dosage systems allows intimate contact to 
be formed between the system and the walls of the gastrointestinal tract (GIT) 
prolonging residence time [7]. There have been reports of different attempts to 
successfully create a system which will adhere to the mucus of the GIT [1, 7, 
8]. 
In vitro mucoadhesion tests have demonstrated micropartic1es prepared with 
chitosan develop strong interactions with mucin in solution, the extent of the 
interactions was found to be proportional to the positive values for zeta 
potential of the microspheres indicating the importance of charge in these 
interactions [9]. The high surface area of micro spheres compared with a single-
unit tablet is likely to enhance the adhesion to the GIT lining. The pass 
method has previously been used in our group to prepare microparticles with 
mucoadhesive properties introduced through the incorporation of chitosan 
[10]. Interactions were found to exist between chitosan and mucin in solution, 
with the interactions increasing for increased amounts of chitosan (w/w) in the 
particles. 
Although in vitro mucoadhesive tests have demonstrated successful adhesion 
of mucoadhesive systems to mucins in solutions [11], as well as in rat gut loop 
studies [12], it should be noted that the levels of mucoadhesivc success seen in 
in vitro have rarely been replicated in in vivo studies. Gamma scintigraphic 
studies have revealed that compared with a control, bioadhesivc fonnulations 
prepared using Carbopol 934P and polycarbophil did not significantly change 
the time taken for the system to arrive at the colon [13]. Similarly, chitosan 
based systems have also been analysed using gamma scintigraphy [14] and, 
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although in vitro investigations into the mucoadhesive properties of the 
microspheres demonstrate high levels of mucoadhesion, subsequent in vivo 
analysis did not replicate such successful adhesion with retention time being 
found to be short and not reproducible [14]. The major obstacles for 
mucoadhesive formulations include the high mucus turnover rate and strong 
peristaltic forces [15]. These limit the retention time ofmucoadhesive systems, 
as a consequence to this in the present work a combination of mucoadhesion 
and buoyancy have been bestowed upon the drug delivery system in an effort 
to improve retention time. 
Progress in the design of gastroretentive delivery formulations has brought 
about the emergence of systems which combine the gastroretentive potential of 
floating systems and mucoadhesive systems. A problem with the floating 
systems would be that as the stomach empties the delivery system would 
empty with the liquid. By introducing a mucoadhesive material, the delivery 
system would bind to the gastric walls during emptying. This will maintain the 
system within the stomach and enhance gastric residence time. Clarithromycin 
loaded microparticles prepared with chitosan-alginate-ethylcellulose enabling 
both floating and mucoadhesion, demonstrated a highcr conccntration of the 
clarithromycin at the gastric mucosa compared to a control [16]. In vitro 
analysis of a floating and bioadhesive system for sotalol IICI confirmed 
potential as a novel oral delivery system following analysis of characteristics 
such as controlled release, bioadhesiveness, and buoyancy in an acidic 
environment [17]. As a recent development in oral delivery these floating and 
bioadhesive systems are not as yet widely reported, however as outlined above 
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they do posses the potential to improve upon those systems which demonstrate 
only buoyancy or only mucoadhesion. 
Mucous membranes are coated in a VISCOUS secretion known as mucus, 
synthesised within the goblet cells. Mucus is composed of 95% water, >4% 
mucins, and <1% proteins, lipids, and mucopolysaccharides [7, 18]. Mucins 
are high molecular weight glycoproteins which play an instrumental role in 
defence [19], with their gelling properties contributing to the viscosity of the 
mucus layer [20]. Typically, mucins consist of two distinct regions, the first 
being a large central protein core to which numerous O-linked 
glycosaccharides are attached, secondly there are terminal peptide regions with 
little or no glycosylation but rich in cysteine residues. The cysteine residues 
provide thiol groups which give rise to disulphide bridges in and between 
mucin monomers allowing the formation of the intricate network of 
glycoproteins and the highly viscous nature of mucus [7]. 
Mucoadhesive polymers typically contain numerous hydrophilic groups such 
as hydroxyl, carboxyl, amide, and sulphides which enable the attachment of 
the material to mucus or the cell membrane itself [1]. When selecting suitable 
polymers for mucoadhesion various properties must be considered; it has been 
reported that the presence of certain functional groups, the degree of hydration, 
the molecular weight, charge, and the degree of cross linking arc all important 
factors to consider [7]. Anionic polymers are often selected for mucoadhesion 
and may form strong interactions with mucin via hydrogen bonds. The 
presence of carboxyl and sulphate groups on these polymers leads to an overall 
negative charge. Poly (acrylic acid) and its related polymers Carbopol (Poly 
(acrylic acid) cross-linked with allyl sucrose), and polycarbophil (poly (acrylic 
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acid cross-linked with divinyl glycol) have been extensively tested in 
mucoadhesive systems with the cross-linked polymers performing better than 
the uncross-linked poly (acrylic acid) [21]. 
Cationic polymers, notably chitosan, have also been considered for their 
mucoadhesive properties. Chitosan is a polysaccharide produced by the 
deacetylation of chitin. Unlike poly (acrylic acid) which interacts with the 
mucus through hydrogen bonding, chitosan utilises ionic interactions between 
the amino groups in the chitosan and the sialic acid groups which are present 
as glycosidically bound branches in the mucin glycoproteins found in mucus 
[22]. Chitin, being the second most abundant polysaccharide in nature 
(following cellulose), is readily available and this, along with good 
biocompatibility has led to the popularity of chitosan for usc in delivery 
systems [23]. Other polysaccharides such as alginic acid, hyaluronic acid, and 
carboxymethylcellulose have also been used in mucoadhesive systems. 
The ionic and hydrogen based interactions with mucus are non-specific In 
nature. More recently second-generation mucoadhesivcs have made way for 
exploring specific covalent bonding. Introduction of thiol groups to polymers 
allows covalent disulphide interactions to occur with the cysteine rich areas 
within the mucins present in mucus. This process directly mimics the natural 
mechanism of secreted mucus glycoproteins which use disulphidc bond:; to 
anchor themselves within the mucus and therefore was thought to hold great 
potential. Indeed, thiolated polymers have shown good potential as 
mucoadhesives and consistently show improved mucoadhesivc properties 
when compared to their non-thiolatcd counterparts [21, 24]. 
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The mucoadhesive properties of chitosan have been m di ft d thr ugh th 
production of various thiolated derivatives (Figure 6.l.). hit an-4-thi -butyl-
amidine (chitosan-TBA), which is the product of a reaction betw n hit an 
and 2-iminothiolane, has demonstrated the pot ntial to impr ve mu adh t n 
by up to 100-fold [25] . Chitosan-thioglyco lic acid (chito an-
have also demonstrated up to 10 fold improvement in mu adh i n In 
comparison with the unmodified chitosan [26]. The third typ f m dift d 
chitosan, and the type adopted in the pre ent w rk, are th hito an-
cysteine (chitosan-NAC) conjugates. Previous in vitro adh i n tudi 
have reported this polymer to show a 50 fold impr vern nt in r id n tim . 
Figure 6.1 The structures of i) Chitoson-NA ii) lIilosoll-TB ami iii 
Chitosan-TGA 
A study comparing the mucoadhe iv capa iti f mi r ph mpri s d f 
various bioadhesive materials demon trat d an flh rl ' oli nor 
acyclovir at its absorption ite in upp r mall int tin 27]. f th' ari )lIS 
polymers tested, thiolated high st I11U 
along with most improved bioavailability f th drug. 
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This chapter aims to augment the gastroretentive properties of a novel buoyant 
microparticulate system through the inclusion of the mucoadhesive polymer 
chitosan or its thiolated derivative chitosan-NAC. Confirmation of successful 
incorporation of the mucoadhesive polymers will be carried out using 
morphological investigations as well as spectroscopic analysis using ToF-
SIMS, the novel properties bestowed upon the system will be analysed using a 
combination of in vitro techniques. 
6.2 Materials and Methods 
6.2.1 Materials 
Low molecular weight chitosan, N-acetyl cysteine, N-(3-
Dimethylaminopropyl)-N' -ethylcarbodiimidc hydrochloride (EDAC). periodic 
acid 99%, porcine mucin (type III), and fluorescein isothiocyanate (FITC) 
were obtained from Sigma Aldrich. Basic Fuchsin was obtained from National 
Diagnostics. Materials used in particle preparation arc as described in Chapter 
3. All chemicals were used as supplied. 
6.2.2 Methods 
6.2.2.1 Preparation of N-Acetyl Cysteine Modified Chltosan (chitosan-
NAC) 
The chitosan-NAC conjugate was prepared by attachment of N-acetyl cysteine 
to the amine groups in the chitosan. This process is outlined in Figure 6.2 
below. 
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Figure 6.2 The synthesis of chitoSQI1- ~ ~
The covalent attachment of N-acetyl cy t in A ) t hit . an urs 
through the production of an amide gr up fr m th int ra ti n b t\) n Ih 
primary amino group of chitosan and a arb yli acid r up of [2 1. 
The primary amino group of chito an xhibits a pKa alu [2 ] 
therefore at pH 5 the amino group i pr t nat d enabling int ra ti n \i ilh Ih 
carboxyl group in the NA . 
The preparation of the chito an c njugat chit san- A WH. arri I ut us 
previously described [30]. Briefly 1 g low m 
Aldrich) was dissolved .in 100 ml of aceti a id and th pJl mad 
5 M Hel and 1 M NaOH. 6 g N-ac tyl and 2 \i 'I' 
dissolved in 100 ml dH20. Th two luti n W I' th n unit d and in 'ubnl ' I ol 
room temperature under constant agitati n in th dark ~ ~ r h. Th' luti n \. tI . 
then dialyzed (Mw 10,000 cut off) at 1 0 initially ag in t 111M 111 
containing 2 11M EDTA for 3 day , fo il W d by a furth r da a ain t Ih' 
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same medium with the addition of 1 % NaCI and a final 3 days against 1 mM 
HCl. The resultant product was then frozen and lyophilizcd for a pcriod of 3 
days until product is completely dry. It is then storcd in the dark at 4°C until 
required. 
6.2.2.2 Preparation of FITC Labelled Chitosan 
The synthesis of FITC labelled chitosan was based on the rcaction bctwecn the 
isothicyanate group of FITC and the primary amino group of chitosan [31]. 
Briefly, 200 mg chitosan was dissolved in 20 ml 2% acetic acid and 5 mg 
FITC was dissolved in 10 ml DMSO. The two solutions were united and lcft 
stirring in the dark for 12 h. Following this the solution was prccipitated in an 
excess of acetone and dialysed against dlhO for 3 days. The FITC-chitosan 
was then freeze dried for 5 days. 
6.2.2.3 Nuclear Magnetic Resonance (NMR) Spectroscopy 
IH NMR spectroscopy was used to confirm the modification of chitosan with 
N-Acetyl-Cysteine. Samples were analysed using a Bruker Advancc 600Mllz 
spectrometer. Prior to analysis the sample was dissolved in 0.6 ml dcutcratcd 
water (D20) containing 2 drops of deutcratcd hydrochloric acid (DCI) for 
chitosan samples and 2 drops of dcuteratcd chloroform (CDCh) for polymer 
samples. The data was processcd using TopSpin (version 2.0) 
6.2.2.4 Ellman's Assay 
Ellman's reagent (5,S'-dithiobis-(2-nitrobcnzoic acid) or DTNO) is frequently 
used to quantify the sulfhydryl groups in a sample. Briefly, the reaction 
involves cleavage of the disulphide bond in DTNB, rcsulting in 2-nitro-S-
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thiobenzoate (NTB} In water at neutral pH NTB" ionizes and the resultant 
NTB"2 has a yellow colour. This reaction is dependent on the reaction pll, the 
pKa of the sulfhydryl group. The intensity of the yellow colour can be 
analysed using UV-VIS spectrophotometry and quantification of the sultbydrl 
groups present may be calculated using a standard curve prepared with 
cysteine. Alternatively, the extinction coefficient (cited to be 14150 M"'cm" 
[32] at 412 nrn) of the NTB"2 may be used to calculate concentration. 
The assay was carried out as follows; initially the DTNB reagent was prepared 
by dissolving 137 mg sodium acetate trihydrate and 15 mg DTNB in 20 ml 
dH20. Tris buffer was prepared by dissolving 121 mg Tris base in 1 litre dIhO 
and made to pH8.0. The samples were prepared by dissolving 5 mg of 
modified chitosan in 2.5 ml dlhO; 10111 of this was then added to 100 III tris 
buffer and 50 III DTNB and made up to 1 ml with dI hO. The sample was then 
analysed for absorbance at 412 nm using UV Nis. 
6.2.2.5 Post-Processing Surface Modification of PLGA Particles 
Coating microparticles for drug delivery with a polyelectrolyte has been 
reported to convey novel properties onto the microparticlcs. A common 
example in drug delivery is the ability to adhere to certain biological surfaces 
such as mucus [33, 34]. Chitosan is often the polymer of choice for 
mucoadhesion because of its cationic charge, biocompatibility, and strong 
mucoadhesive properties. The pKa (acid dissociation constant) value of 
chitosan is 6.S therefore the chitosan is positively charged and soluble in acid-
neutral solutions and thus in the low pH of the stomach the chitosan will be 
highly charged (positively), and be able to bind to negatively charged 
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components of mucus. The attachment of the Chitosan to the surface ofPLGA 
particles occurs through electrostatic bonds between the protonatcd primary 
amino group of the chitosan and the negatively charged carboxyl group on the 
PLGA. 
In this study 100 mg chitosan was dissolved in 25 ml 2% acetic acid made to 
pH4.5. To the chitosan solution 100 mg PLGA particles were introduced and 
left to stir for 1 h. Following this, the particles were filtered off the solution 
and washed initially with 50 ml acetic acid followed by 50 ml dl hO and 
collected before freeze drying for 3 days. 
6.2.2.6 Incorporation of Mucoadhesive Polymer into Formulation and 
Preparation of Particles using PGSS .Method 
Incorporating the mucoadhesive polymer during the production allows the 
manufacture of the system to remain a simple, one-step process. Although 
chitosan does not undergo plasticisation or melting it is possible to incorporate 
the chitosan in a similar way to the encapsulation of an active phannaceutical 
ingredient. In this way the chitosan will be present throughout the polymer 
matrix. The particles were prepared as described in Chapter 2 (Section 2.1) 
with the following formulation to be weighed out and introduced to the mixing 
chamber: 
161 
Chapter 6 
~ ~ 55% PLGA -12 KDa (w/w) 
~ ~ 20% PLGA -25 KDa (w/w) 
~ ~ 5% Drug (w/w) 
~ ~ 5% SPAN80 (w/w) 
~ ~ 10% PEG 35 KDa (w/w) 
~ ~ 5% Low molecular weight chitosan (w/w) 
6.2.2.7 Scanning Electron Microscopy 
SEM was carried out as described in detail in Chapter 2 (Section 2.2). 
6.2.2.8 X-ray Microtomography 
microCT was carried out as described in detail in Chapter 2 (Section 2.3). 
6.2.2.9 Fluorescent Microscopy 
Particles were prepared for fluorescent microscopy through the addition of 
0.5% w/w coumarin to the formulation. A corresponding 10 mg PLGA 
(Resomer RG502H) was removed from the formulation to maintain batch size. 
Particles were imaged using fluorescent microscopy and images analysed as 
described in detail in Chapter 2 (Section 2.4). 
6.2.2.10 Time-or-Flight Secondary Ion Mass Spectroscopy 
ToF-SIMS surface analysis was carried out as described in detail in chapter 2 
(Section 2.12). 
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6.2.2.11 Mucous Glycoprotein Assay 
A periodic acid! Schiff reagent (PAS) colorimetric assay as previously reported 
[35] was utilised to determine the concentration of free mucin in a solution. 
This allows a value for the amount of muein lost from a known mucin solution 
to be detennined and therefore the amount of mucin that has adsorbed to the 
particle surface deduced. 
This staining procedure is often employed in histological staining. Incubation 
with periodic acid results in oxidization of the polysaccharide which usually 
occurs at the vicinal diols in the compound [36]. The oxidisation results in the 
formation of aldehydes which then react with decolourised Schiff reagent to 
produce a coloured product. There are two different mechanisms reported in 
the literature for reaction of Schiff reagent with aldehydes. The first 
mechanism was proposed by be decolourised by sulfonation of the central 
carbon atom. The mechanism of action has been proposed previously [37]. 
The mucin assay was carried out by incubating 10 mg PLGA particles in I ml 
of a known concentration of porcine mucin for a period of 1 h in a rotamixcr. 
Following this time the mucin solution was removed from the particles nnd this 
solution was incubated at 37°C with 100 III 50% (w/v) periodic acid for 2 h. 
Once returned to room temperature 200 III Schiff reagent was introduced and 
the samples were analysed for absorbance at 570 nm using UVNis. 
6.2.2.12 Adhesion of Particles to a Mucus Producing Cell Line 
Calu-3 cells were cultured to confluence in 75 cm2 flasks at 5% CO2, 37 "C. 
Once confluent, cells were detached from the flasks by incubating with 
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trypsinlEDTA solution and seeded on Transwell® penneable inserts at a 
density of 105 cells/cm2. Cells were maintained at 5% C02, 37°C in EMEM, 
supplemented with FBS (10% v/v) and antibiotic/antimycotic solution, which 
was replaced regularly (every 48 h). Air-liquid interface (ALI) was created on 
day two following seeding of the cells on filters. Cell growth and tight junction 
formation was assessed by trans epithelial electrical resistance (TEER) 
measurements. TEER is a measurement of resistance to ion flux across an 
epithelial layer and reflects the degree of confluence demonstrated by the cells. 
Briefly, sterilised electrodes are placed in the culture medium on the apical and 
basal side of the cell layer. The resulting readings were recorded and adjusted 
to take into account background filter resistance. 
Cell mono layers were typically used for TEER and penneability experiments 
between days 8-10 in culture. Bioadhesive analysis was carried out by the 
addition of 10 mg dry particles to each transwell followed by a 30 min 
incubation period. Following this time the cells were thoroughly washed 3 
times using PBS to remove any unadhered particles and the plate was imaged 
by the time elapse camera lIamamatsu 1394 ORCA-285, and the software used 
for video acquisition and data generation was Volocity software version 5.2. 
6.3 Results 
6.3.1 Preparation of NAC Modified Chitosan 
The structure of the product was confinned initially using III NMR. On 
comparison of the spectra obtained for unmodified chitosan (Figure 6.4) and 
that obtained for the NAC conjugate (Figure 6.5) a large resonance peak at 
around 2.2 ppm is apparent. On further comparison with the spectrum 
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obtained for N-acetyl cysteine (Figure 6.3) it appear that thi th P ak 
corresponding to the side chain which incorporate the - H gr up. 
The amount of thiol moieties on the chito an conjugat wa d t rmin d 
spectrophotometrically using the Ellman's a ay. The m di fi d P Iym r 
exhibited 4.755x lO-4 moles thiol groups per gram fpolymer. 
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6.3.2 Morphological Analysis of Particles Following Po t-Proce ing 
Surface Modification 
SEM analysis of the different formu lations reveal that wh n th at ing 
process is carried out following production by the PG m th d th r m 
disruption to the surface of the microparticles (F igur 6. ) and an in In 
open pores is shown at the surface. 
i) 
ii) 
iii) 
iv) 
Figure 6.6 Morphological analysis of i) control (1111 oaf ~ d d , , ii) 'hitmuIII 
coated post processing iii) chitosan-NA oaletlpost pro" , sillg iv) hito.wlII 
incorporated into formulatiolt (10 %(w/ w)) . Both SEM alltl IIIi 'ro T illlfl[.: 'S 
are presented. 
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The fluorescent images in Figure 6.7 show the difference in appearance of 
particles following the coating after production (i , and ii) and incorporation of 
chitosan during the production step (iii , and iv). F igures i) and ii ) allow a 
detailed visuali sation of the contours of the surface of the microparticles. 
Images corresponding to particles labell ed with coumarin-6 offer an insight as 
to how a low molecular weight excipient may be distributed throughout the 
matrix. The high amount of background fluorescence in the coumarin-6 
incorporated particles may prevent the defined surface contours from being 
apparent. 
Figure 6. 7 Fluorescent images o/particles containing F1TC-chitoson a." a 
post processing coating (i) and ii) alongside cllitosan incorporatel/ illlo 
coumarin-6labelled particles (iii) iv)) 
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6.3.3 ToF-SIMS Surface Analysis 
Although the fluorescent images provide evidence for th pr r FIT -
CS on the surface of the microparticles ToF- 1M allow th acqUi iti n 
more detailed data including the identification and I ali ati n f p ifi 
materials on the surface of the microparticle . 
Figure 6.8 confirms that the coating pr c s wa ful and th r 
chitosan present on the surface of the particle . Furtherrn r th tra al 0 
show how the PLGA peak decrease in the coat d ample. 
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Figure 6.9 ToF-SIMS ion images demonstrating the distribution of the eN, 
eNO-, and HS" ions in the differentformulations. 
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The ion images presented in Figure 6.9 demonstrate the distribution of the 
chit os an polymer and the chitosan-NAC in samples in both incorporation 
methods. In all cases the chitosan distribution is not unifonn with patches of 
higher intensity evident for the chitosan associated peaks (CN", and CNO) 
The SH" images show a higher intensity for the chitosan-NAC Images as 
expected due to the presence ofthiol groups in the derivative. 
Following review of the individual spectra obtained for the individual 
components of the system, peaks were selected to represent PLGA. and 
chitosan in the depth profile. Peaks at m1z 73 (C2IIOn. m1z 87 (C3I1jOJ). and 
m1z 89 (C3HS03") were found to be representative ofPLGA with C2IIO]" being 
selected to represent PLGA in depth profiles. Peaks which were found to be 
diagnostic for the presence of chitosan include m1z 26 (CN"). m1z 42 (CNO"). 
m1z 50 (C3N"), m1z 56 (C2IhNO"), and m1z 82 (C4I14NO"). The intensity of the 
CNO" peak was selected to represent chitosan in depth profiling. 
Figure 6.10 shows the depth profile for the microparticlcs coated with chitosan 
post-production. The depth profile confinns that on the surface there is a 
relatively high intensity of ions originating from the chitosan compared to 
PLGA, the intensity of the chitosan then decreases past these surface layers 
and the PLGA intensity increases. This confinns that the chitosan is confined 
to a shallow layer at the surface (although the actual depth cannot be quantified 
due to the individual nature of the sample). A di fferent situation can be seen in 
Figure 6.11, where the chitosan powder was incorporated during the 
processing step. In this case it would be expected that the intensity of both the 
PLGA and the chitosan would remain almost constant through the depth of the 
sample. However, the intensity of chitosan is markedly highcr on the surface 
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than through the deeper layers of the sample. This was unexpected as the 
chitosan is incorporated into the formulation and therefore was anticipated to 
be distributed homogenously throughout the sample. During depressurisation it 
appears that the chitosan will locate towards the surface of the particle . The 
chitosan intensity past the very surface (> 100 seconds) then decrea es however 
remains higher relative to post-process ing coating, indicating the pre ence of 
chitosan throughout the sample. 
Time (seconds) 
Figure 6.10 Depth profile demonstrating the intensity of the PLGA (r Id) iOlls 
and the chitosan ions (blue) as the analysis is carried oul through Ihe depth 
of the sample after post production coating. 
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Figure 6.11 Depth profile demonstrating the intensity of the PLGA (r Id) iOlls 
and the chitosan ions (blue) as the analysis is carried olltthrough the depth 
of the sample after the chitosan has been incorporated il1to the form Illation. 
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Following the depth profiling as with the surface analysis ion images were 
constructed and the z view of these images is shown in Figure 6.12. The 
images show the high intensity of CN- and CNO- at the surface of the particles 
and interestingly for the particles coated post production this coating extends 
through what appears to be discrete channels into the depth of the sample. 
Such channels may be an indication as to the location of the pores in the 
system. 
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Figure 6.12 ToF-SIMS ion images demonstrating the distribution of the CN 
,CNO-, and HS ions in the z view following depth profiling. 
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6.3.4 Mucous Glycoprotein Assay 
Surface analysis confirmed the presence of chitosan at the surface of the 
particles. In order to investigate what mucoadbes ive properti e the presence of 
this polymer conveys on the sample, a mucin assay was carried out. Following 
incubation in a known concentration of mucin the colorimetric periodic 
acid/Schiff assay was applied to the so lution to determine the end 
concentration. This gives an indication of the amount of mucin which has 
adhered to the particle surface. Figure 6.13 gives a compari on of the amount 
of mucin adhered to the particles for the different formul ations. There is no 
mucin lost from the solution in the contro l microparticle , without the 
mucoadhesive polymer the microparticles do not show any mucoadhe ive 
behaviour. Coating the microparticles with the chitosan-NA re ult in the 
highest mucoadhesion in this assay. Whether the chito an wa incorpora ted 
post or during production did not appear to re ult in a differen III 
mucoadhes ive behaviour. 
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Figure 6.13 Chart comparing the amount ofmllcin which adheres 10 
microparticles following incubation in a mllcin soilition (,,=3 D). 
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6.3.5 Adhesion to a Mucus Producing Cell Culture Model 
The mucoadhesive properties of the chitosan containing systems were assessed 
using a mucus secreting cell culture model. Particles were introduced to Calu-
3 cell mono layers grown on transwell supports and were then imaged prior to 
and following washing (Figure 6.14). This technique allows direct visual 
comparisons to he made of the mucoadhesion of the different samples. The 
images illustrate that there is no observable mucoadhesion of particles 
containing no mucoadhesive polymer. The presence of either chitosan, or the 
chitosan-NAC, results in substantial surface area of the cell monolayer covered 
with remaining particles. The adhesion does not appear to differ if particlcs 
were either coated with chitosan post-production or chitosan added during the 
production stage. Interestingly, despite higher mucin adhesion, chitosan-NAC 
does not appear to improve mucoadhcsion in this study. On thc, contrary, there 
appears to be less particles remaining adhered to the mucus layer following 
washing step for the chitosan-NAC formulation, relative to the unmodified 
chitosan system. 
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i) 
ii) 
iii) 
iv) 
v) 
Figure 6.14 Fluorescent and bright field images showing the particles 
adhered to the surface of the eel/monolayer i) distribution of jill 0 res cell t/y 
labelled particles prior to washing ii) FITC-ehitosan coated p a r t i c c ~ s s iii) 
FITC-chitosan-NAC coated particles ivy chitosan incorporated particles 
labelled with coumarin-6 v) control particles labelled with cOlllllarill-6 
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6.4 Discussion 
In this chapter the incorporation of mucoadhesive excipients, and the 
introduction of novel properties to the formulation, has been explored. 
Chitosan was selected as the mucoadhesive polymer and has previously been 
widely used in drug delivery systems to improve bioavailability [38]. The 
PGSS method has been described as a simple, and successful, one step method 
towards the production of drug encapsulated microparticles [39], however 
chitosan does not undergo plasticisation, as the PLGA and PEG do, on 
exposure to the scC02• Therefore chitosan could not be incorporated in the 
same way PLGA and PEG are resulting in the introduction of a second step in 
processing with the coating being achieved through a post-processing 
modification. This involved the microparticles being suspended in a chitosan 
solution. The SEM analysis revealed that this process may cause some changes 
to the surface morphology of the particles, which was perhaps unsurprising due 
to the low pH conditions that the coating process must be carried out to ensure 
solubility of chitosan [40]. 
The pKa value of the amino group in chitosan is ..... 6.5 although this may vary 
depending on deacetylation degree [29], therefore at low to neutral pI I level 
chitosan is charged. The main interaction between the positively charged 
chitosan and the PLGA is considered to be electrostatic. The carboxyl group in 
the PLGA demonstrates a pKa of3.85 [41] and a fraction of these groups will 
be negatively charged allowing ionic interactions between chitosan and PLGA. 
It has also been reported that the coating process may continue even after a 
positive microparticle surface has been achieved and therefore the interactions 
may be in part governed by hydrogen bonding, or van deer Waal's forces [42]. 
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Detailed analysis of the internal morphology following the coating process 
exposed the change in the porous network which was not unlike what we have 
previously encountered following release studies in the low pH of SGF 
medium (see Chapter 4 Figure 5.5) suggesting that during the coating process 
there is some disruption to the structure of the microparticles. 
For this reason another approach was explored to introduce chitosan during the 
particles formulation. The chitosan powder was added into the material 
mixture and, although it will not be plasticised and mixed under the SC02 as 
PLGA and PEG polymers, the chitosan particles will be expected to be 
distributed within the polymer matrix. This protocol does not require the 
suspension and exposure of particles to the chitosan coating solution. SEM and 
microCT analysis confirm that, as a result, there is no disruption to the surface 
or to the porous network in these particles. Through incorporation of the 
chitosan during the particles production allows a one-step process, it should be 
noted however the chitosan is not restricted to the surface and ToF- SIMS data 
indicated that it is present deeper in the matrix and should be found throughout 
the microparticle this may have an impact on other properties. ToF-SIMS 
surface analysis confirmed that the chitosan in both the post-processing coated 
samples is most prevalent on the surface. The depth profiles show the 
distribution of ions in the two coating methods, with both methods confirming 
the high intensity of chitosan originated ions on the surface. 
By submerging the particles in the chitosan solution the coating is limited to 
the upper surface of the microparticles which results in this defined depth 
profile pattern. However, when the chitosan powder is incorporated with the 
molten PLGA and PEG matrix, the intensity of chitosan signal still 
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demonstrates a significant decrease through the layers although it does not fall 
as low as with post-processing coating. There is a general decrease in intensity 
for both ions towards the deeper layers. It has been reported that this decline in 
intensity maybe a result of the development of roughness in the raster area 
[43]. The sputter induced topography may have an impact on the depth 
resolution and also secondary ion yield [44]. 
The z view images illustrating the ion intensity through the sample (Figure 
6.12) show interesting differences in chitosan distribution. The depth profile 
for the post-processing coating is confirmed by the ion images as the higher 
intensity signal from the CN- and CNO- ions appears towards the upper most 
layers with the intensity decreasing through the layers. The opposite is seen in 
the ion images for the PLGA ions where the upper layers are darker where the 
chitosan coating is located on the surface. The z view image also show that the 
coating penetrates into the exposed pores and this may confound the intensity 
data for these chitosan ions as the intensity is taken as an average of the whole 
area. As expected when the chitosan is incorporated during processing this 
high intensity is no longer restricted to the surface of the microparticles and the 
intensity appears to remain almost homogenous throughout the sample. 
The chitosan was modified to produce the derivative chitosan-N-acctyl-L-
cysteine. This chitosan derivative has previously demonstrated improvements 
in mucoadhesive properties, as the thiol group allows the formation of covalent 
bonds between the polymer and the mucus which results in stronger 
interactions [28, 45]. The modification procedure was found to be successful, 
with the final product containing 4.755xlO-4 moles thiol groups per gram of 
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polymer. The presence of the SH- is confirmed by NMR, and can also be 
detected in the ToF-SIMS ion images (Figures 6.9 and 6.12). 
The in vitro mucin assay confirmed that the presence of the thiol group in the 
polymer increases the amount of mucin which adheres to the particles surface. 
This was expected due to the enhancement in the interactions as introduced by 
disulphide cross linking. This data however is not backed-up by the results of 
the cell mucoadhesion study. The images (Figure 6.14) illustrate the non 
modified chitosan incorporated particles demonstrate greater adhesion to the 
mucus following washing in comparison to the NAC modified PLGA particles. 
This is not in agreement with reports in the literature [45] where the modified 
chitosan improves the mucoadhesive properties and results in improved 
retention times. 
Cysteine is considered to be a mucolytic and is used in therapies for respiratory 
conditions such as cystic fibrosis, bronchitis, and chronic obstructive 
pulmonary disorder. The actions of NAC as a mucolytic agent may mean that 
the previously reported success with mucoadhesive polymers modified with 
cysteine, could be a result of improved mucus penetration rather than 
improvements in mucoadhesion [28]. 
Here, the chitosan-NAC derivative may be acting as a mucolytic allowing the 
mucus layer, along with any adhered microparticles, to be removed during the 
washing steps. N-acetlycysteine has been used to remove mucus from the 
epithelia in an attempt to prevent mucoadhesion [46]. 
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6.5 Conclusion 
Two different methods of introducing mucoadhesive functionality to PGSS 
produce particles were explored in this chapter. Chitosan was either introduced 
post production of PLGA particles or it was incorporated into the formulation 
mixture and encapsulated during production. Both incorporation methods were 
found to successfully introduce chitosan into the system and little difference 
was found in mucoadhesive properties gained. 
The chitosan derivative, chitosan-NAC, was also explored, as the introduction 
of the thiol groups in the cysteine has been reported to allow covalent 
interactions between the polymer and the mucins via disulphide bridges. 
Although the chitosan-NAC demonstrated better adhesion of mucin from 
solution, following contact with a mucus producing cell monolayer this 
polymer appears less mucoadhesive. An explanation for this may lie with the 
mucolytic actions of NAC and although the polymer is adhering to the mucins 
present in the mucus layer the mucolytic action cleaves the mucus allowing it 
to be washed away during the washing step. 
This chapter concludes that the introduction of a mucoadhesive polymer into 
the floating particles could augment the gastroretentive behaviour of the 
particles. 
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Chapter 7 
Pharmacokinetic Analysis of Metformin Hydrochloride 
Following Administration of Gastroretentive PLGA 
Particles 
7.1 Introduction 
The previous chapters compare the in vitro release of the two model drugs 
demonstrating differing solubility levels, furosemide, and riboflavin. This 
chapter introduces metformin; this drug is frequently reported in the literature 
in oral delivery systems for pharmacokinetic analysis in the rat model allowing 
comparisons to be made. Additionally, the high solubility of this drug will 
provide further information towards the characterisation of drug release 
behaviour. Metformin is an anti-hyperglycaemic agent and is the first-line drug 
of choice for type II diabetes. Although its anti-hyperglycaemic actions were 
characterised in the late 1920's [1], metformin was first employed in diabetes 
therapy only in 1957 [2]. Metformin reduces hepatic gluconeogenesis through 
activation of AMP-activated protein kinase (AMPK) [3]. AMPK is a multi-
subunit enzyme which is involved in energy homeostasis and more 
specifically, it holds roles in fatty acid oxidation, muscle glucose uptake, 
hepatic lipogenesis. Its chronic activation may induce the expression of muscle 
hexokinase and glucose transporters [3]. 
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Type II diabetes rates are rapidly increasing in line with the increasing 
incidence of obesity and therefore the emergence of a successful therapy is 
highly desired. Although metformin provides adequate therapeutic intervention 
[4, 5], it could be improved if the oral bioavailability (around 55%) could be 
further increased [6-8] and required dosing frequency reduced. Metformin 
therapy is also commonly associated with gastrointestinal related side effects 
such as gastric discomfort, nausea, and diarrhoea. Incidences of 
gastrointestinal related adverse effects are observed in around 30% of patients 
[9-11] . 
The biological half-life of metformin is approximately 3 h [8] and therefore by 
conventional delivery systems dosing is required three or four times a day [12]. 
There have been various attempts to decrease dosing frequency and improve 
the bioavailability of metformin through gastroretentive formulations [13-19]. 
A floating tablet formulation, prepared with sodium alginate and sodium 
carboxymethylcellulose as the gelling agents and Eudragit NE 30 D to provide 
controlled release and reduce initial burst, confirmed the system had 
appropriate sustained release and the gastroretentive properties suggesting its 
successful application in once-a-day therapy [17]. Another formulation, based 
on a hydrodynamically balanced system with appropriate in vitro buoyancy, 
showed prolonged gastric residence time and revealed increased AUe 
compared to immediate release formulations [20]. Gelucires arc a family of 
lipid based materials which have been successfully applied in sustained drug 
delivery and floating times of up to 8 h have been reported for single unit 
Gelucire 43/01 matrices. Along with suitable controlled release of metformin 
over 9 h, this system holds the potential as an effective carrier for metformin 
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for controlled, gastroretentive release [21]. A combination of floating with 
bioadhesive properties in a delivery system based on PLGA, poly (acrylic 
acid), alginate, and pectin demonstrated good in vitro release of metfonnin and 
gastro-adhesive properties, although metformin drug encapsulation efficiency 
was relatively low at 18-54% [22]. Other systems which hold potential for 
controlled release and gastroretention for metfonnin delivery include 
microballoons [18], gastroretentive tablets [14] and microbeads [15]. 
Although these systems have shown good potential in in vitro release and 
mucoadhesion assays, replication of this success is rarely reported in in vivo 
studies. An example where this success has been reported is a mucoadhesive 
matrix pellet, prepared with HPMC and cellulose, revealed retention in the 
upper small intestine of rabbits for 10 h with metfonnin release being sustained 
over this period [13]. Extended release metformin tablets (Glumctza™) are 
currently available on the market and have demonstrated good efficacy [23]. 
This delivery system achieves improved drug bioavailability through 
increasing its size (up to 150% of the initial value) on contact with the gastric 
media, reaching the size that is preventing its emptying into the intestine. 
The varied environment within the GIT is contributing to difficulties In 
establishing in vitro - in vivo correlation. Many factors contribute to this varied 
environment. One of the factors, particularly affecting mucoadhesive systems, 
is the high turnover rate of the mucus lining [24], as previously discussed in 
Chapter 1 (Section 1.4.3). Drug delivery devices designed for adhesion within 
GIr to this mucus lining are only as successful as the integrity of the mucus to 
which they are adhered [25]. 
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The selection of an animal model for gastroretentive systems is difficult 
because there are significant variations in gastrointestinal physiology between 
species. These physiological, anatomical, and biochemical differences between 
species can result in significant variations in drug absorption from the oral 
formulations [26]. Canine models are considered to demonstrate good 
correlation with man for GI physiology, with similar motility patterns and pH 
profiles. Differences such as gastric emptying rates and intestinal transit times 
however may affect drug absorption, in particular for gastroretentive systems 
[27]. 
Regarding the use of rats in studies of oral formulations a comparison of the 
gastrointestinal physiology of that of the rat and man confirms that such small 
animal models are useful in the determination of bioavailability from powder 
and solution formulations; whereas larger animal models (dog, pig, or sheep) 
may be more appropriate for determination of absorption from 'larger' 
formulations, if only because they are easier to administer [26]. Nevertheless, 
the application of the rat model has been reported in pharmacokinetic studies 
of gastroretentive formulations of metformin as follows. A pharmacokinetic 
and pharmacodynamic study of the effect of controlled release formulations of 
metformin was carried out in diabetic rats showing gastric retention times of 
up to 10 h and with improvements in glucose lowering effect compared to the 
I.V administration [28]. Floating alginate beads loaded with metformin 
demonstrated significantly greater and more prolonged hypoglycaemic effect 
in comparison with non-floating beads in a diabetic rat model [29]. The rat 
model has also been applied in investigations involving mucoadhesive systems 
showing promise for the use of mucoadhesive excipients in the improvement 
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of metfonnin delivery [30]. The use of the rat model provides an adequate 
early indication of the efficacy of novel fonnulations; however larger animal 
models are usually required prior to testing in man. 
7.2 Materials and Methods 
7.2.1 Materials 
Metfonnin hydrochloride (Figure 7.1) was obtained from Sigma Aldrich, 
Ammonium Dihydrogen Phosphate (99.9% extra pure), and phosphoric acid 
(85+% solution in water) were obtained from Acros Organics. Sodium 
alginate, acetonitrile, and HPLC grade water were obtained from Fisher 
Scientific. Other materials utilised in particle preparation are described in 
Chapters 3 and 6. 
Figure 7.1 Chemical structure of metformin. (solubility >300 mg/ml) 
7.2.2 Methods 
7.2.2.1 Incorporation of Metformin Hydrochloride into PLGA Particles 
Particles were produced using the pass method as described in detail in 
Chapter 2 (Section 2.1). The following formulation material was used weighed 
for a 2 g batch for buoyant particles. 
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> PLGA (RG502H -12KDa) 55% (w/w) 
> PLGA (RG503 - 25 KDa) 20% (w/w) 
> PEG 35 KDa 10% (w/w) 
> SPANTM80 5% (w/w) 
> Metformin 10% (w/w) 
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And the following materials were weighed out for the buoyant mucoadhesive 
particles. 
> PLGA (RG502H -12KDa) 50% (w/w) 
> PLGA(RG503 - 25 KDa) 20% (w/w) 
> PEG 35 KDA 10% (w/w) 
> SPANTM80 5% (w/w) 
> Metformin 10% (w/w) 
> Chitosan 5% (w/w) 
7.2.2.2 Preparation of Non-Buoyant Particles 
Particles were also prepared without the application of supercritical carbon 
dioxide technology in order to provide a non-buoyant particles control. For 
animal studies these particles the formulation material, as described above was 
heated until the PLGA polymer became molten. The mixture was then stirred 
for a period of 1 h before cooling at 4°C overnight. The product was then 
ground and sieved as described in Chapter 2 (Section 2.1). 
7.2.2.3 In Vitro Metformin Release 
In vitro release was carried out as described in Chapter 2 (Section 2.11). 
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7.2.2.4 High Performance Liquid Chromatography (HPLC) Analysis 
Quantification of metformin HCI in rat serum samples was carried out using a 
high-performance liquid chromatography (HPLC) following the method modified 
from Wanjari et al 2008 [31] and using an Agilent liP 1090 IIPLC system. 
Mobile phase was prepared by mixing 0.15 M ammonium dihydrogen 
phosphate (99.9% extra pure, Acros) (adjusted to p1l3.0 using phosphoric acid 
(acid for analysis 85+% solution in water, Acros» and 5% acetonitrile. The 
elution was carried out on a CI8 column (250 x 4.6 mm (ACE-12I-2546» and 
the flow rate was maintained throughout the study at 0.5 mVmin. The presence 
of drug was detected using UVNis at 236 nm. Concentration was determined 
using a calibration curve. 
7.2.2.5 Pharmacokinetic Analysis of Metformin in a Rat Model 
All animal experimentation was carried out in compliance with current UK 
legislation on animal experimentation (Animals (Scientific Procedures) Act 
1986) and within the requirements of Commission Directive 86/609IEEC 
concerning the protection of animals used for experimental and other scientific 
purposes Male Sprague Dawley rats (Charles River) of average weight 300 g 
were divided into 5 groups of 6 rats. The rats were administered a 100 mg/kg 
dose of metformin via different formulations. The different groups were as 
follows: i) buoyant particles ii) buoyantlmucoadhesive particles, iii) non-
buoyant particles iv) oral solution of metformin v) intravenous (I.V.) solution 
of metformin. 
The particulate formulations were administered by oral gavage suspended in 2 
ml of 0.5% sodium alginate with the gavage tube washed through with a 
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further Iml of sodium alginate solution. Blood samples were taken from the 
tail vein at 0.5, 1, 2, 4, 6, and 8 h following dosing. Blood samples were 
centrifuged to remove serum; serum samples were analysed using 
Pharmacokinetic analysis and perfonned on the metfonnin concentration 
versus time profile using WinNonlin (Pharsight, U.S.). 
7.2.2.6 Deproteinisation of Rat Serum Samples for HPLC Analysis 
In order to prepare the rat serum for HPLC analysis 200111 acetonitrile was 
added to 100111 serum and this was vortex-mixed for 30 seconds. The mixture 
was then left to stand for 10 minutes before being centrifuged at 10000 rpm for 
10 mins. The upper layer was transferred to a separate tube and 20 III used for 
HPLC analysis. 
7.3 Results 
7.3.1 Encapsulation and In Vitro Release of Metformin Hydrochloride 
The initial loading of drug into fonnulation was increased from 5%, as used in 
Chapters 4 and 5 to 10% w/w. This was deemed necessary to provide an 
adequate dose of metfonnin in the amount of the formulation that can be 
administered to a small animal (rat). In order to assess possible effects of this 
increased loading on the drug release behaviour, in vitro, analysis of drug 
releaseas carried out and compared for 5% and 10% loading formulations 
(Figure 7.2). No significant difference was revealed for these two formulations. 
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It should be noted however that the release profiles obtained for metformin 
(Figures 7.2 and 7.3) are dramatically different to the release profiles for he 
ribioflavin and furosemide formulations in previous chapters (Chapter 4 Figure 
4.4). A high burst of 60% dose is revealed for both drug loadings. The release 
data were analysed applying the release models (as described in Chapter 5), 
and summarized in Table 7.1. Linearity values for metformin release appear 
poor in comparison to the previous results (Chapter 5 Table 5.1) for release 
data from this system. The Higuchi model revealed a linearity of .-2=0.8089 
(Figure 7.4) indicating diffusion driven release. 
Table 7.1 The regression parameters obtained for release data for metformin 
loaded particles (lO%w/w) for the different kinetic model .... 
Zero-order First-order Higuchi Korscmcycr-Pcppas 
n 
0.6465 1.324 0.609 0.071 0.809 7.966 0.4930 0.0335 
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Figure 7.4 Release data applied to the Higuchi ki"etic model for 
1 0% met/ormin. 
7.3.2 Development of HPLC Method for Quantitativ Analysi of 
Metformin Hydrochloride in Rat erum 
Quantification of metformin in rat erum was carri ed out u ing t n adapt d 
reverse phase HPL method [3 1]. Prior t ana ty i the IlP m th d wa 
qualified accord ing to linearity, and y tern precis ion. All rum ampl w r 
deproteinized before analys is (Section 7.2.2. ) and r c v ry quantitat d. 
Initially two calibration curves were e tab ti h d u ing ri< I di luti n f 
metfonnin in either mobile phase (ammonium dihydr g n ph sphat pIt 
or rat serum (Figure 7.5). The r lati n hip b tw n p ak 'Ir a and 
concentration was linear ( ~ = 0 . 9 9 6 4 4 for metfi rmin in rat rum ~ l g l l r r 7. 
Calibration curves demonstrate that th extracti n t p r ult tn a ss r 
approximately 50% of the drug from th erum. It i p ib l to aunt fI r 
this loss when carrying out the analy i . 
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Figure 7.5 Linearity o/peak area in the given concentration range/or 
metformin in rat serum and mobile phase (n=6±SEM) 
The relative standard deviation (RSD) for peak area a llows sy t m preci i n t 
be assessed. As a biological sample the RSD va lue pre en ted ( ab l 7.2) ar 
considered to be low. These va lues provide viden c t upport th 
of the method, indicating low variab ili ty in quantification . 
Table 7.2 Relative Standard Deviation (RSD) values given for peak ar ~ a a ov r 
a large concentration range o/metformin in rat serulII. 
Concentration Avarea 
~ m g / m l } }
0.1000 3924.1700 38.204 
0.0500 1952.5290 40. 2 2.0652 
0.0250 101 2.99 10 28.8954 2. 525 
0.0125 5 13.3302 6. 1994 1.2077 
0.0063 297.5582 5. 372 I. 617 
0.0031 158.7190 5. 1 0 .270 1 
0.0016 90.4060 5. 7 9 6. 1 12 
0.0008 47.6659 1.2 1 2.55 
0.0004 27.7138 3.7455 
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Typical chromatograms obtained for metformin in mobile phase, and rat serum 
are presented (Figure 7.6) alongs ide blank serum and a 'sp iked' serum of 0.05 
~ g g m l . . Chromatograms indicate a di stinct peak corresponding to the elution of 
metformin at a retention time of 5.8 minutes demonstrating good reso lution. 
Figure 7.6 Typical chromatograms showing the resolution of the metjormin 
peak (demonstrated by the pointer) in i) mobile phase (0.05 pg/ml) ii) blank 
serum iii) Spiked serum sample (0.05 J.,lg/ml) and ivy Typical chromatogram 
for a group 4 animal at 60mins. 
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7.3.3 Analysis and Quantification of Metformin Hydrochloride in Rat 
Serum Following Oral Application of Different Formulations 
The mean plasma concentration-time profiles of metformin following oral 
administration of the different formulations are presented (Figure 7.7) along 
with the corresponding pharmacokinetic parameters shown in Table 7.2. 
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Figure 7.7 Log plasma concentration profile for metformin following oral 
administration of a 100 mg/kg dose from the different formulations. 
/. V data is also provided for absolute bioavailability calculations 
(n=6±SEM). 
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Table 7.3 Pharmacokinetic parameters ofmetforminfollowing oral 
administration of the various metformin loadedformulations. 
Parameter Group 1 Group 2 Group 3 Group 4 Group 5 
Buoyant-
Control 
Group Buoyant particle mucoadhesive Oral solution I.V solution 
particles 
particles 
Mean SO Mean SO Mean SO Mean SO Mean SD 
AUCo-s 
(Jlglml hr) 8.50 6.17 12.25 3.4) 8.13 1.03 6.20 0.58 )0.03 1.48 
Cmax 
(I'glml) 3.30 2.15 3.03 0.9) 3.37 0.43 2.69 0.40 )5.57 1.8) 
Tmu(hr) 1.67 2.14 2.00 1.10 1.00 0.00 1.00 0.00 1.00 0.00 
tIll (hr) 3.24 4.05 4.32 3.99 0.34 0.0) 1.17 0.54 0.58 0.2) 
FvsI.Ora) 
(%) 137.02 99.54 )97.53 55.04 131.09 )6.63 
FvsIV (%) 84.68 61.5) )22.07 34.0) 81.0) )0.28 61.80 5.78 
Note: AUCo-s = area under the metformin concentration-time curve from time 0 to 8 
hours. F = absolute bioavailability. Cmu = the maximum concentration of mctformin 
achieved in the rat serum. T mu = the amount of time after metformln administration 
when the maximum plasma concentration is reached. till'"" this Is the biological half life 
for metformin in rat serum. 
Pharmacokinetic analysis demonstrates that the buoyant mucoadhesivc 
particles formulation improves the bioavailability compared to the I.V. dose 
(Fvs.I.V 122.07%) and increases the T max to 2.00 h. AVe is similar for the 
buoyant and non-buoyant particles (8.50±6.l7 ~ g l m l l h, and 8.13±1.03 ~ g l m l l
hr, respectively) whereas the introduction of the mucoadhesive chitosan 
increases AVe ofbuoyant-mucoadhesive particles to 12.25±3.4 ~ g l m l l hr. The 
half life for metformin from the non-buoyant particles (0.341:0.01 h) is 
improved following administration of both the buoyant particles (3.24 h) and 
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more so for the buoyant-mucoadhesive particles (4.32 h). All particulate 
formulations improve bioavailability compared to the oral bolus (FvsOral). 
7.4 Discussion 
This chapter reports a pharmacokinetic investigation in the rat model of the 
buoyant mucoadhesive PLGA particles developed in this thesis. As a suitable 
candidate drug, metformin was encapsulated in the PLGA particles and release 
was initially assessed in vitro. An increase in burst release with metformin (to 
60%) is revealed (Figure 7.2 and 7.3 in comparison to the release profiles for 
riboflavin and furosemide (Figure 4.5). This may be a consequence of the high 
water solubility of metformin (>300 mg/ml at 25°C [12, 32] compared to 
riboflavin's solubility of 0.01 mg/ml or furosemide's solubility of 0.006 
mg/ml). It has been suggested that water solubility, along with the partition 
coefficient of drugs can influence the release, with high solubility generally 
leading to rapid release in aqueous media [33]. 
In vitro analysis provides evidence suggesting the buoyant-mucoadhesive 
system may demonstrate gastroretentive behaviour suitable for the 
improvement of the oral bioavailability of drugs including good buoyancy 
(Figure 3.10), and mucoadhesion (Figure 6.14). It is generally recognized that 
it is difficult to correlate in vitro with in vivo performance of oral delivery 
systems [34]. In vitro / in vivo correlation has been described in USP as 'the 
establishment of a relationship between a biological property or a parameter 
derived from a biological property produced by a dosage form, and a 
physicochemical characteristic of the same dosage form' [35]. In this study the 
buoyant particles, mucoadhesive buoyant particles, and non-buoyant particles 
were all loaded with 10% metformin hydrochloride and administered at the 
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same dose of 100 mg/kg. A 100 mg/kg dose was also administered by I.V. and 
an oral solution to allow calculation of pharmacokinetic parameters. 
Pharmacokinetic analysis demonstrates that despite the poor sustained release 
of metformin from the system the mucoadhesive buoyant particles maintain 
increased drug plasma levels of the drug over a prolonged period of time in 
comparison to the oral solutionlbolus dose. However the buoyant particles 
without mucoadhesive properties demonstrate similar pharmacokinetics to the 
oral solutionlbolus dose. It should be noted that the in vivo evaluation of 
designed formulations was conducted in rats, the largest particles size which 
could be administered through the gavage tube effectively was the >250 ~ m m
size fraction. This fraction showed a reasonably good buoyancy in in vitro 
characterisation but larger particle sizes showed improved buoyancy potential 
and employing larger, more porous particles may have further enhanced 
bioavailability for the buoyant particles through better floating ability. 
The AVe value (Table 7.3) shows the amount of mctformin ( ~ g / m l ) ) that 
reached systemic circulation over the 8 h time course of the study. The similar 
AVe values were obtained for buoyant particles and non-buoyant particles 
(8.50±6.l7 and 8.13± 1.03 respectively) with an increase to a value of 12.25 
~ g l m l . h r r upon the introduction of mucoadhesive properties. This indicates that 
a combination of buoyancy and mucoadhesion may enhance drug delivery in 
comparison to buoyancy alone. The combination of both properties has been 
previously evaluated in vitro [36-38] but how this translates in vivo is less 
widely studied. 
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All formulations administered via the oral route demonstrated similar plasma 
concentration values at 30 mins with T max for buoyant particles, control 
particles and oral solution dose at 1.67, 1.00, and 1.00 h respectively. Cmax 
occurs slightly later at 2.00 h following the introduction of the mucoadhesive 
polymer and plasma metformin concentrations are sustained for longer 
exhibiting a broader peak. This peak shape is comparable to the plasma 
concentration profile upon delivery of extended release gastric retentive tablets 
to healthy humans [39]. Broad, low peaks indicate sustained exposure to the 
drug at the absorption window with such peaks demonstrating improvements 
in bioavailability by 115%. 
This improvement upon the introduction of the mucoadhesive property is 
consistent with metformin demonstrating a narrow absorption window in the 
upper small intestine and suggests the potential suitability of the system for 
once a day dosing of metformin. The application of a once-daily extended 
release system for metformin has demonstrated to be as effective as twice-daily 
immediate release dosing [23]. 
Orally administered metformin is subjected to high elimination values as a 
result of gastrointestinal first pass effects (53.8%) and demonstrated a low F 
value of29.9% [40]. In the present study, the Fvaluc (vs. LV) for oral solution 
administration is 61.80% ±5.78 which is improved upon encapsulation of the 
drug within a polymeric matrix to an average of 81.01%, 84.68%, and 
122.07% for the non-buoyant, buoyant, and buoyant-mucoadhesive particles 
respectively. This suggests that the practice of simply encapsulating the drug 
may improve bioavailability. This is in contrast to previous work where a 
deterioration in bioavailability for two sustained release tablets compared to a 
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rapidly dissolving tablet and oral solution was reported [41]. This may be the 
case as these systems exhibits controlled release behaviour without 
gastroretention and the decrease in bioavailability arises from the fast gastric 
transit time carrying the system past the absorption window before the 
controlled release system has had a chance to release a significant amount of 
drug. 
A relatively high standard deviation values obtained for pharmacokinctic 
parameters following administration of gastroretentive delivery system may be 
explained by inter-subject gastrointestinal variation. The plasma concentration 
profile clearly demonstrates more pronounced error bars for those formulations 
administered via the oral route in comparison with the I.V. administration. This 
has been reported previously [39]. 
The pKa of metformin is relatively high (11.5) [42], therefore in the 
gastrointestinal tract it is present in its ionized form. It has been reported that 
the positive charge of metformin results in its high affinity with the negative 
intestinal wall [28] this may slow down drug absorption rate and explain the 
similarities in pharmacokinetics between oral solution and buoyant particles. 
Pharmacokinetic studies in this project used the rat as a model, although being 
aware that this may not be considered as suitable animal for in vivo testing of 
solid oral dosage forms due to their small size [43] and presenting difficulties 
in administration of devices developed for therapy in man. Prior testing in a 
larger animal model will be required before studies in man. 
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7.5 Conclusion 
This chapter provides pharmacokinetic evidence to suggest that the 
combination of mucoadhesive and buoyant functionalities may bestow 
properties on the delivery system which enable an improvement in its 
pharmacokinetics. Ave values are improved from 6.20 Ilglml with oral 
solution, and 10.03 Ilglml for the LV solution to 12.25 Ilg/ml for the 
mucoadhesive buoyant particles. This demonstrates an increase in FvsI.V of 
122.07% and in FvsOral of 197.53%. There is an improvement in FvsOral with 
all particulate formulations regardless of gastroretentive properties. This may 
be a result of the reduced rate of release from these formulations. An 
improvement in FvsIV for buoyant mucoadhesive particles (122%) confirms 
the success of the PGSS method in the fabrication of particles suitable for 
enhanced delivery of metformin. The data suggests the application of the 
system for once-daily delivery of metformin. The system lends itself to study 
with other candidate drugs demonstrating a narrow absorption window in the 
upper small intestine. 
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Chapter 8 
Summary and Future Directions 
8.1 Overall summary 
Oral drug delivery is an area of research widely investigated as a result of the 
good patient compliance and convenience demonstrated by this drug 
administration route. It is the most common and usually the preferred route of 
administration; however, there are various obstacles to oral drug dclivery. 
These include the low pH levels in the stomach, rapid gastric transit times, the 
first-pass effect of the liver, and finally it is estimated that around one third of 
the population experience difficulties swallowing pills. The drugs themselves 
also present issues when delivered via the oral route as many drugs 
demonstrate narrow absorption windows in the upper small intestine. These 
drugs (which include metformin, furosemide, riboflavin, atenolol and many 
others) will only reach the systemic circulation if they are released from the 
delivery system before it passes this narrow absorption window [1]. 
In light of these disadvantages, various strategies have been investigated to 
improve oral drug delivery. The gastroretentive systems present an approach 
which aims to retain the delivery system in the stomach and therefore proximal 
to its absorption window, typically in the upper small intestine, for a prolonged 
period of time. There have been various attempts to achieve gastrorctention 
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including expanding, floating, mucoadhesive, or high density systems [2, 3]. 
Among these technologies the floating fonnulations have demonstrated much 
promise with examples existing on the market. 
The aim of this thesis was to develop a multi-unit drug delivery system 
demonstrating (i) density lower than the gastric fluid to enable its buoyancy, 
with no lag-time, and (ii) sustain drug release for the duration of the system's 
gastroretention. The project explored the potential of combining buoyancy 
with mucoadhesion in an effort to augment the gastroretentive potential. 
Furthermore, the application of the novel 'green' technology which produces 
inherently porous materials was investigated. 
The production of multi-unit drug delivery systems is traditionally carried out 
using emulsion techniques which introduce major issues concerning the usc of 
volatile organic solvents. A recent emergence in the field of polymer 
processing is the supercritical fluid technologies. In SCC02 offers an organic 
solvent-free route to the production of polymeric particles at relatively low 
temperatures. The particles from gas saturated solutions (paSS) method was 
employed in this thesis in the production of polymeric particles. This particular 
method exploits the ability of scC02 to decrease the glass transition 
temperature of polymers enabling drug particles to be mixed into the liquefied 
polymer. The presence of scC02 in the mixture allowed for the production of 
an intricate porous network as on depressurisation, this C02 return to the 
gaseous state and will diffuse out of the rapidly solidifying polymeric matrix. 
The initial challenge faced in this project was the development of a suitable 
formulation which demonstrates a high yield and a product which 
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demonstrates a low density. PLGA material has been previously used in the 
PGSS method [4] and was therefore initially selected for processing into 
particles. However, the poor yield obtained with PLGA resulted in the 
introduction of processing aids in order to improve the processability of the 
liquefied mixture, improving yield and particle morphology. The incorporation 
of myristic acid at a relatively high content somewhat improved product yield 
with the density of the PLGA and myristic acid formulation was above that of 
the gastric contents. An in vitro buoyancy test was carried out verifying that 
the PLGA / myristic acid formulations did not reveal adequate buoyancy in a 
simulated gastric fluid. Various formulations were explored in an attempt to 
reduce the density of the product. Of the various formulations investigated a 
combination of PLGA (approximate molecular weight 12 KDa), PLGA 
(approximate molecular weight 25 KDa), and SPANTM 80 in the ratio 75:20:5, 
respectively produced particles which demonstrated the most appropriate 
density (Table 3.1). 
Following pass processing, the formulation was ground and sieved to 
produce discrete size fractions and allow a comparison of the density and 
porosity of the different size particles to be carried out. microCT porosity 
analysis of the different size fractions demonstrated an increase in porosity 
with increasing particle size from 0% with particles size < 100 llm up to over 
50% for particles> 800 llffi. The different size fractions were also analysed for 
density using helium air pycnometry with the larger and more porous particles 
demonstrating lower densities. The smaller size fraction « 100 J..lm) 
demonstrated density values above reported values for gastric media with 
particles >250 J..lffi demonstrating densities lower than 1.003 gcm-3• Chapter 3 
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reported on the production of a system offering the appropriate low density to 
allow buoyancy in a simulated gastric fluid. 
The model drugs riboflavin and furosemide were introduced into the 
formulation at theoretical loadings of 5%. Encapsulation efficiency was 
measured to be in excess of 80% for both drugs at all size fractions, with ToF-
SIMS surface analysis illustrating a uniform distribution of drug across the 
surface of the samples with depth profiling providing data to suggest that the 
intensity of the drug remains constant throughout the matrix. 
In vitro drug release was carried out at both pH 7.4 and in a simulated gastric 
fluid at pH 1.2. A size dependant release rate at pl17 .4 was revealed with 
larger particles demonstrating the fastest release of both drugs. In the simulated 
gastric fluid (pH 1.2) release was decreased from almost 80% (furosemide 
release from particles > 1 000 ~ m ) ) to under 20% for the same formulation at 
pH1.2. Morphological analysis comparing particles before and after the release 
study confirmed that there is an increase in surface porosity creating sponge 
like structures for particles exposed to PBS (pH 7.4), contrasting with the 
smooth, less porous morphologies which are exposed following release in SGF 
(PH 1.2). The different morphologies offered an explanation for the di fferent 
release rates in the two different media. 
The hydrophilic polymer, PEG, was introduced to the formulation (10% w/w) 
in an attempt to increase the release over the 24 hours. The introduction of 
PEG ( ~ 3 3 KDa) increases the rate of release in the PBS pH 7.4 medium. This 
was not the case in SGF, where the presence of PEG actually resulted in a 
decrease in drug release rate for system encapsulating riboflavin. MicroCT 
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porosity measurements showed a marked increase in porosity following 
exposure to PBS for particles containing PEG ~ 3 3 KDa which may contribute to 
the increase in release for these formulations. The data demonstrated that 
modulation of the release rate from PLGA particles may occur through the 
introduction of hydrophilic excipients. 
The gastroretentive behaviour of the buoyant particles was augmented through 
the introduction of the mucoadhesive polymer chitosan and its thiolated 
derivative chitosan-NAC. Previous work in the field has demonstrated that the 
introduction of a mucoadhesive polymer to a floating drug delivery system 
enables prolonged gastric residence times and may enhance performance of the 
drug delivery system [5, 6]. In the present study, particles were either coated 
with chitosan and its derivative following POSS processing or the polymers 
were incorporated into the formulation and processed. ToF-SIMS surface 
analysis suggested both methods were successful in introducing the 
mucoadhesive, as judged from the increased intensity of the chitosan 
originated ionic species at the surface of the particles. 
The mucoadhesive ability of the formulations was assessed using an in vitro 
mucin assay which confirmed that the NAC modified chitosan demonstrated 
the most effective adhesion to mucin; however this was not replicated when 
particles were introduced to a mucus producing cell line. In the cell study, 
chitosan incorporated particles demonstrated better adhesion following 
washing in comparison to the chitosan-NAC. As NAC is a well known 
mucolytic, the removal of these particles following washing may be a result of 
the mucus cleaving actions of NAC allowing the mucus to be washed away 
during the washing step. 
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Finally, this thesis assesses the success of the system in an in vivo model. The 
anti-diabetic drug metformin was loaded into the PLGA particles at an 
increased loading of 10% to achieve appropriate drug dose within the 
administered amount of the particles. A comparison of pharmacokinetic 
parameter for the buoyant particles, buoyant-mucoadhesive particles, and non-
buoyant particles, with I.V. and orally applied drug solution illustrates that the 
combination of buoyancy and mucoadhesion improve bioavailability to 
122.07% (AVe value of 12.25 Ilglml.hr) with the buoyant particles revealing a 
bioavailability of 84.68% (AVe value of 8.50 Ilg/ml.hr). The data obtained 
from the in vivo rat study suggests that the gastroretentive system developed in 
this thesis may hold promise in the improvement of oral drug delivery, in 
particular for drugs exhibiting narrow absorption windows in the upper small 
. intestine. 
8.2 Future Directions 
Overcoming the obstacles presented by oral drug delivery, in particular for 
drugs exhibiting narrow absorption windows in the upper small intestine is 
currently an area which is being widely researched. Although these systems 
often demonstrate the appropriate characteristics in the in vitro setting they are 
not as yet widely available on the market. This thesis provides a foundation for 
the manufacture of a system which demonstrates prolonged gastric residence 
times and therefore improved pharmacokinetics over a conventional delivery 
system. However, it would be naive to suggest that good performance in the rat 
model is indicative of success in man and therefore further in vivo analysis 
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would be required in a larger animal model before eventual studies in man in 
order to confirm the success of the system. 
Pharmacokinetic analysis does not enable conclusions to be drawn on the 
ability of the gastroretentive system to remain in the stomach for prolonged 
periods of time. In order to acquire this data the use of gamma scintigraphy [7] 
or MRI [8] studies could follow the transit of the delivery system through the 
GIT. 
In this thesis it was shown that changes in the formulation may be used to 
modulate drug release characteristics, in this way, additional modifications 
could be explored to further improve release characteristics. Pharmacokinetic 
analysis illustrates improvements in bioavailability on the introduction of 
chitosan-NAC to the formulation. Various modified chitosans have been 
reported in the literature with different levels of mucoadhesion being achieved. 
In particular Chitosan-TBA has demonstrated 100 fold increase in 
mucoadhesion in comparison to an unmodified chitosan [9]. A comparison of 
mucoadhesive properties following incorporation of some alternative 
mucoadhesive polymers may increase gastroretention further. 
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